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Summary 
Heart failure is a complex clinical syndrome characterised by typical symptoms 
(like dyspnoea, fatigue, palpitations or chest pain) and signs (like oedema, 
pulmonary crackles, displaced apex beat and increased jugular venous pressure). 
The possible importance of symptoms as predictors of subsequent outcomes has 
received little attention in the medical literature yet is clearly of great potential 
clinical importance (for example in identification, monitoring and treatment of 
high risk patients).  
Fatigue and dyspnoea are the two most prevalent symptoms in patients with 
heart failure ranging from 50-91% for fatigue and similar (53-89%) for dyspnoea. 
However, the underlying pathophysiological mechanisms of dyspnoea and fatigue 
in heart failure remain unclear. It has been proposed that decreased oxygen 
delivery to muscle due to an impaired pump function of the failing heart leads to 
a build-up of anaerobic metabolic products which may account for both 
symptoms. Some hypotheses attribute the impaired oxygen delivery to muscle to 
reduced blood flow due to persistent vasoconstriction and endothelial 
dysfunction, rather than just to a limited cardiac output. Other potential 
mechanisms include abnormalities in muscle metabolism, possibly due to 
changes in cellular subtype, which limit the ability to utilise oxygen and a miss-
match between energy requirement and energy production. It has now been 
recognised that disturbances of central hemodynamic function are no longer the 
major determinants of exercise capacity in patients with heart failure. If central 
hemodynamic parameters are improved, there is no immediate change in 
symptoms, which points to an impaired ability of the muscle to extract oxygen, 
leading to dyspnoea. 
The lack of consensus and understanding of the pathophysiological mechanisms 
of heart failure symptoms, together with poor and subjective tools for their 
measurement has led to a delay in the development of effective symptomatic 
treatment. This in turn may have important prognostic implications such as 
decreased quality of life, increased hospital admissions and even increased 
mortality. 
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The aim of this work was to examine the correlates of symptoms and change in 
symptoms. Additionally I set out to examine the association between symptom 
severity (at baseline and the change in symptom severity over 6 months) and 
clinical outcomes (namely heart failure hospitalisation, cardiovascular death and 
all-cause mortality) after adjustment for a series of other known prognostic 
factors. 
A cohort of 3830 men and women with LVEF (left ventricular ejection fraction) 
≤35% who participated in the Controlled Rosuvastatin Multinational Trial in Heart 
Failure (CORONA) was examined. This population was chosen because the trial 
medication (rosuvastatin) had no effect on the primary outcome (composite of 
death form cardiovascular causes, nonfatal myocardial infarction and nonfatal 
stroke) (HR 0.92; 95% CI 0.83 to 1.02; P = 0.12) or death from any cause (HR 0.95 
in the rosuvastatin group 95% CI, 0.86 to 1.05; P=0.31) compared to placebo, 
meaning that any result I obtain is unlikely to be due to an effect of the trial 
drug and because this cohort would be representative of a population with heart 
failure who were well treated with contemporary evidence-based medicine  
CORONA was a multicentre, randomised, double-blind, placebo-controlled study 
which enrolled a total of 5011 patients aged ≥ 60 years with symptomatic (NYHA 
class II-IV), systolic (LVEF ≤ 40% but no more than 35% in patients with NYHA 
class II) heart failure. Patients were randomised to receive 10 mg of rosuvastatin 
or matching placebo once daily. 
Symptoms were measured at baseline (randomisation visit), 6 weeks after 
randomisation, and 3 monthly thereafter in this trial population. (1) 
Investigators were asked to evaluate symptoms using the following statement: 
“State symptoms during the past few days: Tick lowest level of physical activity 
causing symptoms”.  
Fatigue “during the past few days” was measured using a five-point exertion 
scale (0 none, 1 heavy exertion, 2 moderate exertion, 3 slight exertion, 4 rest), 
recorded by the investigator. Dyspnoea “during the past few days” was 
measured using a four-point exertion scale (1 heavy exertion, 2 moderate 
exertion, 3 slight exertion, 4 rest); a four- rather than five-point scale was used 
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for dyspnoea because the presence of dyspnoea at baseline was an inclusion 
criterion for CORONA.  
Data were analysed in several ways to comply with the objectives of this thesis. I 
examined prevalence and severity of fatigue and dyspnoea by using descriptive 
statistics. I also analysed baseline characteristics (at visit prior to randomisation 
and randomisation visit) according to fatigue and dyspnoea severity, reporting 
means and standard deviations for continuous variables (medians and 
interquartile ranges for variables that were not normally distributed) and 
percentages for categorical variables and comparing across symptom groups by 
running appropriate tests. 
Ordered logistic regression was used to examine which baseline characteristics 
were independently associated with symptom severity at baseline, while Cox 
proportional hazards regression was used to examine how symptoms were 
related to the risk of clinical events. I used multinomial logistic regression to 
identify independent predictors of change in symptom severity from baseline to 
the 6 month visit (chi2 was used to obtain p values), classifying patients as 
showing a decrease (reduction in score), an increase (an increase in score) or no 
change (unchanged score) in symptoms and analysed the relationship between 
change in symptoms and subsequent clinical outcomes using Cox regression. 
Finally, I examined the effect of rosuvastatin treatment for six months on 
symptom severity using Cox regression survival analysis. 
Additionally, a cohort of 8399 patients with chronic symptomatic heart failure 
with reduced ejection fraction from PARADIGM-HF was examined. Dyspnoea and 
fatigue on effort in PARADIGM-HF were recorded in every visit as “present” or 
“absent”. 
I found that at baseline 95% of CORONA trial participants reported some level of 
fatigue on exertion and most of them (85%) reported high symptom severity 
(from moderate exertion to symptoms at rest). In PARADIGM-HF 52% reported 
fatigue on effort. Dyspnoea showed a similar pattern, although some level of 
dyspnoea was an inclusion criterion for CORONA where 91% reported dyspnoea 
from moderate exertion to dyspnoea at rest, while 86% reported dyspnoea on 
effort in PARADIGM-HF. 
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I found that a limited number of variables (history of hypertension and coronary 
heart disease; NYHA functional class; and use of mineralocorticoid receptor 
antagonists) were independently associated with both fatigue and dyspnoea 
(only with fatigue for PARADIGM-HF), with no variables clearly associated with 
only one of these symptoms. This similarity in variables associated with each 
symptom and the lack of association of dyspnoea with ejection fraction or NT-
proBNP suggests that “peripheral” (i.e. changes in muscle bulk and metabolism), 
rather than “central” mechanisms may explain the origin of both symptoms. 
I also found that worst baseline symptom severity is strongly associated with 
adverse clinical outcomes, but this association is lost after adjustment for other 
well-known cardiovascular prognostic variables like NT-proBNP, LVEF and NYHA 
class, in both cohorts. However in CORONA, change in symptom severity after 6 
months was strongly associated with clinical outcomes, even after adjustment 
for the previously mentioned prognostic factors; with a decrease in symptom 
severity proving to be protective while an increase over six months being 
associated with a higher risk of CV death, HF hospitalisation of all-cause 
mortality. Statin treatment had no convincing effect on symptom severity. 
In conclusion, I found that both fatigue and dyspnoea were highly prevalent in 
both cohorts and that they seem to have the same baseline correlates. This 
supports the theory that both symptoms might be different expressions of the 
same pathophysiological process. Change in symptom severity after 6 months 
seems to be strongly associated with outcomes independent of other known 
prognostic factors, which shines a light on the importance of prompt and 
targeted interventions to improve symptom severity, or at the very least to 
prevent deterioration. 
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1 Introduction 
In this thesis I will examine the two most common symptoms of heart failure 
(i.e. shortness of breath and fatigue) in a clinical trial population. 
The thesis will be organised in the following way:  
In this first chapter I will start off by briefly defining and describing heart failure 
and its epidemiology in Europe and the United states. I will then review the 
published literature surrounding fatigue and shortness of breath in heart failure 
patients in chapters 2 and 3. 
In chapter 4 I will present the data source and methods and briefly describe the 
general principles surrounding the statistical procedures I selected to analyse 
data. From chapter 5 to chapter 10 I will report the results of analyses relating 
to these prominent symptoms performed on a cohort of patients from a clinical 
trial, CORONA where the investigated treatment (rosuvastatin) had no effect on 
the primary outcome of the trial. (2)  
I will then report in chapter 11 the results of analyses relating to symptoms on 
effort performed on another cohort of patients from a contemporary clinical 
trial PARADIGM-HF, which had hardly any missing data and is the most important 
heart failure clinical trial of recent years. (3) 
Finally, I present a summary and discuss my findings in chapter 12. 
Results from sensitivity analyses will be presented in supplementary appendices. 
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1.1 Definition of heart failure 
The American Heart Association defines heart failure as “a complex clinical 
syndrome that can result from any structural or functional cardiac disorder that 
impairs the ability of the ventricle to fill or eject blood”(4), while the European 
Society of Cardiology defines heart failure as “an abnormality of cardiac 
structure or function leading to failure of the heart to deliver oxygen at a rate 
commensurate with the requirements of the metabolizing tissues, despite 
normal filling pressures (or only at the expense of increased filling pressures)”. 
(5, 6) 
Whichever the definition, heart failure is widely recognised as a clinical 
syndrome that is characterised by typical symptoms like breathlessness (from 
now on referred to as dyspnoea) and fatigue, and signs like oedema, pulmonary 
crackles, displaced apex beat and increased jugular venous pressure. (4, 5) 
1.2 Diagnosis of heart failure 
Several criteria have been described to diagnose heart failure (7-10) and they all 
share symptoms together with an adequate medical history and physical 
examination as a crucial part of the diagnosis. However, because many of the 
symptoms are not specific to heart failure, and thus non-discriminating, the 
European Society of Cardiology requires the demonstration of an underlying 
cardiac dysfunction at rest for diagnosis. (5, 10) This evidence can derive from 
an echocardiogram, an electrocardiogram and/or laboratory tests. (5) 
1.2.1 Symptoms and signs in heart failure 
Signs and symptoms are essential in the initial evaluation of patients with 
suspected heart failure, however they are, as previously mentioned, not 
specific. The characteristic symptoms of heart failure are dyspnoea, fatigue and 
ankle swelling. The origin of such symptoms is not fully understood and it is well 
known that they correlate poorly with level of cardiac dysfunction. (11, 12) 
Once the diagnosis of heart failure has been made, symptoms should be used to 
guide therapy and classify the disease. The most widely used nomenclature to 
quantify the degree of functional limitation caused by heart failure symptoms is 
the New York Heart Association classification (NYHA) first conceived in 1928 (13) 
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which was revised and widely accepted by 1964. (14) With this tool, patients are 
classified into a functional class, depending on the degree of effort needed to 
provoke symptoms:  
• Class I patients have no limitation of physical activity; ordinary activity 
does not cause undue fatigue, dyspnoea or palpitations. 
• Class II patients have a slight limitation of physical activity, but are 
comfortable at rest; ordinary activity results in fatigue, dyspnoea or 
palpitations. 
• Class III patients have marked limitation of physical activity and are still 
comfortable at rest; less than ordinary activity results in fatigue, 
dyspnoea or palpitations. 
• Class IV patients are unable to carry out any physical activity without 
discomfort; symptomatic at rest. 
The American Heart Association proposed in 1994 an additional classification 
complementary to the traditional NYHA classification. It also classifies patients 
into four categories (4):  
• A - No objective evidence of cardiovascular disease. No symptoms and no 
limitation in ordinary physical activity; 
• B - Objective evidence of minimal cardiovascular disease with mild 
symptoms and slight limitation during ordinary activity but comfortable at 
rest; 
• C - Objective evidence of moderate cardiovascular disease with marked 
limitation in activity due to symptoms, even during less than ordinary 
activity and comfortable only at rest; 
• D - Objective evidence of severe cardiovascular disease with severe 
limitations and symptomatic even at rest. 
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In Europe, this “objective assessment classification” is seldom used, but 
objective evidence of cardiac dysfunction is embedded in the definition of the 
disease. 
NYHA class is widely accepted and correlates to quality of life measures (15-17) 
and prognosis. (18) However, it is also recognised that NYHA classification 
reflects a subjective assessment by a medical professional and some authors 
have shown that there can be large variation between clinicians while 
determining and assigning NYHA class (19-22) and symptoms (weighted kappa 
values1 ranging from 0.55 to 0.78 (20, 24)). Additionally, NYHA class can change 
in short periods of time; this is why the American Heart Association argues that 
their objective assessment classification proposed in 1994 should be widely 
implemented, as although NYHA class can fluctuate widely over time, once a 
patient has developed a heart failure syndrome and been classified as either C 
or D, they can never go back to not having heart failure and should receive 
medical treatment accordingly. 
As I have mentioned in a previous paragraph, symptoms in heart failure are quite 
nonspecific, subjective and often difficult to assess (5). More importantly, the 
mechanisms underlying the exercise intolerance in patients with heart failure 
are not fully understood. As mentioned previously, symptoms correlate poorly to 
measures of cardiac performance (11, 12) and often patients with low left 
ventricular ejection fractions are asymptomatic, while patients with preserved 
ejection fraction may be very symptomatic. (25) The reasons behind this 
discordance are not fully understood, but may well reside in the pathophysiology 
of each individual symptom.  
The prototypical symptoms in heart failure are fatigue and dyspnoea on 
exertion; though relatively recently, a new symptom has been described: 
bendopnea (or shortness of breath when bending forward) (26) and seems to be 
associated with elevated right and left ventricular filling pressures, similar to 
another common symptom of heart failure which is orthopnoea (shortness of 
breath while in the supine position). (27-29) It has been hypothesised that this 
                                         
1 A weighted Kappa adjusts for the chance agreement and can range from -1 (no agreement) to +1 
(complete agreement) with 0 indicating agreement due to chance alone.  
23. Fleiss JL, Cohen J. The Equivalence of Weighted Kappa and the Intraclass Correlation 
Coefficient as Measures of Reliability. Educational and Psychological Measurement. 
1973;33(3):613-9. 
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symptom of bendopnea could be associated with worse outcomes in patients 
with heart failure. 
1.3 Classification of heart failure 
Traditionally, heart failure has been described on the basis of left ventricular 
ejection fraction, which is the end-diastolic volume minus the end-systolic 
volume (also known as stroke volume) divided by the end-diastolic volume. This 
characterisation of heart failure is commonly used in clinical trials as 
inclusion/exclusion criteria; and classifies patients as having heart failure with 
reduced ejection fraction (commonly abbreviated as HF-REF) with a traditional 
cut-off point at ≤35% (>50% is considered normal) and heart failure with a 
preserved ejection fraction (abbreviated as HF-PEF) with a cut-off point at >45-
50%. (5) The above is due to the fact that historically the major heart failure 
trials where effective therapies have been identified mainly enrolled patients 
with a LVEF ≤ 35% (30-37), additionally patients with LVEF≤35% have been shown 
to have shorter survival times when compared to those patients with LVEF >35% 
(38-40) and benefit the most from an implantable cardioverter defibrillator 
(again due to their high risk of death). (38) It is important to note that these are 
the criteria used by the European Society of the Cardiology, although other cut-
off points and criteria have been proposed and are used in other parts of the 
world. (41-43) 
Another way of classifying heart failure involves symptoms using NYHA class and 
is typically used to identify patients who would benefit from therapy. 
A further approach to classifying patients with heart failure relates to the time-
course of the disease, where patients who have had heart failure for some time 
are referred to as having chronic heart failure. Patients with chronic heart 
failure whose symptoms have remained largely unchanged for at least 30 days 
are classified as stable. If such a patient would worsen, then he or she would be 
considered to have a decompensated chronic heart failure; if this deterioration 
should happen suddenly, then the patient would be considered to have acute-
decompensated heart failure. (44, 45) 
Congestive heart failure is a historical term that is falling into disuse although it 
is sometimes still employed in the United States to describe patients with a 
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diagnosis of heart failure and evidence of fluid retention or congestion. This is 
often determined by an elevated jugular venous pulsation, which is estimated by 
distension of the jugular veins with the patient sitting at 45°. This sign 
correlates to with elevated pulmonary artery occlusion pressure. (46) 
Congestive heart failures merits immediate medical attention. 
1.4 Treatment in heart failure 
The aims of treatment in patients with heart failure revolve around relieving 
symptoms and signs, preventing hospitalisation and reducing mortality. (5) 
Although most clinical trials focus on the latter, the relief of symptoms that 
leads to an improvement in quality of life and increase in functional capacity is 
of paramount importance to patients and effective treatment that would 
improve mortality and hospitalisation should also impact signs and symptoms. 
(47) 
There are three pivotal drugs in the treatment of heart failure, as they have 
been shown to modify the course of systolic heart failure. These are: an 
angiotensin converting enzyme inhibitor (ACE inhibitor)-or an angiotensin II 
receptor blocker, a beta-blocker and a mineralocorticoid receptor antagonist. 
They are usually combined with a diuretic to alleviate symptoms of congestion. 
(4, 5) 
Recently, a new drug has been identified that has shown to reduce risk of death 
and hospitalisation due to heart failure. This angiotensin-neprilysin inhibitor 
called LCZ696 was compared to enalapril in a double-blind multinational trial 
that was stopped early because the boundary for an overwhelming benefit had 
been crossed. (3) This drug was approved for marketing by the FDA (Food and 
Drug Administration in the US) in July 2015. 
1.5 Epidemiology of heart failure 
1.5.1 Prevalence 
Heart failure is a major and devastating health problem that impacts patients 
and healthcare systems all over the world. It was estimated in 2010 that 
approximately 900,000 people in the UK have heart failure;(48) with around 1-2% 
in the western world (49), and greater than 10% prevalence in the elderly (≥70 
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years of age). A more recent US study reports a prevalence of 2.2% (95%CI 1.6-
2.8%), increasing to 8.4% in patients 75 years or older. (50) The Rotterdam 
study, a large population based cohort from the Netherlands estimated in 2004 
that the prevalence of heart failure was 0.9% in those aged 55-65 increasing to 
over 17% in those aged ≥85. (51) The British Heart Foundation estimates that 
about 1-2% of the population in the UK is affected by heart failure (52) and more 
than 23-26 million people worldwide have the disease (45, 53) with prevalence 
rising.  
Although the incidence of heart failure seems to be stabilising (see section 
1.5.2), the prevalence continues to rise (54, 55), probably due to an increased 
survival associated with better recognition and treatment of the disease (56, 
57). The most common underlying aetiology of heart failure is coronary heart 
disease, and the improved survival rates for myocardial infarction (58) leads to 
an aging population which could largely be driving the increasing prevalence of 
heart failure. 
1.5.2 Incidence 
The annual incidence in the UK is about 1.85/1000 population (52), rising to 11.6 
per 1000 population per year in the elderly (over 85 years of age) with 
approximately 60,000 new cases each year (59, 60); although there is less 
information on incidence than there is on prevalence. The Rotterdam study 
group report an incidence rate of 14.4/1000 (95% CI 13.4-15.5) person-years. 
(51) The Framingham heart study (61) provides insight on the incidence of heart 
failure over a 34 year follow up period in the United States of America. They 
reported an annual incidence 2 new cases/1000 in persons aged 45–54 years 
increasing to 40 new cases/1000 in men aged 85–94 years. The incidence is 
higher in men than in women, independent of age. (51, 60) 
1.5.3 Costs of heart failure 
Heart failure is a very expensive problem. It has been estimated that heart 
failure’s direct costs can range anywhere from €26 to €70 (in one million € per 
one million population) (62) and that it accounts for 1-2% of total healthcare 
costs in developed countries. (56) In the UK, heart failure accounts for 1 million 
inpatient beds per year and 5% of all emergency medical admissions to hospital 
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per year, and it is estimated that the total annual cost of heart failure to the 
NHS is about 2% of the total budget (with approximately 70% of this total due to 
the costs of hospitalisation). (63, 64) According to the CDC (Centers for Disease 
Control and prevention) in the United States of America it is estimated that the 
costs derived from heart failure are around $32 billion (about £20 billion) per 
year. (65) 
1.5.4 Prognosis of heart failure 
Thanks to the implementation of evidence-based medicine provided by large 
clinical trials, treatment for heart failure has greatly improved in the past 
decades, leading to a reduction in mortality and increasing prevalence. It was 
estimated in the year 2000 that survival probability for heart failure was 50% and 
10% at 5 and 10 years respectively and for patients with severe disease, more 
than half will die within a year (66, 67). Nonetheless, estimates for heart failure 
with reduced ejection fraction differ from those for heart failure with preserved 
ejection fraction. Patients with HF-PEF (it is estimated that about half the 
patients with heart failure have a preserved ejection fraction) seem to have a 
better prognosis than those with HF-REF. (68-70) 
1.6 Summary and rationale 
Heart failure is a highly prevalent, expensive, devastating, and complex clinical 
syndrome, characterised by evidence of cardiac dysfunction and typical 
symptoms like fatigue, dyspnoea, chest pain and ankle swelling. Signs include 
elevated jugular venous pressure and pulmonary crackles. (5) Symptoms in heart 
failure provide important insight on deteriorating status which in turn may affect 
both patients’ and clinicians’ decision for seeking/providing treatment. (71) 
However, they are subjective and difficult to assess. (5) Consequently, they are 
frequently underestimated and overlooked as an important factor related to 
quality of life, morbidity and prognosis in heart failure both by patients and 
doctors. (72-74) This is compounded by the fact that their identification relies 
mostly on self-reporting. (71, 75) 
Traditionally, it has been said that fatigue and dyspnoea are caused, 
respectively, by the inability of the heart to function as a pump leading to 
reduced oxygen supply to the muscle (fatigue) and fluid backlog due to the 
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requirement for increased left ventricular filling pressures to maintain cardiac 
output leading to pulmonary interstitial oedema (dyspnoea). (76-78) It is now 
well known that left ventricular function relates poorly to symptoms and still 
their cause remains unclear and little is known about their prevalence, severity 
and predictors.! (73, 76, 79-83) It has even been suggested that both symptoms 
might be different manifestations of the same pathophysiological process. (76, 
80, 84) However, in two separate studies each symptom has been shown to 
predict outcome independently of the other, suggesting they might be 
biologically distinct. (85, 86) 
As I mentioned in section 1.4 above, the main focus of clinical trials studying 
heart failure has been a reduction of mortality and hospitalisation, although 
improvement of symptoms is considered a therapeutic goal. If more studies show 
that independent symptoms (and change in symptom severity) are associated 
with outcome (not only NYHA class, as it does not distinguish between individual 
symptoms), then clinicians should be do more to investigate and record 
symptoms and identify red flags that might predict how symptoms will evolve.  
Given the importance of fatigue and dyspnoea in heart failure and the 
uncertainty surrounding them I have set out to determine which patient 
characteristics are associated with each of these symptoms and whether the 
variables related to fatigue and dyspnoea are similar or different.!Additionally, I 
will examine how these two symptoms (and their change over time) relate to 
outcomes.  
 
27 
 
2 Fatigue in heart failure 
Fatigue is a subjective symptom and is difficult to assess, it is distressing and 
persistent (87) and some argue that it might be underreported due to being 
attributed to aging (88, 89). Fatigue has a large impact on the quality of life of 
patients and its wide prevalence has led to an increasing interest in the study of 
fatigue in heart failure (90, 91), though prior studies have been small or failed to 
examine the relationship with outcomes. (71, 73, 91-102) 
The importance of fatigue as a marker of prognosis has not been fully studied. I 
will examine the factors associated with fatigue in HF and whether it predicts 
morbidity and mortality. 
2.1 Methods 
2.1.1 Search Strategies 
Electronic databases MEDLINE and EMBASE were searched (MEDLINE from 1946 to 
July week 1 2015; EMBASE 1996 to 2015 week 28), limited to human subjects and 
English language (for EMBASE additional limits were applied, excluding reviews 
and meta-analysis and limiting to adults). Relevant MeSH (Medical Subject 
Headings) terms were identified. Terms and keywords were combined according 
to the search criteria and to the requirements of the database. Hand searching 
the bibliographies of relevant studies identified no further publications. 
Heart failure was defined using MeSH terms “Heart Failure”, “Cardiomyopathy, 
Dilated”, “Ventricular Dysfunction”, and “Cardiac Output, Low” and the 
following keywords: heart failure; congestive heart; cardiac failure; heart 
decompensation; myocardial failure; paroxysmal dyspnoea; cardiac asthma; 
cardiac oedema; congestive heart failure; left sided heart failure; right sided 
heart failure; congestive cardiomyopathy; low cardiac output; left ventricular 
dysfunction; right ventricular dysfunction. 
Fatigue was defined using MeSH terms “Fatigue” and “Asthenia”, and the 
following keywords: asthenia, fatigue, exhaustion, muscle fatigue, tiredness and 
lassitude. 
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Search strategies and terms were discussed with and approved by the College 
Librarian for the School of Medicine (Ms Heather Worlledge). I screened titles 
and abstracts to identify relevant studies. All relevant publications with a focus 
on heart failure that looked at individual symptoms were included in this 
literature review. Detailed search strategies can be found in Appendix 1. 
2.2 Aims 
The aims of this review were to: 1) Identify the demographic characteristics 
associated with fatigue in patients with heart failure; 2) Determine whether 
fatigue (and change in fatigue over time) is associated with worse morbidity and 
mortality in patients with heart failure and 3) Determine if fatigue is associated 
with statin use and if treatment with co-enzyme Q10 plays a role in fatigue 
severity. A secondary aim was to identify literature describing the aetiology of 
fatigue in heart failure. 
2.3 Results 
1243 studies were identified in the MEDLINE (OVID) search and a further 1478 
were identified in EMBASE (OVID). 
2.3.1 Aetiology of fatigue 
Sixteen publications describing the aetiology of fatigue in heart failure were 
identified. Most of the publications are reviews looking at the possible 
mechanisms underlying the origin of symptoms on exertion in patients with heart 
failure. In 2005, Mann et al (103) published a review summarising advances in 
the study of heart failure, with a focus on therapeutic and including an overview 
of the origin of symptoms. Similarly, in 2010 Piepoli et al (104, 105) published a 
2-part review aiming to summarise the existing evidence for the origin of 
symptoms in heart failure with reduced ejection fraction. A further review was 
published by Witte and Clarke in 2007 (106) describing the possible mechanisms 
by which heart failure causes fatigue and dyspnoea. Generally, although the 
authors present a thorough and clear description of the aetiology of symptoms in 
heart failure, the summaries are largely descriptive and the authors fail to 
clearly state how the evidence was selected to be included in the review.  
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In 1994, a study was published by Carell et al (107) looking at the relationship 
between maximal exercise tolerance and resting radionuclide indexes of left 
ventricular systolic and diastolic function. It involved 64 patients with 
cardiomyopathy (ischemic or idiopathic) who underwent symptom-limited 
exercise testing with on-line measurement of oxygen consumption. Their results 
determined that resting left ventricular ejection fraction poorly predicts 
maximal exercise capacity, contradicting the perception of symptoms being 
caused by reduced pump function of the heart. 
Clarke et al (108) in 2005 published a detailed summary of the possible 
pathophysiological mechanisms underlying the origin of dyspnoea and fatigue on 
exertion in patients with heart failure; however, the authors fail to clearly 
define objectives and methodology in their paper. On the other hand, in 2008 
another group of investigator led by Bunny Pozehl (109) ran a pilot study with 23 
patients looking at the effect of a 24-week exercise training program on fatigue 
and dyspnoea in patients with heart failure with reduced ejection fraction; their 
results provide some support to the theory attributing symptoms to a build-up of 
metabolic products. Even though the study was very small, it seems to be robust 
and results analysed in an adequate manner (as per their methods section). 
In summary, the aetiology of fatigue in HF is unclear and numerous mechanisms 
have been proposed. (103-105) It has long been recognised that there is little 
relation between measures of haemodynamic function and exercise capacity 
(110), and the lack of relationship between left ventricular filling pressures and 
maximal oxygen uptake is well known (111, 112). It is now generally accepted 
that fatigue arises from decreased oxygen delivery to muscle due to an impaired 
pump function of the failing heart, which leads to a build-up of anaerobic 
metabolic products. (108, 109) Some approaches attribute the impaired muscle 
blood flow to persistent vasoconstriction and endothelial dysfunction, rather 
than to limited cardiac output. (76, 84, 107, 113) Other potential mechanisms 
include abnormalities in muscle metabolism, which limit their ability to utilize 
oxygen and a miss-match between energy requirement and energy production. 
(76, 90, 113, 114) Although the controversy persists, the theory that intrinsic 
muscle abnormalities are responsible for the exercise limitation in patients with 
heart failure (115) is gaining acceptance and is now commonly recognised as the 
main mechanism. (115-118) 
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It has been shown that there is evidence of a switch from aerobic to anaerobic 
metabolism in the skeletal muscle of patients with chronic heart failure, a 
reduced activity of oxidative enzymes, this together with muscle wasting-which 
has been recognised since the times of Hippocrates- and reduced blood flow 
probably secondary to alterations in vasomotor tone make up what is called the 
“muscle hypothesis” for the origin of symptoms in heart failure. (84, 113, 119-
121) 
2.3.2 Correlates of fatigue 
Thirty publications were identified in relation to the correlates of fatigue in 
heart failure. Four papers (75, 99, 122-124) were excluded because they did not 
distinguish between individual symptoms (i.e. did not discriminate between 
dyspnoea and fatigue) and 2 more (75, 108) due to them being reviews. 
Fatigue in HF has been associated with NYHA functional class in several studies 
(71, 93, 96, 100, 101, 125), however several other studies could not confirm this 
association (91, 95, 97, 98). The association between sex and fatigue in HF 
patients has had similar conflicting results with some authors finding that 
women report more fatigue than men (94, 100, 102) and other authors finding no 
association between the two. (92, 95, 96, 101) 
Except for one study by Smith et al. (100), fatigue and age have not been 
significantly correlated (95-97, 101, 102, 125). The authors who examined 6 
fatigue trajectories found that age equal or greater than 60 years was associated 
with a lower likelihood of being in group reporting a low exertion fatigue (OR 
0.35 p value=0.02; meaning that younger patients were more likely to be in the 
low exertion fatigue group). They chose to dichotomise age, leading to a 
substantial loss of information and potentially leading the reader to make 
incorrect assumptions as they fail to provide confidence intervals for these 
results which makes it difficult to assess the magnitude of the effect of age on 
fatigue.  
Depression, on the other hand, has been clearly identified as a predictor of 
fatigue in HF patients. (73, 93, 95, 97, 101, 125, 126) Depression was said to 
explain anywhere from 6.5% to 74% of the variance in fatigue in the cited 
studies. All these studies report exclusively the r-squared (it measures how close 
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the data are to the fitted regression line in a linear regression model), but 
authors fail to provide residual plots. While r-squared will provide an estimate of 
the strength of the relationship between the chosen model and the response 
variable, it does not provide a proper hypothesis test for said relationship. (127) 
It has also been stated that up to 30% of patients with heart failure also report 
depression, this data is derived from observation alone, providing no evidence 
on the statistical significance of the association. (128, 129)  
Other factors found to be associated with fatigue are: dyspnoea with a 
correlation coefficient of 0.30 in one study, and 0.45 in the other, both 
relatively weak correlations(130, 131); anaemia both studies reporting that 30% 
of the variance in fatigue was explained by a decreased haemoglobin level (one 
considered low haemoglobin ≤125 g/L while the other considered ≤11.0 mg/dl) 
(96, 97); symptom distress, or degree of discomfort associated with fatigue 
(measured by Swedish version of Symptom Distress Scale) with one study 
reporting a 39% of the variance in fatigue was explained by symptom distress 
while the other reported only 4% of the variance in fatigue was due to symptom 
distress (93, 95). 
Poor sleep quality (98, 125) has also been linked to fatigue, however both 
studies derived their conclusions from univariate analyses using a chi2 test; 
however, chi2 tests do not provide information about the strength of the 
relationship between the two variables, they are sensitive to small expected 
frequencies and are sensitive to sample size. 
Left ventricular ejection fraction (LVEF) has been inversely correlate to fatigue 
in patients with heart failure (lower ejection fraction is associated with higher 
fatigue), although only beta coefficients are reported for both studies (one 
reports a β-value of 0.14 and the other of -0.72; they fail to report individual R2 
values however) (101, 126). 
Others factors that have been associated with fatigue in patients with heart 
failure are: decreased exercise capacity (73, 100, 131); comorbidities such as 
hypertension (131) or diabetes mellitus (100); not having a biventricular 
pacemaker (126); use of beta-blockers (associated with chronic fatigue, not 
fatigue on exertion) (126) or psychotropic agents (100); type D personality (131); 
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quality of life (92); and finally marital status, with married patients reporting 
higher levels of fatigue (91). 
Although several studies have looked at the relationship between resting 
haemodynamic indices and exercise capacity in patients with heart failure (107, 
132-136), few studies have looked at objective haemodynamic findings and their 
association to individual symptoms (as opposed to exercise tolerance or overall 
NYHA class) (137, 138). Guglin et al found a weakly positive correlation between 
pulmonary artery pressures and fatigue as the main reason for stopping exercise 
training (137).  They also found that fatigue was inversely correlated to serum 
sodium, potassium and albumin. Correlations are linear associations between 
variables, meaning that as the average value of one variable changes, so does 
the average value of the other variable, and this association can be influenced 
or caused by other observed or unobserved variables. Although correlations are 
commonly used and relatively easy to interpret, a correlation does not tell us 
how the two variables are interacting, the do not indicate direction of 
interaction. Is fatigue decreasing as sodium increases or is sodium increasing as 
fatigue decreases? Correlation does not imply causation- a correlation merely 
tells us that the two variables are interacting. Lipkin et al found that fatigue was 
inversely correlated to maximal cardiac output during exercise (138). Again, the 
same problem arises, where correlation does not imply causation.  
Equally important as correlates of fatigue in heart failure are the markers that 
have been found to have no association to symptoms, such as NT-proBNP and 
improved haemodynamic measures (137, 139), lending support to the muscle 
hypothesis as an origin of symptoms in heart failure (described in section 2.3.1) 
Table 2-1 presents a summary of the publications I found to be relevant in 
identifying the correlates of fatigue in patients with heart failure. I present the 
objectives of each study, the number of patients included in each one, the 
method used to measure fatigue and the relevant findings. 
2.3.3 Prognostic value of fatigue 
Only 5 studies investigating the prognostic value of fatigue in heart failure 
patients were identified. The Carvedilol or Metoprolol European Trial (COMET) 
enrolled 3029 patients with HF. In a secondary analysis of COMET, fatigue, as 
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well as dyspnoea and orthopnoea, correlated significantly with mortality and 
hospitalisation due to worsening HF (worse fatigue associated with higher event 
rates). However, after performing multivariable Cox regression analysis 
(adjusted for the baseline characteristics of age, gender, NYHA class, duration of 
HF, aetiology of HF, previous myocardial infarction, coronary artery disease, 
angina, hypertension, diabetes; stroke, and concomitant medication) the 
authors found that only dyspnoea and not fatigue was associated with increased 
mortality. Fatigue remained a significant predictor for the development of 
worsening heart failure (RR 1.09 per unit increase of fatigue; 95% CI 1.02–1.17; P 
=0.02). (86) This study remains the most important one looking at the prognostic 
value of symptoms in heart failure as the model was adjusted for well-known 
prognostic factors (including NYHA class though they did not measure NT-
proBNP) and analysed a large number of patients, even though it is a secondary 
analysis, which deducts weight from their results. Additionally, the cohort was 
not very different from the patients studied in CORONA, which provides a solid 
base for performing further analyses in said cohort. 
Two more studies identified fatigue as a predictor of adverse events. (100, 126) 
The first examined fatigue as measured by the Dutch Exertion Fatigue Scale 
(DEFS) and identified six fatigue categories with the third level (moderate offset 
exertional fatigue with an observed mean DEFS score at baseline of 19.94) as the 
reference group. The study reported that compared the reference group 
mentioned above, the low exertion fatigue class was associated with lower all-
cause mortality (HR=0.12, 95% CI 0.02-0.93, p=0.04) and severe exertion fatigue 
class with greater all-cause mortality (HR2.59, 95% CI 1.09-6.19, p=0.03). (100) 
In another study, patients with high levels of fatigue on exertion had an 
approximately two fold increased risk of experiencing an adverse cardiac event 
such as cardiovascular hospital readmission or death (HR=1.78, 95% CI 1.18-2.68, 
P=0.006). (126) Importantly, these studies measure fatigue on exertion as 
opposed to chronic fatigue; fatigue on exertion has an acute onset, has a short 
duration and a short recovery period(140-142).   
Another small (n=61), a 9 months prospective study of older patients (mean age 
61 ± 15 years) identified anergia (defined as criterion-based syndrome based on 
7 questions) as an independent predictor of hospitalisation due to any cause 
(odds ratio of 7.7, 95% CI 1.43–41.56,p= 0.02) after a 3-month follow up period. 
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(143) From their methods section, although it is not completely clear it seems 
that the multivariate logistic regression looks at the prognostic significance of 
the presence of anergia in this cohort (with the outcome being hospitalisation or 
no hospitalisation), however the authors do not specify if they are referring to a 
lack of energy at baseline, or during follow up. Additionally, survival analysis 
would be more adequate than multivariate logistic regression when analysing the 
prognostic value of a symptom, and an outcome of hospitalisation due to heart 
failure, as opposed to hospitalisation due to any cause, would be more 
acceptable because such an outcome would address how fatigue is associated 
with heart failure as elderly patients can be hospitalised for a number of reasons 
which have nothing to do with their heart failure status. 
A further study by Chase et al analysed the reason for stopping cardiac exercise 
testing (fatigue vs. dyspnoea), investigating 183 patients with heart failure who 
were followed up for time to first cardiac-related event for a maximum of 2 years. 
They found that differences in event-free survival were significant between 
patients who had stopped due to dyspnoea and those who stopped due to fatigue, 
with a higher event rate in the dyspnoea group. Their results show that within the 
fatigue group, 84.6% were event free at 20 months (16 events in 104 patients), vs. 
68.4% in the dyspnoea group (25 events in 79 patients); log rank p value=0.02. 
(144) These results are derived from univariate analysis and do not look at the 
prognostic significance of individual symptoms, but rather a comparison between 
the two symptoms. Additionally, the authors looked at the reason for stopping 
exercise testing, which addresses a slightly different issue than fatigue (or 
symptoms) during daily living. 
2.3.4 Statin use/co-enzyme Q10 and fatigue 
I was able to find some references on the association between statin use and 
fatigue in patients with heart failure by hand searching the literature, as well as 
the association between co-enzyme Q10 and fatigue. I summarise my findings 
next.  
Although there is evidence of muscle related adverse events associated with 
treatment with high doses of simvastatin (145), and it is well known that the 
most common adverse events associated with statin use are muscle related (146, 
147), there is no convincing evidence that low dose statins impair muscle 
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function or exercise capacity. (148-152) One study by Golomb et al reported 
that, compared with placebo, 6 months treatment with a modest dose of 
simvastatin or pravastatin had an adverse effect on a cumulative measure of 
energy and fatigue. (153) 
HMG-CoA reductase inhibitors block the synthesis of co-enzyme Q10 which is 
recognized component of mitochondrial ATP production. (154) There has been 
much interest in the potential role of coenzyme Q10 as a therapeutic agent in 
heart failure. (155-157) It has even been proposed that treatment with 
ubiquinone (co-enzyme Q10) should be included in guidelines for congestive 
heart failure (158); however, few studies have looked at the association 
between statin use, co-enzyme Q10 levels and fatigue in patients with heart 
failure (159-161) and they have conflicting results. While two of the studies 
support the idea that supplementation with ubiquinone (co-enzyme Q10) is 
beneficial for symptom reduction in patients with heart failure (159, 161), these 
studies have been small (n=50 and 79) and the associations have been either 
weak (161) or the authors have failed to adequately analyze their data (i.e. 
presenting descriptive results without statistical testing of modeling). (159) One 
other study found no association between treatment with co-enzyme Q10 and 
exercise capacity in patients with congestive heart failure (160), although the 
authors did not look specifically at fatigue but rather exercise capacity. 
2.3.5 Discussion 
Although a number of studies have been published looking to identify predictors 
of fatigue in heart failure patients and fatigue as a prognostic tool, the results 
are conflicting. Most of the studies are small and underpowered to detect an 
association between fatigue and clinical outcomes and very few look at 
objective measures. The paper by Evangelista et al (73) is the most widely cited, 
and although it is well written with robust statistical analyses and includes 
thorough demographic and clinically relevant covariates, it has a small sample 
size and does not include information on potentially important laboratory values 
like NT-proBNP, electrolyte levels or thyroid hormone levels. Smith (99, 100, 
126, 131, 162, 163) and Falk (95, 96, 164, 165) are the two most prolific authors 
looking at the role of fatigue in patients with heart failure but their focus has 
mostly been on the impact of symptoms on quality of life and not on the 
correlates of fatigue or its prognostic value. Although all the publications 
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included in this review clearly state their objectives and methods, most of them 
rely on subjective data (i.e. quality of life, depression, social support or 
emotional distress) and are not supported by objective data (i.e. laboratory of 
haemodynamic measures). 
An association between younger age and worse health related quality of life 
(measured with the MLHFQ) in patients with heart failure has been documented; 
female sex was also an independent predictor or worse quality of life in this 
study. (166) It is also well known that depression and fatigue are closely linked. 
Having said this, it has been documented that both the prevalence and the 
incidence of major depression double after 70-85 years of age (167-169); 
however, an elderly person is slightly less likely than someone who is middle-
aged to report symptoms of depression. (170) This could mean that older age 
might influence how patients experience and report symptoms of heart failure, 
making them less likely to report them. In other words, depression could be 
confounding the association between age and fatigue. Moreover, cultural 
differences in the experience of symptoms have been documented (171, 172)  
Evidence supporting the concept that statins have a deleterious effect on fatigue 
in patients with heart failure is scarce. Similarly, the evidence-base supporting 
the benefit of treatment with co-enzyme Q10 on fatigue severity in patients 
with heart failure is weak. 
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Table 2-1 Evidence table for published literature relating to fatigue and heart failure 
Author 
Year of 
publication 
N Objectives Method Used to 
Measure Fatigue 
Factors Associated 
with Fatigue 
Lipkin  
1986 (138) 
25 To evaluate the response to exercise in patients with heart 
failure and determine what metabolic, haemodynamic and 
ventilator changes correlate to symptoms. 
Reason for stopping 
exercise test (fatigue 
vs. dyspnoea) 
Inversely related to 
maximal cardiac output 
during exercise. 
Friedman 
1995 (130) 
57 Examine the contribution of physical and psychological factors 
to the variance in fatigue. 
Cohen-Hoberman 
Inventory of Physical 
Symptoms. 
 
Shortness of breath 
Tiesinga 
 2001 (102) 
  
138 To test the sensitivity, specificity, and usefulness of the Dutch 
Fatigue Scale (DUFS), which is based on NANDA’s defining 
characteristics of fatigue. 
The Dutch Exertion 
Fatigue Scale 
 Women with heart 
failure report more 
fatigue than men 
Shah 
2002(139) 
201 Evaluate the association between symptoms and changes in 
hemodynamic variables on pulmonary-artery catheterization. 
 
Yale Dyspnoea-
Fatigue Index 
No correlation between 
reduction in filling 
pressures/ increase in 
cardiac contractility and 
symptoms 
Ekman  
2002 (94)  
158 Describe and compare the experience of fatigue in a group of 
elderly women and men with severe chronic heart failure. 
Fatigue Interview 
Schedule 
Women report more 
fatigue than men 
Falk 
2006 (96) 
93 Describe the fatigue experience and its relationship to 
haemoglobin (Hb) concentration and to evaluate its effect on 
health-related quality of life in a hospitalised CHF population. 
Multidimensional 
Fatigue Inventory 
Scale 
Lower Haemoglobin 
levels (<=125 g/L) 
Higher NYHA 
Smith  
2007 (131) 
136 To examine the role of clinical and psychological 
characteristics as predictors of fatigue in HF. 
 
Dutch Exertion 
Fatigue Scale 
 
Decreased exercise 
capacity, dyspnoea, 
hypertension, depressive 
symptoms, type-D 
personality, sleep 
problems 
Evangelista 
2008 (73) 
150 Determine the prevalence of fatigue and identify its 
demographic, clinical, and psychological correlates. 
Profile of Mood 
States-Fatigue 
Lower maximal 
workload, lower physical 
and emotional health 
scores, and depression 
Smith 2008 
(163) 
506 Examine the effect of the stage of ischemic heart disease and 
type-D personality on fatigue and depressive symptoms and 
whether the effect of type-D personality on these symptoms is 
moderated by ischemic heart disease stage. 
The Maastricht 
Questionnaire(173) 
Type-D personality is an 
independent predictor of 
fatigue. 
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Stephen 
2008 (91) 
53 
 
Describe fatigue and the relationships among fatigue intensity, 
self-reported functional status, and quality of life in older adults 
with stable heart failure. 
Profile of Mood States 
fatigue subscale 
  
Marital status-married 
  
Falk 
2009 (95) 
112 
  
Examine the association between fatigue, depression and 
symptom distress and to explore the relationships between 
individual symptoms and the dimensions of fatigue in patients 
with CHF. 
Multidimensional 
Fatigue Inventory 
Scale 
Increased Emotional and 
symptom distress 
Depression 
 
Fink 
2009 (97) 
  
 
87 Determine the psychometric properties of 2 fatigue 
questionnaires in patients with HF, compare fatigue in patients 
with HF to published scores of healthy adults and patients with 
cancer undergoing treatment, and identify the physiological 
and psychosocial correlates of fatigue in HF 
Fatigue Symptom 
Inventory (174) and 
the Fatigue subscale 
scores on the Profile 
of Mood States. 
Depressed mood, 
reduced physical 
functioning, lower 
haemoglobin (below 
11.0 mg/dL) 
Smith  
2009 (126) 
387 Examine the factors associated with changes in fatigue in 
chronic heart failure and determine their prognostic impact. 
  
Dutch Exertion 
Fatigue Scale 
 
Lower LVEF, not having 
a biventricular 
pacemaker, use of beta-
blockers, and cognitive 
affective depressive 
symptoms. 
Albert 
2010 (71) 
276 
 
Examine prevalence of signs and symptoms relative to 
demographics, care setting, and functional class. 
Self reported through 
checklist 
Higher NYHA 
Hospitalised patients 
report more fatigue 
Chen 
2010 (93) 
105 Examine the level of fatigue perceived by patients with heart 
failure and to explore the potential factors influencing fatigue. 
Piper fatigue scale 
(PFS) 
Higher NYHA class, 
increased symptomatic 
distress, depression, 
anxiety and appraisal 
support by health care 
providers (not family). 
Tang 
2010 (101) 
 
107 Examine the associations among age, gender, NYHA, EF, 
beta-blocker use, Haemoglobin, depression and fatigue in 
patients with HF and determine the contribution of 
physiological and psychological factors to the variance in HF 
patients’ fatigue. 
Fatigue Visual 
Analogue Scale 
Tang Fatigue Rating 
Scale 
Higher NYHA, 
depression and lower 
LVEF 
Smith 
2010 (100) 
310 To identify distinct trajectories of fatigue over a 12-month 
period and to examine their impact on mortality in chronic heart 
failure. 
The Dutch Exertion 
Fatigue Scale 
 
Female gender, older 
age, physical inactivity, 
diabetes mellitus, co-
morbidities, higher 
NYHA class, impaired 
exercise capacity, and 
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use psychotropic 
medication 
Austin 
2011 (92) 
200 Report on patterns and severity of fatigue in surviving patients 
in a 5-year heart failure programme. 
 
Question 13 of the 
Living with Heart 
Failure Questionnaire 
(University of 
Minnesota MLHF) 
Increased impairment in 
QoL measured with 
MLHF questionnaire. 
Bunevicius 
2012 
(175) 
83 Evaluate the possible associations of fatigue and exercise 
capacity with function of adrenal and thyroid axis in patients 
with coronary artery disease 
The Dutch Exertion 
Fatigue Scale 
 
Low thyroid hormone 
concentrations and low 
cortisol levels associated 
with fatigue 
Fink  
2012 (125) 
59 To examine the relationship among fatigue, cytokines and 
projected mortality and elucidate the biological and clinical 
correlates of fatigue  
Profile of Mood States 
fatigue subscale 
 
NYHA, depression, poor 
sleep quality 
Guglin 
2012(137) 
433 Evaluate if there is a correlation between haemodynamic, 
echocardiographic and laboratory data and presenting 
symptoms of heart failure 
4 point Likert scale Positive correlation to 
pulmonary artery 
pressures 
Redeker 
2012 (176) 
 
173 Evaluate nocturia severity and nocturia-related differences in 
sleep, daytime symptoms and functional performance among 
patients with stable HF. 
The global fatigue 
score of the 
Multidimensional 
Assessment of 
Fatigue scale (MAF) 
Presence of nocturia 
was associated with 
increased fatigue 
Riegel 
2012 
(177) 
280 Explore the correlates of fatigue in patients with HF as a 
secondary objective 
Items from the Kansas 
City Cardiomyopathy 
Questionnaire (15) 
 
Worse sleep quality 
score and worse 
functional class 
 
Comin-Colet 
2013(178) 
552 Evaluate the effect of iron deficiency and/or anaemia on 
health-related quality of life in patients with HF 
Living with Heart 
Failure Questionnaire 
(University of 
Minnesota MLHF) 
Iron deficiency was 
significantly associated 
with physical aspects of 
the questionnaire 
(including fatigue) 
Eckhardt 
2014 (179) 
102 Describe fatigue in patients with HF and determine if specific 
demographic, physiological or psychological variables were 
correlated to fatigue, and if fatigue is associated with health-
related quality of life. 
Fatigue Symptom 
inventory  
 
Depressive symptoms 
were the only predictors 
of fatigue 
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3 Dyspnoea in heart failure 
3.1 Search Strategies 
The electronic database MEDLINE was searched (from 1946 to July week 1 2015), 
limited to human subjects and English language. Relevant MeSH terms were 
identified. Terms and keywords were combined according to the search criteria 
and to the requirements of the database. Hand searching the bibliographies of 
relevant studies identified no further publications. 
Heart failure was defined in the same way as detailed in Chapter 2. 
Dyspnoea was defined using MeSH terms “Dyspnea”, “Dyspnoea”, “Paroxysmal 
Dyspnoea” and “Paroxysmal Dyspnea”, and the following keywords: dyspnea, 
dyspnoea, shortness of breath, breath shortness and breathlessness. 
Search strategies and terms were discussed with and approved by the College 
Librarian for the School of Medicine (Ms Heather Worlledge). I screened titles 
and abstracts to identify relevant studies. All relevant publications with a focus 
on heart failure that looked at individual symptoms were included in this 
literature review. Detailed search strategies can be found in Appendix 2. 
Search strategies described above were applied to EMBASE (OVID) and resulted in 
20803 additional potential publications. A preliminary scan of titles and 
abstracts of the first 3,000 publications proved unsuccessful in identifying 
additional relevant publications for the purpose of this literature review so the 
search was limited to MEDLINE for the final document. 
3.2 Aims 
The aims of this review were to: 1) Identify the demographic characteristics 
associated with dyspnoea in patients with heart failure; 2) Determine whether 
dyspnoea (and change in dyspnoea over time) is associated with worse morbidity 
and mortality in patients with heart failure. A secondary aim was to identify 
literature describing the aetiology of dyspnoea in heart failure. 
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3.3 Results 
3810 studies were identified in the MEDLINE (OVID) search. 
3.3.1 Aetiology of dyspnoea in heart failure 
Dyspnoea has been defined in a consensus statement by the American Thoracic 
Society as a “subjective experience of breathing discomfort that consists of 
qualitatively distinct sensations that vary in intensity”. (180, 181) It is a common 
and complex symptom that accompanies many disorders and diseases and is 
derived from multiple pathophysiological sources, rather than from a single one. 
(182) Although dyspnoea on exertion can be normal, it is considered pathological 
when it occurs with a level of activity that should usually be well tolerated. 
(183) 
Dyspnoea occurs when there is a mismatch between the feedback from the 
central respiratory centres and the efferent motor signals to respiratory 
muscles. (184-186) Traditionally, it was thought that symptoms were derived 
from haemodynamic changes in heart failure that lead to an increased left 
ventricular pressure to maintain cardiac output by the Frank-Starling principle, 
leading to stiff lungs or apparent alveolar fluid overload, but now it is well 
known that the degree of left ventricular dysfunction is not closely related to 
symptoms, a mechanism often referred to as the “central hypothesis” for the 
origin of symptoms. (81, 84, 113) The precise mechanisms of why heart failure 
causes dyspnoea are not thoroughly understood and it has become widely 
accepted that generalised changes in muscle bulk, metabolism, endurance, and 
blood flow may all contribute to the origin of dyspnoea. (106, 187)  
As mentioned in chapter 1, a new term of bendopnea has been introduced to 
describe dyspnoea when bending forward in patients with heart failure (26), and 
while orthopnoea has been best correlated to elevated left ventricular pressures 
(not dyspnoea on exertion) (188) so has bendopnea been associated with high 
PCWP supporting the concept that both symptoms have the same underlying 
pathophysiology. Orthopnoea, nocturnal paroxysmal dyspnoea and bendopnoea 
are more specific to heart failure, but are also less common than exertional 
dyspnoea. (5) The focus of my thesis is on dyspnoea on exertion. 
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The frequent coexistence of dyspnoea and fatigue and the weak association 
between dyspnoea relief and improvement of haemodynamic parameters support 
the notion that structural abnormalities of skeletal muscle may be involved in 
the generation of dyspnoea. 
3.3.2 Correlates of dyspnoea  
I identified 12 publications looking at the correlates of dyspnoea in patients with 
heart failure. Reviews, editorials and meta-analyses were not considered for this 
section, only studies that analysed individual symptoms in patients with heart 
failure with reduced ejection fraction were included. Three publications (27, 
137, 189) determined that dyspnoea was not associated or was weakly 
correlated to haemodynamic measures like pulmonary artery pressures or 
pulmonary capillary wedge pressures, while Solomonica et al (190) found that 
improved pulmonary capillary wedge pressure (OR 1.80, 95% CI 1.22-2.65) and 
mean pulmonary artery pressure (OR 2.98, 95% CI, 1.91-4.66) were associated 
with improvement of dyspnoea at rest. Other variables associated with dyspnoea 
relief are opioid use (191, 192), higher respiratory rate, higher haemoglobin 
levels, higher serum sodium levels and history of peripheral artery disease. (193, 
194) 
Several other studies looked at the relationship between pulmonary/respiratory 
function and dyspnoea. Bronchodilator use showed benefit in alleviating 
dyspnoea in patients with concomitant airway obstruction (Borg score 0.7 ± 1.2 
pre-bronchodilator use versus 0.9 ± 1.3, p = 0.002 post-bronchodilator use) 
(195); however, two earlier studies (196, 197) showed that dyspnoea had no 
association with spirometric measures or measures of airway obstruction. 
Inspiratory muscle training nonetheless proved beneficial in two small studies. 
(198, 199) Another factor which has shown to have inconclusive associations with 
dyspnoea is NT-proBNP level, where one research group (193) showed a 
correlation with dyspnoea while another failed to do so (200).  The paper that 
provides evidence for an association of dyspnoea with NT-proBNP levels report 
an increase of 5% in the odds of reporting relief in dyspnoea with a doubling of 
NT-proBNP levels (95% CI 1.01-1.08, p<0.01), which is rather counter-intuitive as 
one would assume that higher NT-proBNP levels represent a worse health status; 
the authors fail to provide an explanation or speculate as to the reasons for this 
finding. Although the confidence interval is narrow, and the p value is small, the 
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authors do not provide information on interactions, if any were performed. This 
finding could either be a spurious finding or could be influenced by confounding 
factors, like weight or renal function, which can affect NT-proBNP levels. 
Another possible explanation for this association between increased NT-proBNP 
levels and a higher likelihood of reporting symptom relief could be due the 
biological effects of natriuretic peptides, which promote diuresis, vasodilation 
and inhibition of renin and aldosterone secretion. (201)  
Table 3-1 presents a summary of the publications I found to be relevant in 
identifying the correlates of dyspnoea in patients with heart failure. I present 
the objectives of each study, the number of patients included in each one, the 
method used to measure dyspnoea and the relevant findings. 
3.3.3 Prognostic value of dyspnoea 
A secondary analysis from the PROTECT trial (Placebo-controlled Randomized 
Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients 
Hospitalized with Acute Decompensated Heart Failure and Volume Overload to 
Assess Treatment Effect on Congestion and Renal FuncTion)(202) which included 
1998 patients identified early dyspnoea relief (as defined by moderately or 
markedly better dyspnoea at both 24 and 48 hours from randomisation) as a 
significant independent predictor for lower mortality at both 14 and 30 days (HR 
at 14 days 0.28, 95% CI 0.15-0.50; HR 30 days 0.35, 95% CI 0.22-0.55). It is 
important to note that PROTECT included patients with dyspnoea at rest or 
minimal activity and looked at patients who were hospitalised for acute heart 
failure. 
As mentioned in section 2.3.3, in a secondary analysis of The Carvedilol or 
Metoprolol European Trial (COMET) dyspnoea correlated significantly with 
mortality (1.14 per unit increase in dyspnoea: 95% CI 1.04–1.26; p=0.01) and 
hospitalisation due to worsening HF (1.09 per unit increase in dyspnoea: 95% CI 
1.02–1.17; p=0.02). (86) 
Moser et al (203) hypothesised that patients who reported greater variability in 
their symptom severity would have more difficulty recognising worsening 
symptoms and would in consequence have worse outcome. In their study they 
followed 71 patients with heart failure and asked them to record their heart 
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failure symptoms daily for 30 days and were followed-up for an average of one 
year. They found that high variability in daily ratings of dyspnoea was associated 
with higher risk of the composite outcome of heart failure hospitalisation or 
death when compared to a stable symptom pattern (OR 4.09, 95% CI 1.16-14.39). 
The authors determined high or low symptom variability patterns by averaging 
the daily ratings and determining the standard deviation for each patient, 
subsequently classifying them. Nonetheless, the authors failed to adjust for 
average symptom severity, comparing only the groups who had some variation. 
The results would have been more robust if they could show that symptom 
variability was associated with outcome independently from average dyspnoea 
levels. 
In 2005, a very large retrospective cohort study (n=74,580) from the United 
States identified dyspnoea on exertion as an independently significant predictor 
for 30-day rehospitalisation, stating that this symptom was the primary clinical 
variable associated with rehospitalisation. (204) They report that having no 
dyspnoea was associated with a 45% lower risk of being re-hospitalised within 30 
days of the index hospitalisation when compared to having dyspnoea at rest (HR 
0.55, 95% CI 0.51-0.60). In this study, Madigan et al speculate that the dyspnoea 
patients reporting during home health-care visits could be influenced by both 
the disease process and deconditioning associated with inactivity. Although the 
authors identify the reason for rehospitalisation as cardiac related in 42% of the 
cases, they also report that 32% of the re-hospitalisations had a secondary 
diagnosis of COPD, which could contribute heavily to the sensation of dyspnoea. 
(8, 205) 
A small study (n=58) performed in Brazil by Weber et al identified higher 
baseline levels of dyspnoea (as self-reported with a 5-point Likert scale) to be 
independently associated with hospitalisation due to cardiovascular causes, even 
after adjusting for NYHA class and NT-proBNP. However, the authors fail to 
describe if and how adverse events (including hospitalisations) were 
adjudicated. Additionally, the sample was selected from a pre-transplant clinic, 
which might be more representative of a “sicker” population rather than the 
majority of heart failure patients. (206) 
A retrospective study including 134 individuals with heart failure by KM Anderson 
published in 2014 identified dyspnoea as a significant predictor for 60-day 
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hospital readmission. The author, however, fails to describe how dyspnoea was 
measured or if it was dyspnoea at rest or on exertion, simply stating that 
demographic data and patient history were obtained from medical records. (207) 
More recently, Mentz et al (208) performed analyses on an American registry for 
acute decompensated heart failure, a large cohort that they linked to Medicare 
files (48616 individuals). The authors identified dyspnoea at rest (on admission 
for acute heart failure) compared to dyspnoea with moderate activity as an 
independent predictor for increased 30-day mortality and HF readmission (all-
cause mortality HR 1.89, 95 % CI 1.60-2.24; HF readmission within 30 days HR 
1.35, 95% CI 1.14-1.59). The excluded patients who had no record of dyspnoea 
on admission or who reported no dyspnoea, effectively eliminating data on over 
23,000 subjects, they also excluded patients with an elective hospital admission.  
In late 2008, a study comparing fatigue vs. dyspnoea as the reason for stopping 
exercise testing in 271 patients with chronic heart failure found that there was 
no difference in adverse outcome (death) at 36 months follow-up when 
comparing the two symptoms (HR 1.02, 95% CI 0.63-1.64). The authors conclude 
that symptoms experienced by patients with chronic heart failure with no 
concomitant pulmonary disease during exercise testing do not provide additional 
prognostic information over other indicators such as NYHA class or peak oxygen 
consumption (209), although previous, larger studies have shown differently. For 
example, a study published in 2005 that analysed data from 17991 patients who 
underwent stress testing determined that dyspnoea was associated with a 
significant increase in the risk of death due to cardiac causes (HR 1.9, 95% CI 
1.5-2.4)(210). Another group of seemingly healthy males who underwent 
exercise testing that was followed-up for 26 years published in 2014 found that 
after adjusting for other important covariates (age, smoking, total cholesterol, 
systolic blood pressure, blood glucose and physical fitness), people stopping due 
to difficulty breathing had a 1.55 fold increase (95 % CI 1.10-2.18) in the risk of 
dying from coronary heart disease when compared to stopping due to fatigue. 
(211) Similarly, Chase et al found that patients who stopped exercise testing due 
to dyspnoea were more than 2 times more likely to have a cardiac related event 
than those who stopped due to fatigue (HR 2.1, 95% CI 1.1-4.0), sample size was 
183 men and women and follow-up time was 2 years. (144) 
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3.3.4 Discussion  
I found a very weak evidence base for correlates of dyspnoea in patients with 
heart failure. Most of the literature identified what is not associated with 
dyspnoea (i.e. haemodynamic measures, pulmonary function), which gets us one 
step closer to effectively identifying the pathophysiological process underlying 
dyspnoea, by eliminating potential mechanisms. Nevertheless, eliminating 
causes does not provide evidence of what is effectively responsible for dyspnoea 
in patients with heart failure and more importantly the potential role of 
dyspnoea as a predictor of outcome remains unclear. Few studies look at 
correlates of dyspnoea on exertion, most focus on variables associated with 
dyspnoea relief and few studies look at dyspnoea in a non-acute setting, which is 
the focus of this thesis. 
Although dyspnoea is recognised widely as a pivotal symptom of the disease, and 
is commonly associated with outcome, the pathophysiology underlying this 
complex symptom is still poorly understood. Additionally, most studies looking at 
the importance of dyspnoea as a predictor of outcome focus on acute heart 
failure in a hospital setting, while the majority of patients living with this 
devastating disease are ambulatory and live with exertional dyspnoea that limits 
their activities on a daily basis and has an important influence on their quality of 
life.  
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Table 3-1 Evidence table for published literature relating to dyspnoea and heart failure 
Author 
Year of 
publication 
N Objectives Method Used to 
Measure Dyspnoea 
Factors Associated 
with Dyspnoea 
Lipkin  
1986 (138) 
25 To evaluate the response to exercise in patients with heart 
failure and determine what metabolic, haemodynamic and 
ventilator changes correlate to symptoms. 
Reason for stopping 
exercise test (fatigue 
vs. dyspnea) 
Associated with a rapid 
rise in plasma lactate 
concentration and fall in 
arterial pH. 
 
Evans 
1996(196) 
37 Examine if airway obstruction and bronchial hyper-
responsiveness contribute to dyspnoea and reduce exercise 
capacity in patients with heart failure 
Borg score No relationship between 
measures of airway 
obstruction and 
dyspnoea on exertion  
Russell 
1998(189) 
71 Identify factors responsible for the symptom of dyspnoea in 
patients with heart failure 
10-point Likert scale No correlation with rest 
or exercise 
haemodynamic, 
spirometric or metabolic 
variables. 
Laoutaris 
2004(199) 
35 To investigate the effect of inspiratory muscle training on 
exertional dyspnoea in patients with chronic heart failure. 
Borg score Inspiratory muscle 
training for 10 weeks 
was associated with 
alleviated dyspnoea 
Witte 
2004(212) 
120 To examine the effect of aspirin on the ventilatory response 
to exercise in a group of patients with chronic heart failure 
10-pont Likert scale Aspirin had no effect on 
dyspnoea on exertion  
Drazner 
2008(27) 
194 Determine if estimated hemodynamics from history and 
physical examination reflect invasive measurements and 
predict outcomes in advanced heart failure. 
Data obtained from 
CRF where dyspnoea 
was recorded as: at 
rest, walking in a room 
or walking less than a 
block.  
Dyspnoea on exertion 
was not associated with 
hemodynamic 
measures. 
Bosnak-
Guclu 
2011(198) 
36 Investigate the effects of inspiratory muscle training on 
dyspnoea in heart failure patients 
Modified Medical 
Research council 
dyspnoea scale 
Inspiratory muscle 
training decreases the 
perception of dyspnoea 
Eckman 
2011(213) 
72 Investigate if lowering breathing rate with the help of a 
respiratory modulation device could improve symptoms in 
patients with chronic heart failure 
5-point Likert scale Device guided 
respiratory modulation 
did not improve 
symptoms compared to 
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those who only listened 
to music. 
Guglin  
2012(137) 
433 Investigate the haemodynamic, echocardiographic and 
laboratory correlations to various heart failure symptoms. 
Presence or absence 
of dyspnoea on 
admission, discharge 
and 3-month follow-
up. 
Weak correlation with 
haemodynamic 
measurements of 
pulmonary artery 
pressures during systole 
and diastole. Inverse 
relation to systemic 
systolic and diastolic 
pressures and right and 
left atrial size. Inversely 
correlated to serum 
creatinine, albumin, 
sodium, total bilirubin, 
haemobglobin and 
haematocrit. 
Minasian 
2012(195) 
116 Evaluate the effect of maximal bronchodilation with combined 
inhaled salbutamol and ipratropium bromide on pulmonary 
function and dyspnoea in patients with chronic heart failure. 
Borg dyspnoea score Bronchodilators were 
associated with 
improved dyspnoea. 
Gomutbutra 
2013 (191) 
115 
 
Describe the management of moderate-to-severe dyspnoea 
in palliative care patients 
Self reporting of 
moderate-to-severe 
dyspnoea on a four-
point categorical scale 
 
The combination of 
opioids and 
benzodiazepines was 
associated with an 
improvement 
Kociol 
2013(200) 
308 Investigate the relationship between markers of decongestion 
and dyspnoea relief in patients hospitalised for acute 
decompensated heart failure. 
Dyspnoea visual 
analogue scale 
Weight loss, fluid loss 
and NT-proBNP 
reductions were poorly 
correlated with 
dyspnoea relief. 
Mentz 
2013(193) 
7141 Examine the characteristics of acute HF patients associated 
with moderate or marked dyspnoea relief at 6 h following 
initiation of nesiritide. 
7-point Likert scale Higher respiratory rate 
age, lower sodium 
levels, presence of 
oedema on chest 
radiograph, higher NT-
proBNP, higher BNP, 
NYHA class I, higher 
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systolic blood pressure, 
lower BUN 
Oxberry 
2013(192) 
35 Assess the longer-term effect of oral opioids on dyspnoea 
due to CHF. 
0-10 numerical rating 
scale and modified 
Borg score 
Long term opioid use (3 
months) was associated 
with dyspnoea relief. 
Solomonica 
2013 (190) 
233 Examine the relationship between hemodynamic measures 
during treatment ant dyspnoea improvement. 
Dyspnoea at rest 
assessed with a self-
reported 7-point Likert 
scale. 
 
Improvement of PCWP 
and mean pulmonary 
artery pressure was 
associated with 
improvement of 
dyspnoea at rest. 
Pang 
2014 (214) 
524 Determine predictors of early dyspnoea improvement for 
three different commonly used scales in patients with acute 
heart failure. 
 
5-point Likert scale, 
10 cm visual analogue 
scale and 7-point 
relative Likert scale 
Peripheral vascular 
disease, longer 
dyspnoea onset time 
and having new onset 
heart failure was 
associated with 
dyspnoea improvement 
if using the 7-point Likert 
scale. 
Baseline dyspnoea was 
associated with 
dyspnoea improvement 
if measured with the 
visual analogue scale or 
the 5-point Likert scale. 
Mentz 
2015(208) 
48616 To describe the characteristics of patients hospitalized for 
acute HF according to dyspnoea severity and to examine 
associations among dyspnoea severity, outcomes and costs. 
Self reported 
dyspnoea on exertion 
as obtained from 
medical records 
Advanced chronic 
kidney disease and 
systolic blood pressure 
≥140 was associated 
with dyspnoea at rest 
vs. dyspnoea with 
moderate activity.  
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Aims and Objectives 
Aims 
Following the results of the literature review, the following aims were 
developed for this thesis: 
• Identify the factors associated with symptoms of fatigue and dyspnoea in 
heart failure patients. 
• Describe the relationship between these two symptoms of heart failure 
and cardiovascular outcomes. 
• Identify the baseline characteristics associated with change in symptoms 
over time. 
• Describe the relationship between change in symptoms and cardiovascular 
outcomes. 
The following objectives were formed from these overarching aims 
Objectives 
• To describe the prevalence and severity of fatigue and dyspnoea at time 
of randomisation in the Controlled Rosuvastatin Multinational Trial in 
Heart Failure (CORONA)  
• To describe the baseline characteristics of CORONA participants according 
to fatigue and dyspnoea severity at time of randomisation. 
• To determine which baseline characteristics are independently associated 
with symptom severity at time of randomisation in CORONA. 
• To examine how symptom severity at time of randomisation is 
independently associated with cardiovascular outcomes in CORONA. 
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• To determine which baseline characteristics are independently associated 
with change in symptom severity from randomisation to 6 months follow-
up in CORONA. 
• To determine in CORONA whether change in symptom severity from 
randomisation to 6 months follow-up is associated with cardiovascular 
outcomes after 6 months. 
• Study any impact that statin use has on symptom severity over time in the 
CORONA population. 
• To describe the prevalence fatigue and dyspnoea on effort at time of 
randomisation in the Dual angiotensin receptor and neprilysin inhibition as 
an alternative to angiotensin-converting enzyme inhibition in patients 
with chronic systolic heart failure: rationale for and design of the 
Prospective comparison of ARNI with ACEI to Determine Impact on Global 
Mortality and morbidity in Heart Failure trial (PARDIGM-HF). 
• To describe the baseline characteristics of PARDIGM-HF participants 
according to presence of fatigue and dyspnoea on effort at time of 
randomisation. 
• To determine which baseline characteristics are independently associated 
with symptom presence at time of randomisation in PARADIGM-HF. 
• Examine how the presence of symptoms on effort at time of 
randomisation is independently associated with cardiovascular outcomes 
in PARADIGM-HF. 
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4 Methods 
4.1  Data Source  
The Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) was a 
multicentre, randomised, double-blind, placebo-controlled study which enrolled 
a total of 5011 patients aged ≥ 60 years with symptomatic (NYHA class II-IV), 
systolic (LVEF ≤ 40% but no more than 35% in patients with NYHA class II) heart 
failure. Patients were randomised to receive 10 mg of rosuvastatin or matching 
placebo once daily. 
The exclusion criteria included: previous statin-induced myopathy or 
hypersensitivity reaction; decompensated heart failure or a need for inotropic 
therapy; myocardial infarction within the past 6 months; unstable angina or 
stroke within the past 3 months; percutaneous coronary intervention (PCI), 
coronary-artery bypass grafting, or the implantation of a cardioverter– 
defibrillator or biventricular pacemaker within the past 3 months or a planned 
implantation of such a device; previous or planned heart transplantation; 
clinically significant, uncorrected primary valvular heart disease or a 
malfunctioning prosthetic valve; hypertrophic cardiomyopathy; acute 
endomyocarditis or myocarditis, pericardial disease, or systemic disease (e.g., 
amyloidosis); acute or chronic liver disease; levels of alanine aminotransferase 
or thyrotropin of more than 2 times the upper limit of the normal range; a serum 
creatinine level of more than 2.5 mg per decilitre (221 µmol per litre); chronic 
muscle disease or an unexplained creatine kinase level of more than 2.5 times 
the upper limit of the normal range; previous treatment with cyclosporine; any 
other condition that would substantially reduce life expectancy or limit 
compliance with the protocol; or the receipt of less than 80% of dispensed 
placebo tablets during the run-in period. (1, 2) 
The ethics committee at each of the participating hospitals approved the trial, 
and patients provided written informed consent. The primary composite 
outcome was death from cardiovascular causes, nonfatal myocardial infarction, 
or nonfatal stroke. The median follow up was 32.8 months. Secondary outcomes 
included death from any cause, any coronary event, death from cardiovascular 
causes, and the number of hospitalisations. Compared with placebo, rosuvastatin 
did not reduce the primary outcome of composite of death from cardiovascular 
53 
 
causes, nonfatal myocardial infarction, and nonfatal stroke, analysed according 
to the time to the first event (HR 0.92; 95% CI 0.83 to 1.02; P = 0.12) or death 
from any cause (HR 0.95 in the rosuvastatin group 95% CI, 0.86 to 1.05; P=0.31). 
(2) 
Symptoms were measured at baseline (randomisation visit), 6 weeks after 
randomisation, and 3 monthly thereafter in this trial population (1) Investigators 
were asked to evaluate symptoms using the following statement: “State 
symptoms during the past few days. Tick lowest level of physical activity causing 
symptoms”.  
Fatigue “during the past few days” was measured using a five-point exertion 
scale (0 none, 1 heavy exertion, 2 moderate exertion, 3 slight exertion, 4 rest), 
recorded by the investigator. Dyspnoea “during the past few days” was 
measured using a four-point exertion scale (1 heavy exertion, 2 moderate 
exertion, 3 slight exertion, 4 rest); a four- rather than five-point scale was used 
for dyspnoea because the presence of dyspnoea at baseline was an inclusion 
criterion for CORONA. The questionnaire for symptom severity was developed for 
the Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure 
(MERIT-HF)(31) and later used for CORONA.  
The scale used in CORONA to measure symptom severity is not validated for 
heart failure, although simple Likert scales are commonly used to measure 
symptoms in a wide spectrum of diseases. For this reason I will look at the 
relationship between NYHA class and symptom severity at baseline as an early 
step in my analyses. 
The focus of my analyses in CORONA will be on patients with LVEF ≤35% (n=3830) 
because patients with a LVEF between 35% and 40% had to be in NYHA class III or 
IV (i.e. could not be in NYHA class II). By excluding patients with LVEF>35% I 
avoid NYHA class acting as a surrogate for LVEF, hence I am able to include both 
of them in the multivariate model. 
Additionally, I will examine symptoms on effort in The Prospective comparison of 
ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart 
Failure trial (PARADIGM-HF). PARADIGM-HF was a large, multicentre, 
randomised, double blind, parallel group, active-controlled, two-arm, event-
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driven trial which compared LCZ696 and enalapril in patients with chronic 
symptomatic heart failure with reduced ejection fraction published in 2014. (3) 
The design and inclusion/exclusion criteria for the PARADIGM-HF trial have been 
described in detail elsewhere. (3, 215-217) Briefly, patients had to be consenting 
adults with symptomatic heart failure (NYHA class II-IV) and LVEF≤40%. If there 
was a heart failure hospitalisation in the prior year, then BNP should be above or 
equal to 100 pg/mL or NT-proBNP≥400 pg/ml; if there was no history of 
hospitalisation due to worsening heart failure, then BNP had to be greater or 
equal to 150pg/mL or NT-proBNP≥600 pg/mL. Patients had to be on ACE-
inhibitor or ARB therapy with a stable dose for the prior 4 weeks to screening 
equivalent to enalapril ≥10mg/day. They also had to be on a beta-blocker with a 
stable dose for the prior 4 weeks. Exclusion criteria included symptomatic 
hypotension, systolic blood pressure less than 100 mmHg at screening or <95 at 
randomisation, eGFR<30 mL/min/1.73 m2, reduction in eFGR>35% from screening 
to randomisation, potassium >5.2 mmol/L at screening or >5.4 mmol/L at 
randomisation, history of angioedema, or a history of unacceptable side effects 
with ACE-inhibitors or ARBs.  
PARADIGM-HF had a single-blind run-in period where all patients were treated 
with enalapril 10 mg PO BID for two weeks then held for a day, then they were 
treated with an angiotensin receptor neprilysin inhibitor (ARNI) at 100 mg PO BID 
then 200 mg PO BID for 4-6 weeks. 8399 patients were randomised to either ARNI 
LCZ696 (sacubitril/valsartan) 200 mg PO BID or enalapril 10 mg PO BID (the goal 
dose from the Effect of Enalapril on Survival in Patients with Reduced Left 
Ventricular Ejection Fractions and Congestive Heart Failure trial [SOLVD]). Doses 
were adjusted for tolerability. Patients were followed-up every 2-8 weeks the 
first 4 months and then every 4 months.  
Median follow-up was of 27 months; the trial was stopped following a positive 
interval efficacy analysis. The ARNI group had a reduction in the primary 
outcome of CV mortality or HF hospitalisation (21.8% vs. 26.5%; NNT 21) as well 
as each of the individual components. Additionally, the ARNI group had a 
significant reduction in all-cause mortality (17.0% vs. 19.8%; NNT 36). (3) 
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The Ethics Committee of each of the 1043 participating institutions (in 47 
countries) approved the protocol, and all patients gave written, informed 
consent. 
Dyspnoea and fatigue on effort in PARADIGM-HF were recorded in every visit as 
“present” or “absent”. I will analyse symptoms at randomisation. 
4.2 Statistical Analyses 
Data were analysed in several ways to comply with the objectives of this thesis. I 
examined prevalence and severity of fatigue and dyspnoea by using traditional 
descriptive statistics. I also analysed baseline characteristics (at randomisation 
visit) according to fatigue and dyspnoea severity or presence/absence of 
symptoms, reporting means and standard deviations for continuous variables 
(medians and interquartile ranges for variables that were not normally 
distributed) and percentages for categorical variables and comparing across 
symptom groups by running a test for trend or chi2 to obtain a p value. 
A logarithmic transformation of NT-proBNP was made for CORONA, as values 
tend to have a very wide range (going from single digits to thousands), 
additionally such a transformation will be consistent with comparable medical 
literature and ease interpretation. For PARADIGM-HF, continuous variables were 
dichotomised to allow for non-linear relationships with outcomes. 
Given the possibility of an issue with co-linearity between NYHA class and 
symptom severity, a Spearman’s rank correlation coefficient (218) was 
calculated to investigate if both variables (NYHA class and symptom severity) 
could be included in multivariable analyses. For fatigue, the correlation 
coefficient was of 0.54 and for dyspnoea it was 0.65, both showing a moderate 
positive correlation (219), but not sufficient to warrant exclusion of NYHA class 
from the multivariable model. The stronger positive correlation between NYHA 
and dyspnoea than between NYHA class and fatigue could be a reflection of how 
NYHA class is assigned by clinicians, where there seems to be a tendency to 
interrogate (and assign functional class based on this) more about dyspnoea than 
other symptoms.  
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For CORONA, I then used ordered logistic regression (220) to examine which 
baseline characteristics were independently associated with symptom severity at 
baseline. Ordered logistic regression and the assumptions underlying it are 
described in detail later in this chapter. 
I also looked at how symptoms are related to the risk of various events using Cox 
proportional hazards regression (221). I later examined in CORONA change in 
symptom severity from baseline to the 6-month visit, classifying patients as 
showing a decrease (reduction in score), an increase (an increase in score) or no 
change (unchanged score) in symptoms and analysed the relationship between 
change in symptoms and subsequent clinical outcomes using Cox regression. 
Finally. I examined the effect of a rosuvastatin treatment for six months on 
symptom severity in CORONA. 
A more detailed description of the method employed will be given in each 
relevant results section. 
In all analyses from CORONA, Group 1 (i.e. no/slight symptoms on exertion) was 
used as the reference group for the symptom groups. In PARADIGM-HF, no 
symptoms on effort is the reference group. 
Unless stated otherwise, analyses were performed on a complete case scenario 
where only patients with complete observations for all variables were included 
in the analyses. Patients with missing observations were excluded for the main 
analyses; however to address the issue of missing data I will report on analyses 
based on averaging across 10 imputed data sets (following the multiple 
imputation technique). The rationale and process of multiple imputation is 
described in section 4.2.4 below.  
Additionally, I ran all the analyses on the entire cohort from CORONA (i.e. 
patients with the entire spectrum of LVEF; n=5011). Results for the sensitivity 
analyses on the entire spectrum of LVEF and imputed data will be presented 
separately in Appendix 5. 
All analyses were carried out using Stata (version 12 or 14 Stata Corporation, 
College Station, Texas, USA). P values are two tailed and a significance level of 
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1% was used (p ≤ 0.01). 95% confidence intervals were calculated. Interpretation 
of the results is based on both p values and confidence intervals and their 
relationship and whether they are consistent with available literature. 
4.2.1 Ordered logistic regression 
4.2.1.1 Introduction to the proportional odds model 
I will analyse the association between baseline characteristics and symptom 
severity at randomisation visit. Symptom severity was recorded using a Likert 
scale, which graded symptom severity in an ordered fashion (see section 4.1). 
The outcome of interest (symptom severity) is, strictly speaking, a categorical 
variable, so some type of logistic regression would be in order for such purposes. 
When examining the dependence of an outcome variable on one or more 
independent variables, the scale of measurement of the response variable 
usually determines the method. (222, 223) This scale can be nominal (yes/no; 
cause of death), ordinal (with specific ranking) or interval (includes both ranking 
and distance between intervals). (223, 224) Standard logistic regression is 
applicable only to binary response variables (yes/no);(222, 224) and multinomial 
logistic regression -although adequate for analysing a polytomous outcome 
variable- would ignore the ranking of response variable. (222) A number of 
variations of logistic/multinomial regression models have been developed for 
analysing ordinal response variables, any such model is called an ordered 
regression model. (220) There are several ordinal logistic regression models, the 
most popular of them is the constrained cumulative logit model called 
“proportional odds model” (POM). (224, 225) The choice between models can be 
made on empirical grounds, dependent on model fit. (220) I have chosen the 
POM for the same reason for which it is most commonly used in medical 
literature; it allows for the effect of a covariate on the response variable to be 
quantified by a single regression coefficient, thus allowing a single odds ratio to 
be calculated, simplifying the interpretation and presentation of results. (224, 
225) 
The POM makes assumptions about the nature of the relationship between the 
response variable and the prognostic factors. If the data do not fulfil the 
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assumptions, the results of a regression applied to them can be misleading or 
have no meaning at all. (222, 224, 225) 
The following sections will focus on the logic behind the proportional odds model 
and the assumptions linked to it.  
4.2.1.2 Proportional odds model 
To be able to extend the logistic regression model to allow for ordinal response 
variables instead of binary response variables, modelling of cumulative logits is 
common. For example, when the outcomes of Y are ordinal and are assigned the 
values 0,1,……,k, cumulative probabilities can be defined by  
Equation 1 Cumulative probabilities 
Cij=Pr(Y≥j|Xi), i=1,….,n, j=1,….,k, 
allowing a logistic model to be written as  
Equation 2 Proportional odds model ln !!"!!!!" = α! + X!!!, i=1,….,n, j=1,….,k, 
where α1>α2>…>αk. j indexes the k possible cumulative probabilities obtained 
from using k cut-offs to dichotomise Y. The regression coefficient β1 for the lth 
explanatory variable X1 is the log-odds ratio for the Y by Xl association, 
controlling for the remaining explanatory variables. Since β1 does not depend on 
j, the model assumes that the relationship between Xl and a dichotomised Y does 
not depend on j, the point at which the dichotomisation is made. This 
assumption of identical odds ratios across the k cut-offs is called the 
proportional odds assumption. (224, 226) 
4.2.1.3 Proportional odds assumption 
This assumption states that the relationship between each pair of outcome 
groups is the same. That is, the coefficients that describe the relationship 
between the lowest versus all higher categories of the dependant variable are 
the same as the coefficients for the next lowest category versus all higher 
categories. In other words, the correlation between an independent variable and 
a dependent variable does not change for the categories in the dependent 
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variable, and the parameter estimations do not change for different cut-off 
points. The fulfilment of this assumption allows for a single coefficient to 
present results. If this were not the case, one would need different sets of 
coefficients to describe the relationship between each pair of outcome groups. 
(220, 224, 226) 
If the data fail to satisfy the proportional odds assumption a valid approach is to 
analyse such data by fitting a partial proportional odds model (222, 226), which 
is an extension of the ordinal logistic regression models that allows non-
proportional odds for a subset of the explanatory variables. (226, 227) This will 
give a single coefficient for explanatory variables that fulfil the proportional 
odds assumption, regardless of the number levels in the outcome variable, and 
will allow separate coefficients for comparing different levels of the outcome 
variable for those explanatory variables that fail to fulfil the proportional odds 
assumption. In other words, an ordered logistic regression is fitted when 
assumptions are fulfilled, and a partial proportional odds regression is run when 
the proportional odds assumption is not fulfilled. 
The proportional odds model was used to model the effect of available baseline 
covariates and their effect on severity of symptoms at baseline. It is important 
to note that the purpose of my thesis is not to build a prognostic model for 
symptom severity, but to identify which baseline demographic and medical 
characteristics are associated with and would independently predict worse 
symptoms at baseline. This was done to try and identify if fatigue and dyspnoea 
have the same predictors and in this manner try to clarify if these two symptoms 
have the same origin. The adjusted analyses used a previously published 
CORONA risk-model for total mortality as this model has been developed for this 
specific trial population. (228) 
Proportional odds assumption was tested by fitting a partial proportional odds 
model and comparing coefficients and confidence intervals in the different 
models. (227) When the assumption was not met, separate odds ratios are 
reported for the relationship between each group of symptoms and the covariate 
of interest compared to the reference group. This was achieved by using a user-
written program in Stata that fits generalised ordered logit models for ordinal 
dependent variables (called ‘gologit2’) which allows three cases of the 
generalised model: the proportional odds model, the partial proportional odds 
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model and the logistic regression model. This program automatically identifies 
the partial proportional odds model that best fits the data when used in 
combination with the autofit option. (229) 
4.2.2 Cox Regression 
Cox regression is a commonly used method to analyse the survival experience of 
a cohort. It studies the time elapsing between two events, time is a numeric 
variable like any other but a specific feature of a time variable is that its 
observations may be censored. 
Survival analysis is preoccupied with following subjects over time and observing 
at which point in time they experience an event of interest. It is common that 
the study does not span long enough to observe the event for all subjects in the 
study, which could be due to several reasons, usually unrelated to the study. 
This is called administrative or right censoring and it means that the information 
is incomplete because the subject did not have an event during the time that 
the subject was part of the study. (230) 
 Typically, the effect of an intervention such as a new pharmacological 
compound that is thought to modify an outcome of interest is examined on a 
basis of time to outcome. I am interested in the association between a variable 
(in this case symptom severity at baseline) and an event of interest (e.g. heart 
failure hospitalisation). However, during follow up more than one type of event 
can occur. While one event is usually chosen as the event of interest, the 
occurrence of another event would prevent the occurrence of the event of 
interest (e.g. death prevents a subject experiencing heart failure 
hospitalisation). Survival analysis treats these competing events as censored 
observations and assumes independence of the time to event and the censoring 
distributions. One way to deal with the competing risks problem is to define a 
composite endpoint that includes a clinical outcome such as death. (221, 231). I 
analysed this cohort using traditional proportional hazards Cox regression and 
using composite outcomes. 
The assumptions underlying Cox regression are detailed below. 
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4.2.2.1 Linearity assumption 
As with all regression models, Cox regression considers a log-linear effect of 
numeric covariates (equivalent to proportional odds assumption mentioned 
above). This means that one unit's increase in a numeric covariate xj should have 
the same effect whatever the value of xj and whatever the values of the other 
covariates (if no interaction effects are included). (221) This assumption was 
assessed by categorising the continuous variables and estimating a separate 
effect for each group, then plotting the median for each group against it’s 
coefficient and assessing the line to see if I got a fairly linear trend for the 
estimates (see Appendix 3). Another valid approach to assess linearity would be 
to include a spline transformation or a quadratic transformation of the 
continuous variable and testing the null that the coefficients are equal to zero. I 
did this in cases where the plots and/or Wald test left doubt about the linearity 
assumption. 
4.2.2.2 Proportional hazards assumption 
The other assumption in Cox regression is the proportional hazards assumption. 
This means that the survival functions for two strata must have hazard functions 
that are proportional over time; in other words, the relative hazard must be 
constant. This assumption was assessed using Schoenfeld residuals by testing the 
null hypothesis of a zero slope in a generalised linear model. (232, 233) I also 
tested this assumption by building log-log plots and assessing if the plotted lines 
were reasonably parallel. 
I tested the prognostic value of each symptom relative to the composite 
outcome of cardiovascular death or hospital stay due to worsening HF, using Cox 
proportional hazard regression models. Cardiovascular death or hospital stay due 
to worsening HF rather than the pre-specified primary outcome of CORONA was 
used in the present analysis as it better reflects disease-specific morbidity and 
mortality related to HF (and the primary endpoint of CORONA was recommended 
by regulatory authorities to reflect the treatment intervention used [e.g. a 
statin]). (234, 235) 
As mentioned earlier, the adjusted analyses used a previously published CORONA 
risk-model for total mortality. (228) The prognostically significant variables in 
that model were: age, sex, NYHA class, LVEF, body mass index (BMI), systolic 
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blood pressure, heart rate, smoking, MI, CABG or PCI, aortic aneurysm, 
hypertension, diabetes, baseline atrial fibrillation/flutter (AF), stroke, 
intermittent claudication, pacemaker and ICD implantations, apoA-1, apoB, 
creatinine, alanine aminotransferase, creatine kinase, thyroid stimulating 
hormone, high-sensitivity C-reactive protein, and log NT-proBNP (228); with 
symptom level at baseline included. The model was run twice, once for 
dyspnoea and another time for fatigue to avoid collinearity issues between the 
two symptoms.  
Kaplan-Meier cumulative event curves are presented by symptom category and 
compared with log-rank tests. Similar analyses were carried out that examined 
the relationship between change in symptoms (baseline to 6 months) and 
subsequent clinical outcomes (from 6 months to the end of the study).  
A more detailed description of each component of the analyses will be given in 
relevant chapters. 
4.2.3 Multinomial logistic regression 
As stated in the aims and objectives, I am interested in identifying which 
baseline characteristics independently predict change in symptom severity over 
6 months. To achieve this, I will use multinomial logistic regression, which is an 
extension of logistic regression used when the dependent variable consists of 
several categories that are not ordinal, it is concerned with modelling the 
probabilities of different possible outcomes of a categorically distributed 
dependent variable. With this type of analysis, the log odds of the outcomes are 
modelled as a linear combination of the predictor variables. (236, 237) 
4.2.4 Multiple imputation 
Multiple imputation is a tool used to deal with missing data. Missing data refers 
to observations and measurements that should have been recorded but for some 
reason were not. This missing data may derive from an array of reasons, like 
dropouts, refusal to answer certain questions, error while measuring or 
collecting data, among others. 
Rubin described the missing data mechanism in 1976 when he and his colleagues 
defined the classification system that is still in use today.  These mechanisms 
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detailed below describe the relationship between measured variables and the 
probability of missing data (238-240): 
• Missing completely at random (MCAR), where the probability that data are 
missing does not depend observed or unobserved data. That is, the 
probability of being missing is the same for all cases. The missing data 
values can be considered a simple random sample from the original data 
set. An example would be if a laboratory sample was accidentally 
dropped. This is a strong assumption that is often unrealistic. 
• Missing at random (MAR), where the probability that data are missing 
depends on the values of the observed data, but does not depend on the 
values of the missing data. Under this assumption, the missing data values 
do not contain any additional information about the mechanism of missing 
data. For example, blood pressure would be missing at random if older 
individuals are more likely to have blood pressure recorded- and age is 
observed. This mechanism of missing data is more general and realistic 
and methods that deal with missing data usually start from this 
assumption. 
• Missing not at random (MNAR), where the probability that the data are 
missing may also depend on the values of the unobserved data. For 
example, people with high blood pressure are more like to have their 
blood pressure recorded than other individuals of the same age. This is 
the most common situation. 
The best practice would be to avoid missing data, but this is rarely possible. 
Commonly in medical literature analyses are run on complete case scenarios 
only, this however will lead to the loss of information in the incomplete cases. 
This approach will ignore any possible difference between the complete cases 
and the incomplete cases leading to a substantial reduction of effective sample 
size, which in turn will lead to a potential misinterpretation of the results form 
multivariate analyses. Additionally, complete case analyses makes the 
assumption that data are missing completely at random, which is often not the 
case. (238, 240)  
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Another approach to dealing with missing data is to consider some sort of 
imputation, or the practice of “filling in” missing data with plausible values like 
a mean or a regression coefficient. However, this should be done with caution; if 
one imputes an observed variable mean for the variable’s missing values, this 
would preserve the sample mean but would distort the covariance matrix. On 
the other hand, imputing predicted values from regression models tends to 
inflate observed correlations. More importantly, treating imputed data as if it 
were “real” in estimation and inference can lead to misleading test results and p 
values, since they fail to reflect the uncertainty due to the missing data.  
Multiple imputation replaces the missing value with two or more plausible values 
by generating M>1 copies of the data set where the missing data simulated 
according to a fixed imputation model. Each of the simulated complete data sets 
in then analysed using a chosen method (commonly regression) and the results 
are then combined. (241) 
To put it in other words, let’s assume that we have only two variables in a data 
set: x1 which is observed only in some units, and x2 which is observed for each 
unit. Multiple imputation will use the data from units where both x1 and x2 are 
observed to learn about the relationship between the two variables. Then, it will 
use this relationship to create M complete data sets by drawing the missing 
observations from (x1|x2). Finally, the results are pooled to run the chosen 
analyses. 
Multiple imputation will be valid under the assumption that data is MAR or 
MCAR. (240) 
The method I chose to impute the data with was using chained equations, which 
uses a sequence of univariate imputation methods with fully conditional 
specifications; that is, it includes all variables in the prediction except the one 
that is being imputed. In other words, it uses the already imputed data to 
predict the missing values, adding a small perturbation to each prediction to 
consider uncertainty surrounding said missing values, and then reruns the 
analyses using those same imputed data to predict other missing values. (242-
244) For this thesis, I created 10 data sets using linear regression if the missing 
value was from a continuous variable or logistic regression if the missing value 
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was from a binary variable. All missing observations were imputed. Results for 
analyses on imputed data are presented Appendix 4. 
66 
 
Results 
In the following chapters I will present results from analyses performed 
surrounding this thesis. I will first report findings from CORONA, including 
previously published results from visit prior to randomisation, followed by 
descriptive statistics for randomisation visit and results from multiple analyses 
performed on the CORONA cohort at this time point. I will then present results 
from PARADIGM-HF in the same manner as for CORONA.  
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5 Symptoms as predictors of outcome: visit prior 
to randomisation 
I have previously published results from analyses (85) looking at the association 
of symptoms at visit prior to randomisation (on average one month prior to 
randomisation) and outcomes. This time-point was chosen for these analyses 
because in CORONA, NT-proBNP was measured at the visit prior to 
randomisation.  In said published paper, I analysed how symptom severity 
related to NT-proBNP tertiles, and choosing the same analysis time point was 
paramount for this purpose. I present a summary of the relevant findings from 
the published paper next. 
5.1 Distribution of symptoms at visit 2 
All of the 3830 patients with LVEF≤35% had an observation for fatigue, 3641 
(95%) reported some level of fatigue on exertion, and most of them (86%) 
reported high symptom severity (from moderate exertion to symptoms at rest); 
1663 (43%) patients reported the highest symptom severity (group 3: fatigue on 
slight exertion or at rest). 
For dyspnoea 3528 patients (92%) reported dyspnoea from moderate exertion to 
dyspnoea at rest, and 48% (n=1843) reported the highest symptom severity with 
dyspnoea on slight exertion or at rest. Figure 5-1 
Figure 5-1 Distribution of symptoms at visit prior to randomisation 
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To achieve sufficient numbers in each severity class, patients were grouped into 
3 categories: fatigue score 0-1 (n= 535 [14%]), 2 (n=1,632 [43%]) and 3-4 (n= 1663 
[43%]); dyspnoea score 0/1 (n=292 [8%]), 2 (n=1,695 [44%]), and 3-4(n=1843 
[48%]). Figure 5-2 
Figure 5-2 Distribution of symptoms at visit 2 after grouping 
 
For the sake of practicality, I will only present now the results from multivariate 
analyses. Details of unadjusted results and baseline characteristics according to 
symptom severity at visit 2 can be found in published paper. (85) 
Briefly, after adjustment for other prognostically significant covariates, fatigue 
on slight exertion or rest was only predictive of heart hospitalisation when 
compared to no fatigue or fatigue on heavy exertion (HR 1.57, 95% CI 1.15-2.14), 
while dyspnoea on slight exertion or at rest was predictive of both 
cardiovascular death and heart failure hospitalisation (CV death: HR 1.80, 95% CI 
1.15-2.81; HF hospitalisation: HR 1.72, 95CI 1.12-2.62). Table 5-1 
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Table 5-1 Hazard ratio for symptom severity and clinical outcomes: Multivariable analysis on symptoms from visit 2 
! Fatigue! Dyspnoea!
! 2!vs.!1! 3!vs.!1! 2!vs.!1! 3!vs.!1!
! HR!(95%!CI)! P!value! HR!(95%!CI)! P!value! HR!(95%!CI)! P!value! HR!(95%!CI)! P!value!
Cardiovascular!
death!or!heart!
failure!
hospitalisation!
1.12!
(0.89,!1.41)!
0.34! 1.28!
(1.00,!1.64)!
0.05! 1.14!
(0.84,!1.55)!
0.41! 1.49!
(1.07,!2.08)!
0.02!
Cardiovascular!
death!
1.02!
(0.76,!1.36)!
0.92! 1.13!
(0.82,!1.54)!
0.46! 1.32!
(0.87,!2.02)!
0.19! 1.80!
(1.15,!2.81)!
0.01!
Heart!failure!
hospitalisation!
1.29!
(0.96,!1.74)!
0.10! 1.57!
(1.15,!2.14)!
0.01! 1.22!
(0.82,!1.82)!
0.32! 1.72!
(1.12,!2.62)!
0.01!
AllCcause!death! 1.06!
(0.82,!1.38)!
0.45! 1.17!
(0.89,!1.55)!
0.26! 1.37!
(0.96,!1.97)!
0.09! 1.60!
(1.08,!2.37)!
0.02!
Adjusted for: Age, sex, New York Heart Association, left ventricular ejection fraction, body mass index kg/m2, systolic blood pressure, heart rate, 
smoking, myocardial infarction, angina pectoris, coronary artery bypass graft, percutaneous coronary intervention, aortic aneurysm, hypertension, 
diabetes, baseline atrial fibrillation/flutter, stroke, intermittent claudication, pacemaker, implanted cardioverter defibrillator, apoA-1, apoB, creatinine, 
alanine aminotransferase, creatine kinase, triglycerides, C reactive protein, high density lipoproteins, low density lipoprotein, estimated glomerular 
filtration rate. 
CV = cardiovascular; HF= heart failure 
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5.2 Symptoms visit 2 vs. visit 3 
Because I wanted to analyse symptoms from randomisation visit for the main 
analysis on this thesis (as outcomes are considered from randomisation 
onwards), I examined how symptoms were different from visit 2 to visit 3. 
Briefly, a total of 3176 patients (83%) reported same level of fatigue at visit 2 
and visit 3. Of the 653 patients who reported different levels of fatigue in visit 2 
and 3, 291 (44.6%) report a decrease in fatigue while 362 (55.4%) report an 
increase. Table 5-2 
Table 5-2 Cross tabulation between fatigue visit 2 (published paper) and fatigue visit 3 
(thesis):  LVEF≤.35% 
Fatigue( Visit(3(
(Visit(2( 0( 1( 2( 3( 4( Total(
0(
145(
(3.8%)(
12(
(0.3%)(
20(
(1.0%)(
10(
(0.3%)(
2(
(0.1%)(
189(
(5%)(
1(
23(
(0.6%)(
250(
(6.5%)(
62(
(1.6%)(
10(
(0.3%)(
1(
(0.03%)(
346(
(9.0%)(
2(
30(
(0.8%)(
64(
(1.7%)(
1,389(
(36.3%)(
142(
(3.7%)(
7(
(0.2%)(
1,632(
(42.6%)(
3(
7(
(0.2%)(
18(
(0.5%)(
167(
(4.4%)(
1,310(
(34.2%)(
25(
(0.7%)(
1,527(
(39.9%)(
4(
3(
(0.1%)(
0(
(0.0%)(
9(
(0.2%)(
41(
(1.1%)(
82(
(2.1%)(
135(
(3.5%)(
Total(
208(
(5.4%)(
344(
(9.0%)(
1,647(
(43.0%)(
1,513(
(39.5%)(
117(
(3.1%)(
3,829(
(100%)(
 
There were 117 overall CV death/HF hospitalisation composite outcomes in the 
patients who report a decrease in fatigue over the course of one month, while 
there were 145 events in those who report an increase. There were overall 262 
composite primary outcomes in the patients that report different levels of 
fatigue between visits 2 and 3, 17% of the total 1568 composite events in 
patients with LVEF≤35%. 
For the other outcomes analysed, 152 had a CV death (961 total CV deaths in 
patients with LVEF≤35%), with 71 in the patients reporting decrease in fatigue 
and 81 in the group reporting an increase in fatigue. 182 had a hospitalisation 
due to worsening heart failure (out of 1040), with 76 being in the group 
reporting a decrease in symptom severity and 106 in those reporting an increase. 
209 patients with all cause death (out of 1205), with 93 of them being in the 
group reporting a decrease in fatigue and 116 in those reporting an increase in 
fatigue. Table 5-3 
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Table 5-3 Clinical outcomes according to change in fatigue severity from visit 2 to visit 3 
! Fatigue!
! Unchanged! Decrease! Increase!
! (n=3176)! (n=291)! (n=362)!
n!(%)! ( ( (
Cardiovascular(death(or(heart(failure(
hospitalisation(
448/858(
(41.1)(
41/76(
(40.2)(
39/106(
(40.1)(
Cardiovascular(death( 809(
(25.5)(
71(
(24.4)(
81(
(22.4)(
Heart(failure(hospitalisation( 858(
(27.0)(
76(
(26.1)(
106(
(29.3)(
AllIcause(death( 996(
(31.4)(
93(
(32.0)(
116(
(32.0)(
 
A total of 3299 patients (86.4%) reported the same level of dyspnoea at visit 2 
and visit 3. Of the 531 patients who reported different levels of dyspnoea in visit 
2 and 3, 204 (38.4%) reported a decrease in dyspnoea and 327 (61.6%) reported 
an increase in dyspnoea severity.  Table 5-4 
Table 5-4 Cross tabulation between dyspnoea visit 2 (published paper) and dyspnoea visit 3 
(thesis):  LVEF≤.35% 
Dyspnoea( Visit(3(
(Visit(2( 0( 1( 2( 3( 4( Total(
0(
1(
(0.03%)(
0(
(0%)(
0(
(0%)(
0(
(0%)(
0(
(0%)(
1(
(0.03%)(
1(
0(
(0.0%)(
238(
(6.2%)(
45(
(1.2%)(
7(
(0.2%)(
1(
(0.03%)(
291(
(7.6%)(
2(
0(
(0.0%)(
81(
(2.1%)(
1,482(
(38.7%)(
126(
(3.3%)(
6(
(0.2%)(
1,695(
(44.3%)(
3(
0(
(0.0%)(
18(
(0.5%)(
190(
(5.0%)(
1,516(
(39.6%)(
19(
(0.5%)(
1,743(
(45.5%)(
4(
0(
(0.0%)(
0(
(0.0%)(
5(
(0.1%)(
33(
(0.9%)(
62(
(1.6%)(
100(
(2.6%)(
Total(
1(
(0.03%)(
337(
(8.8%)(
1,722(
(45.0%)(
1,682(
(43.9%)(
88(
(2.3%)(
3,830(
(100%)(
 
Of those who reported an increase in dyspnoea severity from visit 2 to visit 3, 
141 a CV death/HF hospitalisation, 89 had a CV death, 96 had a heart failure 
hospitalisation and 110 had an all cause death during the course of the trial. 
Of the 204 patients who reported a decrease in dyspnoea severity from visit 2 to 
visit 3, 82 had a composite outcome of CV death/HF hospitalisation, 45 had a CV 
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death, 61 a hospitalisation due to worsening heart failure and 64 an all cause 
death during the course of the trial. Table 5-5 
Table 5-5 Clinical outcomes according to change in dyspnoea severity from visit 2 to visit 3 
! Dyspnoea!
! Unchanged! Decrease! Increase!
! (n=3299)! (n=204)! (n=327)!
n!(%)! ( ( (
Cardiovascular(death(or(heart(failure(
hospitalisation(
462/883(
(40.8)(
21/61(
(40.2)(
45/96(
(43.1)(
Cardiovascular(death( 827(
(25.1)(
45(
(22.1)(
89(
(27.2)(
Heart(failure(hospitalisation( 883(
(26.8)(
61(
(29.9)(
96(
(29.4)(
AllIcause(death( 1031(
(31.3)(
64(
(31.4)(
110(
(33.6)(
 
5.3 Summary of results and discussion 
Fatigue and dyspnoea were both strongly associated with the composite outcome 
of CV death or heart failure hospitalisation, an association that was maintained 
after adjusted for other prognostic variables including LVEF, NT-proBNP and 
NYHA class. Although after adjustment the association between fatigue and fatal 
outcomes (both CV death and all-cause mortality) was no longer statistically 
significant, the association with heart failure hospitalisation endured. Dyspnoea 
at visit prior to randomisation remained predictive of all outcomes in 
multivariate analyses. 
Symptoms between visit 2 and visit 3 differed substantially, with up to 17% of 
the patients reporting different levels of symptoms between the two visits which 
were only 1 month apart. Nonetheless, the proportion of patients experiencing 
adverse events was similar across the groups (Table 5-3 andTable 5-5). 
6 Descriptive statistics randomisation visit: 
CORONA 
In this chapter I will present baseline characteristics and summary statistics 
according to dyspnoea and fatigue severity in CORONA at randomisation visit. 
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6.1 Distribution of symptoms  
Of the 5011 patients randomised to CORONA, 5010 (99.98%) had some level 
dyspnoea on exertion at baseline (which was an inclusion criterion). It is possible 
that a mistake was made while recording dyspnoea, as this patient who reported 
no dyspnoea on exertion should not have been randomised. This patient was 
treated as having mild dyspnoea on exertion (Group 1). 5010 patients had an 
observation for fatigue on exertion at baseline.  
Data on the predictor variables included in the model were missing in 1% or less 
of patients except for NT-proBNP which was missing in 28% of the patients (27% 
for entire spectrum of LVEF). 
As discussed in chapter 4, my focus on CORONA will be on patients with 
LVEF≤35%, so from now on, all results refer to this cohort; however, for the sake 
of completeness, all analyses were run on the entire population randomised in 
CORONA (results will presented in supplementary material). Of the 5011 patients 
randomised, 3830 (76%) had a baseline LVEF≤35%; of these 3830 patients, 3829 
(99.9%) had a baseline measure for fatigue and all of them had a baseline 
observation for dyspnoea. 
Of these 3829 patients with an observation for fatigue, 3621 (95%) reported 
some level of fatigue on exertion, and most of them (85%) reported high 
symptom severity (from moderate exertion to symptoms at rest); 1630 (42%) 
patients reported the highest symptom severity (group 3: fatigue on slight 
exertion or at rest).  
Dyspnoea showed a similar pattern, although some level of dyspnoea was an 
inclusion criterion. 3492 patients (91%) reported dyspnoea from moderate exertion 
to dyspnoea at rest, and 46% (n=1170) reported the highest symptom severity with 
dyspnoea on slight exertion or at rest. Figure 6-1 
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Figure 6-1 Distribution of symptoms at randomisation  
 
To achieve sufficient numbers in each severity class, patients were grouped into 
3 categories: fatigue score 0-1 (n= 552 [14%]), 2 (n=1,647 [43%]) and 3-4 (n= 1630 
[43%]); dyspnoea score 0/1 (n=383 [9%]), 2 (n=1,722 [45%]), and 3-4(n=1770 
[46%]). Figure 6-2 
Figure 6-2 Distribution of symptoms at randomisation after grouping. 
 
 
Overall, 2743 (72%) of the patients reported the same baseline severity of 
fatigue and dyspnoea, 725 (19%) reported greater dyspnoea than fatigue and 361 
(9%) greater fatigue than dyspnoea. 75% (n=2881)of the patients fall on the 
diagonal. Table 6-1 
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Table 6-1 Cross-tabulation between symptoms at baseline  
( Dyspnoea(
Fatigue( 0/1( 2( 3/4( Total(
0/1( 233(
(6.1%)(
253(
(6.6%)(
66(
(1.7%)(
552(
(14.4%)(
2( 77(
(2.0%)(
1257(
(32.8%)(
313(
(8.2%)(
1647(
(43.0%)(
3/4( 28(
(1.0%)(
211(
(5.5%)(
1391(
(36.3%)(
1630(
(42.6%)(
Total( 338(
(8.8%)(
1721(
(45.0%)(
1770(
(46.2%)(
3829(
(100%)2(
                                         
2 Percentages in brackets represent cell percentages (i.e. 3829 is the denominator). 
 
Tables 6-2 and 6-3 show the distribution of fatigue and dyspnoea within each 
NHYA class.  
Table 6-2 Tabulation between fatigue and NYHA class at baseline 
Fatigue!status! ! ! ! NYHA!class!at!baseline! !
( II( III( IV( Total(
0( 153(
(73.6%)(
52(
(25%)(
3(
(1.4%)(
208(
(
1( 299(
(86.9%)(
44(
(12.8%)(
1(
(0.3%)(
344(
(
2( 1143(
(69.4%)(
499(
(30.3%)(
5(
(0.3%)(
1647(
(
3( 203(
(13.4%)(
1290(
(85.3%)(
20(
(1.3%)(
1513(
(
4( 30(
(25.6%)(
57(
(48.7%)(
30(
(25.6%)(
117(
(
Total( 1829(
(47.7%)(
1942(
(50.7%)(
59(
(1.5%)(
3829(
(
 
Table 6-3 Tabulation between dyspnoea and NYHA class at baseline 
Dyspnoea!status! ! ! ! NYHA!class!at!baseline! !
( II( III( IV( Total(
0( 1(
(100%)(
0(
(0.0%)(
0(
(0.0%)(
1(
(
1( 312(
(92.6%)(
25(
(7.4%)(
0(
(0.0%)(
337(
(
2( 1328(
(77.1%)(
392(
(22.8(
2(
(0.1%)(
1722(
(
3( 177(
(10.5%)(
1487(
(88.41%)(
18(
(1.1%)(
1682(
(
4( 11(
(12.5%)(
38(
(43.2%)(
39(
(44.3%)(
88(
(
Total( 1829(
(47.8%)(
1942(
(50.7%)(
59(
(1.5%)(
3830(
(
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6.2 Baseline characteristics according to symptom 
severity at randomisation  
Baseline characteristics by symptom severity are summarised in Table 6-4. In 
summary, patients with higher levels of fatigue (i.e. fatigue on slight exertion or 
at rest) were more likely to be female (26% vs. 15% for no fatigue/heavy 
exertion and 19% for moderate fatigue), and to have lower systolic blood 
pressure than patients with lower levels of fatigue (127 mm/Hg vs. 129 mm/Hg). 
They also had, on average, higher heart rates (73 bpm vs. 69 bpm fatigue 0/1 
and 71 bpm fatigue 2) and were more likely to be in NYHA functional class III or 
IV (86% vs. 18% fatigue 0/1 and 31% fatigue 2) and had a longer history with 
heart failure (4.5 years vs. 3.8 years group 1 and 4.2 years for group 2). Patients 
with greater fatigue more frequently had a history of myocardial infarction (63% 
vs. 51% fatigue 1/61% fatigue 2), angina (76% vs. 61%/70%), hypertension (65% 
vs. 51%/59%), diabetes (32% vs. 23%/28%), atrial fibrillation (27% vs. 16%/22%), 
intermittent claudication (15% vs. 12%/11%) or stroke (15% vs. 8%/11%), lower 
levels of lipids (for cholesterol a mean of 5.3 mmol/L vs. 5.4 mmol/L; LDL 3.5 
mmol/L vs. 3.6 mmol/L), ubiquinone (0.7 mmol/L vs. 0.8 mmol/L) and eGFR (55 
ml/min/1.73m2 vs. 57 ml/min/1.73m2)and higher levels of NT-proBNP (233 
pmol/L vs. 145pmol/L for group 1 and 185 pmol/L in group 2) and hs-CRP (4 
mg/L vs. 2.8 mg/L group 1 and 3.3 mg/L group 2). They were more likely to be 
treated with diuretics (92% vs. 82%/86%), MRAs (49% vs. 31%/35%) and digitalis 
(40% vs. 24%/32%). They were less likely to smoke (8% vs. 13%/9%).  
Patients with higher levels of dyspnoea (i.e. dyspnoea at rest or slight exertion) 
presented with a generally similar pattern, although there was no association 
between level of dyspnoea and smoking status. They were slightly older on 
average (74 years vs. 72/73 years) had higher creatinine levels (118 mg/dL vs. 
116 mg/dL) and were more likely to have an implanted pacemaker (14% vs. 
8%/11%). 
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Table 6-4 Baseline characteristics  
!
!
All!patients!
(n=3830)!
Fatigue!0/1!
(n=552)!
Fatigue!2!
(n=1647)!
Fatigue!3/4!
(n=1630)!
p!value!
Dyspnoea!1!
(n=338)!
Dyspnoea!2!
(n=1722)!
Dyspnoea!3/4!
(n=1770)!
p!value!
Age! 73.0%±%7.1% 72.73%±%6.89% 72.72%±%7.01% 73.36%±%7.29% 0.015% 72.22%±%7.09% 72.57%±%6.95% 73.55%±%7.25% <0.001%
Female! 810%(21.2%)% 81%(14.7%)% 307%(18.6%)% 422%(25.9%)% <0.001% 52%(15.4%)% 326%(18.9%)% 432%(24.4%)% <0.001%
Race!
Caucasian!
Black!
Asian!
Other!
4939%(98.6%)%
13%(0.3%)%
38%(0.8%)%
21%(0.4%)%
544%(98.6%)%
2%(0.4%)%
3%(0.5%)%
3%(0.5%)%
1623%(98.5%)%
5%(0.3%)%
11%(0.7%)%
8%(0.5%)%
1601%(98.2%)%%
4%(0.2%)%%
20%(1.2%)%%
5%(0.3%)%% 0.484%
334%(98.8%)%
1%(0.3%)%
3%(0.9%)%
0%(0.0%)%
1696%(98.5%)%
6%(0.3%)%
10%(0.6%)%
10%(0.6%)%
1738%(98.2%)%%
5%(0.3%)%%
21%(1.2%)%%
6%(0.3%)%% 0.336%
NYHA!III/IV! 2001%(52.3%)% 100%(18.1%)% 504%(30.6%)% 1397%(85.7%)% <0.001% 25%(7.4%)% 394%(22.9%)% 1582%(89.4%)% <0.001%
LVEF!(%)! 28.6%±%5.7% 28.34%±%5.92% 28.76%±%5.56% 28.45%±%5.71% 0.791% 28.31%±%5.88% 28.76%±%5.58% 28.42%±%5.73% 0.462%
Systolic!BP!mm/Hg! 128.5%±%16.9% 129.4%±%17.3% 129.7±%16.6% 127.1%±%16.9% <0.001% 129.3%±%16.4% 129.7%±%16.9% 127.29%±%16.9% <0.001%
Heart!Rate!bpm! 71.8%±%11.3% 69.4%±%10.6% 71.2%±%11.5% 73.1%±%11.2% <0.001% 68.8%±%11.1% 70.65%±%11.1% 73.40%±%11.4% <0.001%
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BMI!kg/m2! 26.9%±%4.4% 26.6%±%4.0% 27.1%±%4.5% 26.9%±%4.5% 0.298% 26.4%±%4.0% 27.0±%4.4% 27.0%±%4.5% 0.077%
BMI!<25!kg/m2!
BMI!≥25!and!<30!
kg/m2!
BMI!≥30!kg/m2!
1324%(34.7%)%
1665%(46.3%)%
830%(21.7%)%
206%(37.5%)%
243%(44.2%)%
101%(18.4%)%
547%(33.4%)%
716%(43.7%)%
377%(23.0%)%
571%(35.8%)%
706%(43.0%)%
377%(23.0%)% 0.4563%
132%(39.2%)%
144%(42.7%)%
61%(18.1%)%
590%(34.4%)%
738%(43.1%)%
386%(22.5%)%
602%(34.7%)%
783%(43.1%)%
383%(21.7%)% 0.194%
Years!with!heart!
failure!
4.3%±%4.7%
3.83%±%4.75% 4.20%±%4.62% 4.54%±%4.77% 0.001% 3.66%±%4.55% 4.11%±%4.62% 4.58%±%4.81% <0.001%
Current!Smoker! 430%(8.6%)% 70%(12.7%)% 146%(8.9%)% 133%(8.2%)% 0.0047% 36%(10.7%)% 153%(8.9%)% 160%(9.0%)% 0.570%
! Past!Medical!History!
MI! 2311%(60.3%)% 284%(51.4%)% 998%(60.6%)% 1028%(63.1%)% <0.001% 168%(49.7%)% 1029%(59.8%)% 1114%(62.9%)% <0.001%
Angina! 2728%(71.2%)% 336%(60.9%)% 1154%(70.1%)% 1237%(75.9%)% <0.001% 193%(57.1%)% 1212%(70.4%)% 1323%(74.7%)% <0.001%
CABG/PCI! 1052%(27.5%)% 156%(28.3%)% 485%(29.4%)% 411%(25.2%)% 0.033% 84%(24.9%)% 518%(30.1%)% 450%(25.4%)% 0.123%
Hypertension! 2308%(60.3%)% 280%(50.7%)% 972%(59.0%)% 1055%(64.7%)% <0.001% 174%(51.5%)% 1018%(59.1%)% 1116%(63.1%)% <0.001%
Diabetes! 1109%(29.0%)% 129%(23.4%)% 456%(27.7%)% 523%(32.1%)% <0.001% 72%(21.3%)% 457%(26.5%)% 580%(32.8%)% <0.001%
Baseline!atrial!
fibrillation/!flutter!
895%(23.4%)% 89%(16.1%)% 362%(22.0%)% 444%(27.2%)% <0.001% 62%(18.3%)% 343%(19.9%)% 490%(27.7%)% <0.001%
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Stroke! 478%(12.5%)% 46%(8.3%)% 181%(11.0%)% 251%(15.4%)% <0.001% 33%(9.8%)% 191%(11.1%)% 254%(14.4%)% 0.001%
Intermittent!
Claudication!
496%(13.0%)% 67%(12.1%)% 182%(11.1%)% 247%(15.2%)% 0.006% 35%(10.4%)% 198%(11.5%)% 263%(14.9%)% 0.001%
Pacemaker! 454%(11.9%)% 62%(11.2%)% 182%(11.1%)% 210%(12.9%)% 0.150% 26%(7.7%)% 182%(10.6%)% 246%(13.9%)% <0.001%
ICD! 122%(3.2%)% 24%(4.3%)% 52%(3.2%)% 46%(2.8%)% 0.105% 10%(3.0%)% 59%(3.4%)% 53%(3.0%)% 0.707%
! Laboratory!measurements!
Cholesterol!
(mmol/L)! 5.34%±%1.07% 5.45%±%1.05% 5.36%±%1.03% 5.28%±%1.12% <0.001% 5.44%±%1.05% 5.41%±%1.03% 5.25%±%1.11% <0.001%
ApoB:ApoA[1!ratio! 0.87%±%0.25% 0.86%±%0.24% 0.86%±%0.24% 0.88%±%0.26% 0.017% 0.85%±%0.24% 0.87%±%0.24% 0.88%±%0.26% 0.140%
ApoB!(g/L)! 1.27%±%0.30% 1.28%±%0.29% 1.27%±%0.29% 1.26%±%0.31% 0.171% 1.27%±%0.29% 1.28%±%0.29% 1.25%±%0.31% 0.021%
ApoA[1!(g/L)! 1.50%±%0.28% 1.52%±%0.28% 1.51%±%0.28% 1.47%±%0.28% <0.001% 1.53%±%0.27% 1.51%±%0.28% 1.47%±%0.28% <0.001%
TSH%(mIU/L)%
!! 2.19%±%4.02% 2.07%±%2.68% 2.12%±%4.47% 2.35%±%4.84% 0.113% 1.88%±%1.40% 2.20%±%4.62% 2.28%±%4.60% 0.176%
ALT!(IU/L)! 17.64%±%39.96% 18.02%±%27.00% 17.02%±%31.44% 17.94%±%49.45% 0.831% 19.62%±%31.38% 16.77%±%29.80% 18.11%±%49.02% 0.919%
LDL!(mmol/L)! 3.5%±%0.9% 3.61%±%0.91% 3.55%±%0.91% 3.49%±%0.96% 0.006% 3.62%±%0.92% 3.59%±%0.90% 3.46%±%0.95% <0.001%
Creatine!Kinase!
IU/L!
(median/IQR)!
54.3%
%[33.0,%65.0]%
50.0%%
[35.5,%70.5]%
48.0%%
[34.0,%67.0]%
41.0%
[30.0,%60.0]%%
<0.001% 50.0%%
[34.0,%74.0]%
48.0%%
[34.0,%67.0]%
42.0%
[31.0,%61.0]%
<0.001%
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Creatinine!
(μmol/L)!
116.8%±%28.3% 115.5%±%26.2% 116.0%±%27.7% 118.0%±%29.6% 0.026% 115.30±%27.0% 115.7%±%27.2% 118.1%±%29.6% 0.010%
NT[proBNP[[
pmol/litre!
(median)!
193.8%[88.7,%
406.4]%
144.5%[74.1,%
293.2]%
184.7%[77.7,%
374.1]%
233.1%[107.1,%
484.2]% <0.001%
144.9%[78.5,%
311.6]%
174.1%[75.9,%
356.2]%
233.9%[106.7,%
477.5]% <0.001%
hs[CRP!mg/litre!
(median)! 3.5%[1.6,%7.4]% 2.8%[1.3,%6.2]% 3.3%[1.5,%6.8]% 4.0%[1.8,%8.6]% <0.001% 2.4%[1.2,%5.6]% 3.3%[1.5,%6.7]% 4.0%[1.8,%8.6]% <0.001%
Co[enzyme!Q10!
(mmol/L)! 0.7%[0.6,%1.0]% 0.8%[0.6,%1.0]% 0.8%[0.6,%1.0]% 0.7%[0.5,%0.9]% <0.001% 0.7%[0.6,%1.0]% 0.8%[0.6,%1.0]% 0.7%[0.5,%1.0]% 0.012%
Estimated!GFR!
ml/min/1.73m2!
55.8%±%15.4% 57.0±%15.04% 56.6%±%15.3% 54.7%±%15.6% <0.001% 57.2%±%15.0% 56.8%±%15.1% 54.7%±%15.7% <0.001%
% %
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! Medication!
Loop/thiazide!
diuretics!
3364%(87.8%)% 453%(82.1%)% 1418%(86.1%)% 1492%(91.5%)% <0.001% 267%(79.0%)% 1473%(85.5%)% 1624%(91.8%)% <0.001%
ACE!inhibitor!or!
ARB!
3548%(92.6%)% 523%(94.7%)% 1523%(92.5%)% 1501%(92.1%)% 0.069% 314%(92.9%)% 1608%(93.4%)% 1626%(91.9%)% 0.160%
MRAs! 1154%(40.6%)% 171%(31.0%)% 582%(35.3%)% 800%(49.1%)% <0.001% 118%(34.9%)% 570%(33.1%)% 866%(48.9%)% <0.001%
Digitalis! 1305%(34.1%)% 131%(23.7%)% 530%(32.2%)% 644%(39.5%)% <0.001% 81%(24.0%)% 523%(30.4%)% 701%(39.6%)% <0.001%
Anticoagulant! 1433%(37.4%)% 203%(36.8%)% 623%(37.8%)% 607%(37.2%)% 0.979% 130%(38.5%)% 637%(37.0%)% 666%(37.6%)% 0.991%
Beta[blockers! 2847%(74.3%)% 409%(74.1%)% 1250%(75.9%)% 1187%(72.8%)% 0.220% 252%(74.6%)% 1308%(76.0%)% 1287%(72.7%)% 0.089%
Nitrate! 1,131%(29.5%)% 120%(21.7%)% 457%(27.7%)% 554%(34.0%)% <0.001% 65%(19.2%)% 452%(26.2%)% 614%(34.7%)% <0.001%
Insulin! 303%(7.9%)% 35%(6.3%)% 122%(7.4%)% 146%(9.0%)% 0.028% 19%(5.6%)% 125%(7.3%)% 159%(9.0%)% 0.013%
Antiarrhythmic! 479%(12.5%)% 60%(10.9%)% 193%(11.7%)% 226%(13.9%)% 0.030% 41%(12.1%)% 204%(11.8%)% 234%(13.2%)% 0.289%
LVEF – left ventricular ejection fraction, NYHA – New York Heart Association functional class, BMI – body mass index BP – blood pressure, CABG/PCI – coronary artery bypass grafting/ percutaneous 
coronary intervention, ICD – implantable cardioverter defibrillator, LDL – low density lipoprotein, NT-proBNP – N-terminal of the prohormone brain natriuretic peptide, hs-CRP – high-sensitivity C-reactive 
protein, TSH – thyroid stimulating hormone, ACE – angiotensin converting enzyme, ARB – angiotensin II receptor blocker, MRA – Mineralocorticoid receptor antagonist. 
Mean and standard deviation (SD) for continuous variables and percentage for categorical variables are presented. 
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6.3 Summary of results  
I found both symptoms to be highly prevalent in this population. I found that 95% 
of the patients reported some level of fatigue, with 99% reporting some level of 
dyspnoea (although dyspnoea was an inclusion criterion as mentioned earlier). 
Most patients reported moderate to severe symptoms, which coincides with 
NYHA classification and provides some construct validity (245) to the scale used 
to measure symptoms in this clinical trial. While I found some level of 
discrepancy between NYHA class and symptom severity, it is important to keep 
in mind that NYHA class measures any symptom to assign a class, and I am only 
looking at fatigue and dyspnoea, it is possible that NYHA class was assigned 
considering chest pain, palpitations or any other symptom, which could explain 
why some patients (fatigue 87 [2%] and dyspnoea 49 [1%]) have symptoms at rest 
(fatigue or dyspnoea 4) while still being classified as NYHA class II or III. 
Results for univariate analyses looking at the correlates of symptoms will be 
discussed in the following chapter. 
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7  Correlates of symptoms in CORONA: 
randomisation visit 
In this chapter I will present the results of analyses examining which patient 
characteristics are associated with dyspnoea and fatigue and whether the 
magnitude of the associations between such characteristics and fatigue and 
dyspnoea are similar or different. 
7.1 Background 
The classic description of heart failure is a syndrome caused by cardiac 
dysfunction and characterised by two prototypal symptoms, namely dyspnoea 
and fatigue. (246) However, the cause of these symptoms, particularly fatigue, 
remains unclear and little is known about their prevalence, severity and 
predictors. (76, 79, 80, 82, 83) It has even been suggested that both symptoms 
might be different manifestations of the same pathophysiological process. (76, 
80, 84) However, in two separate studies each symptom has been shown to 
predict outcome independently of the other, suggesting they might be 
biologically distinct. (85, 86)  
7.2 Methods 
Baseline characteristics are presented by symptom group at baseline, with mean 
and standard deviation (SD) for continuous variables and percentage for 
categorical variables. Baseline characteristics were compared across groups 
using a test for trend (see Table 6-4). 
Linearity of the association between covariates and outcome was assessed in 
several ways (visually, using a Wald test and including spline transformations or 
quadratic terms) and was satisfied for all continuous covariates (see 4.2.2.1 for 
rationale).  
The selected variables were fitted into a generalized ordered logistic regression 
model for ordinal dependent variables. A partial proportional odds regression 
was run for variables that did not fulfil the proportional odds assumption (225, 
229) (see section 4.2.1.3). 
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A detailed description of the ordered logistic regression model (or proportional 
odds model) and the underlying assumptions can be found in the Methods 
chapter (Section 4.2.1). 
Most baseline characteristics were included in the model; some were excluded 
to avoid collinearity (i.e. multiple lipid indicators). Hence the final model 
included the following covariates: age, sex, LVEF, NYHA class, weight status as 
per baseline BMI (i.e. obese, overweight), systolic blood pressure, baseline heart 
rate, years with heart failure, history of myocardial infarction, history of 
diabetes, history of stroke, hypertension, history of angina, baseline atrial 
fibrillation/flutter, intermittent claudication, history of CABG or PCI, 
pacemaker, implantable cardioverter defibrillator; or treatment with a 
mineralocorticoid receptor antagonist, loop/thiazide diuretic, beta-blocker, 
nitrate, insulin, antiarrhythmic drug, ACE-inhibitor or ARB, digoxin, 
anticoagulant, thyroid stimulating hormone, N-terminal prohormone of brain 
natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein, alanine 
aminotransferase, creatine kinase, creatinine and low-density lipoprotein. A 
logarithmic transformation of NT-proBNP was performed (see section 4.2). 
Baseline body mass index was categorized to ease interpretation and comply 
with the WHO criteria (247). 
I also tested the null hypothesis of equivalence between the odds ratio for 
fatigue and the odds ratio for dyspnoea using a Wald test: (H0: 
ORfatigue=ORdyspnoea). 
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7.3 Results from randomisation visit 
7.3.1.1 Unadjusted outcomes 
Baseline characteristics, including co-morbidities and concomitant drug 
treatments are summarised in Table 6-4. 
Correlates with both fatigue and dyspnoea: Patients with higher levels of 
fatigue or dyspnoea (i.e. symptoms on slight exertion or at rest) were more 
likely to be female (fatigue 26%; dyspnoea 24%); to have a history of myocardial 
infarction (fatigue and dyspnoea both 63), angina (fatigue 76%; dyspnoea 75%), 
stroke (fatigue 15%; dyspnoea 14%), intermittent claudication (15% for both 
fatigue and dyspnoea group 3) and diabetes (32%/33%); to be in atrial 
fibrillation/flutter (fatigue 27%; dyspnoea 28%) and NYHA functional class III or 
IV (fatigue 86%; dyspnoea 89%); and have a longer history of HF (fatigue 4.5 
years; dyspnoea 4.6 years). They were also more likely to have a lower systolic 
blood pressure (fatigue and dyspnoea 127 mm/Hg) and lower levels of creatine 
kinase (fatigue 41 IU/L; dyspnoea 42 IU/L), cholesterol (fatigue 5.4 mmol/L; 
dyspnoea 5.3 mmol/L), Apo-lipoprotein A-1 levels (both 1.47 mg/L) and 
estimated glomerular filtration rates (both 54.7 ml/min/1.73m2), but a higher 
heart rate (73 bpm for both) and NT-proBNP (fatigue 233 pmol/L; dyspnoea 234 
pmol/L) and hsCRP levels (both 4 mg/L). More symptomatic patients were more 
likely to be treated with diuretics (both 92%), digitalis (both 40%), 
mineralocorticoid receptor antagonists (49% both) or nitrates (fatigue 34%; 
dyspnoea 35%).  
Correlates with fatigue only: Patients with lower levels of fatigue were more 
likely to be current smokers (13% vs. 8%), while more symptomatic patients had 
lower levels of co-enzyme Q10 (0.7 mmol/L vs. 0.8 mmol/L). 
Correlates with dyspnoea only: Prior pacemaker implantation (14% in patients 
with dyspnoea on slight exertion or rest vs. 11% in those with moderate 
dyspnoea and 10% in those with dyspnoea on heavy exertion) was associated with 
dyspnoea but not fatigue. Patients with more severe dyspnoea had, higher 
creatinine levels (mean of 118 mg/dL vs. mean of 115 mg/dL on those with mild 
or moderate dyspnoea). 
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7.3.1.2 Multivariable analyses  
2724 (71%) patients were included in the complete case analysis, with missing 
NT-proBNP values being the main reason for missing data in the regressions. 
Results are summarised in Table 7-1.  
Correlates with both fatigue and dyspnoea: History of myocardial infarction was 
associated with a higher baseline level of both fatigue (OR 1.85, 95 CI 1.46-2.36, 
p value <0.01 for moderate vs. no/slight fatigue) and dyspnoea (OR 1.39, 95% CI 
1.15-1.69, p value<0.01), as was history of angina (fatigue OR 1.57 95% CI 1.23-
2.01, p value <0.01; dyspnoea OR 1.64, 95% CI 1.22-2.20, p value <0.01: 
moderate symptoms versus no/slight symptoms on exertion). Higher NYHA 
functional class (the higher NYHA class the stronger the association with 
symptom severity for both symptoms; p value <0.001 for all levels and both 
symptoms) and use of a mineralocorticoid receptor antagonist (MRA) (fatigue OR 
1.42, 95% CI 1.19-1.69; dyspnoea OR 1.33, 95% CI 1.10-1.61: p value <0.01 for 
both) were associated with worse symptom severity.  
Correlates with fatigue only: Female sex was significantly associated with 
fatigue (OR 1.54, 95% CI 1.24-1.91, p value<0.01) as well as a history of 
hypertension (OR 1.38, 95% CI 1.16-1.65, p value<0.01).  
Correlates with dyspnoea only: being overweight or obese at baseline was 
associated with dyspnoea only (overweight OR 1.34, 95% CI 1.09-1.65; obese 
[moderate vs. slight dyspnoea] OR 1.89, 95% CI 1.25-2.84; p value<0.01 for both 
of them) but not with fatigue.  
Differences in correlates of fatigue and dyspnoea: Although the two symptoms 
vary slightly in their correlates, no clear difference is seen when testing the null 
hypothesis that the odds ratio for fatigue is equal to the odds ratio for dyspnoea. 
This is true for all predictors except NYHA functional class, where this seems to 
be a stronger predictor for dyspnoea than it is for fatigue.  
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Table 7-1 Multivariable analyses: 
! Fatigue! Dyspnoea! Equality!test!for!
OR!fatigue!vs.!OR!
dyspnoea!
Variable! OR!(95%!CI)! P!value! OR!(95%!CI)! P!value! P!value!
Age$p/10$years! 1.02$(0.90,$1.15)$ 0.806$ 1.15$(1.00,$1.32)$ 0.043$ 0.056$
Female! 1.54$(1.24,$1.91)$ <0.001$ 1.31$(1.03,$1.60)$ 0.025$ 0.391$
LVEF! 1.96$(0.49,$8.60)$ 0.370$ 1.04$(0.20,$5.32)$ 0.170$ 0.429$
NYHA$III/IV*$! $ $ $ $ $
*fatigue/dyspnoea!2!vs.!1!! 5.02$(3.80,$6.63)$ <0.001$ 13.45$(8.22,$22.03)$ <0.001$ <0.001$
*fatigue/dyspnoea!3!vs.1!! 13.14$(10.69,$16.16)$ <0.001$ 29.86$(23.68,$37.64)$ <0.001$ <0.001$
Overweight! 1.13$(0.94,$1.37)$ 0.196$ 1.34$(1.09,$1.65)$ 0.006$ 0.193$
Obese*! $ $ $ $ $
*fatigue/dyspnoea!2!vs.!1!! 1.46$(1.06,$2.03)$ 0.022$ 1.89$(1.25,$2.84)$ 0.002$ 0.139$
*fatigue/dyspnoea!3!vs.!1!! 0.98$(0.75,$1.27)$ 0.862$ 1.14$(0.86,$1.53)$ 0.361$ 0.055$
Systolic$BP$p/10$mmHg! 0.96$(0.91,$1.01)$ 0.151$ 0.98$(0.93,$1.04)$ 0.509$ 0.343$
Heart$rate$p/10$beats/min! 1.04$(0.96,$1.12)$ 0.373$ 1.11$(1.02,$1.21)$ 0.017$ 0.171$
Years$w/heart$failure! 1.00$(0.99,$1.02)$ 0.649$ 1.00$(0.98,$1.02)$ 0.933$ 0.579$
Myocardial$Infarction! $ $ 1.39$(1.15,$1.69)$ 0.001$ $
*fatigue!2!vs.!1!! 1.85$(1.46,$2.36)$ <0.001$ $ $ 0.606$
*fatigue!3!vs.!1!! 1.30$(1.06,$1.58)$ 0.010$ $ $ 0.537$
History$of$Diabetes$ 1.07$(0.87,$1.31)$ 0.526$ 1.20$(0.95,$1.51)$ 0.118$ 0.209$
Stroke! 1.36$(1.06,$1.74)$ 0.017$ 0.98$(0.75,$1.29)$ 0.890$ 0.039$
Hypertension! 1.38$(1.16,$1.65)$ <0.001$ 1.13$(0.93,$1.37)$ 0.229$ 0.105$
History$of$angina*! $ $ $ $ $
*fatigue/dyspnoea!2!vs.!1!! 1.57$(1.23,$2.01)$ <0.001$ 1.64$(1.22,$2.20)$ 0.001$ 0.834$
*fatigue/dyspnoea!3!vs.!1!! 1.17$(0.94,$1.45)$ 0.163$ 1.05$(0.83,$1.34)$ 0.681$ 0.522$
Baseline$atrial$
fibrillation/flutter*!
$ $ 1.13$(0.87,$1.46)$ 0.375$ $
*fatigue!2!vs.!1!! 1.46$(1.04,$2.06)$ 0.029$ $ $ 0.421$
*fatigue!3!vs.!1!! 1.00$(0.78,$1.29)$ 0.980$ $ $ 0.402$
Intermittent$Claudication! 1.15$(0.91,$1.47)$ 0.245$ 1.06$(0.82,$1.39)$ 0.644$ 0.722$
CABG/PCI! 0.90$(0.74,$1.08)$ 0.259$ 0.95$(0.77,$1.17)$ 0.602$ 0.449$
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Pacemaker! 0.88$(0.68,$1.13)$ 0.312$ 1.16$(0.87,$1.54)$ 0.325$ 0.111$
ICD! 0.75$(0.48,$1.16)$ 0.197$ 0.84$(0.52,$1.35)$ 0.462$ 0.429$
MRAs*! 1.42$(1.19,$1.69)$ <0.001$ 1.33$(1.10,$1.61)$ 0.004$ 0.415$
Loop/thiazide! 1.05$(0.81,$1.35)$ 0.727$ 1.02$(0.77,$1.36)$ 0.874$ 0.996$
Beta\blocker! 1.12$(0.93,$1.36)$ 0.238$ 1.11$(0.90,$1.37)$ 0.341$ 0.755$ $
Nitrate$ 1.04$(0.87,$1.26)$ 0.649$ 1.20$(0.97,$1.48)$ 0.092$ 0.150$
Insulin! 0.86$(0.61,$1.21)$ 0.377$ 0.82$(0.56,$1.21)$ 0.323$ 0.956$
Antiarrhythmic! 1.06$(0.82,$1.37)$ 0.653$ 0.89$(0.68,$1.18)$ 0.436$ 0.058$
ACE$inhibitor$or$ARB! 0.90$(0.66,$1.24)$ 0.524$ 1.00$(0.70,$1.43)$ 0.991$ 0.179$
Digoxin! 1.23$(1.02,$1.48)$ 0.031$ 1.15$(0.94,$1.43)$ 0.166$ 0.552$
Anticoagulant! 0.88$(0.73,$1.07)$ 0.201$ 0.91$(0.74,$1.13)$ 0.391$ 0.546$
TSH$mIU/L! 1.00$(0.98,$1.02)$ 0.756$ 1.00$(0.98,$1.01)$ 0.623$ 0.303$
Log(NT\proBNP)! 1.09$(1.00,$1.01)$ 0.045$ 1.04$(0.95,$1.13)$ 0.442$ 0.295$
hs\CRP$mg/litre! 1.00$(1.00,$1.01)$ 0.128$ 1.00$(1.00,$1.01)$ 0.445$ 0.894$
alanine$transaminase$IU/L! 1.00$(1.00,$1.01)$ 0.442$ 1.00$(1.00,$1.01)$ 0.379$ 0.786$
Creatine$kinase$p/50! 0.86$(0.82,1.02)$ 0.093$ 0.93$(0.82,$1.05)$ 0.249$ 0.514$
Creatinine$mg/dL$ 1.00$(0.99,$1.00)$ 0.078$ 1.00$(0.99,$1.00)$ 0.035$ 0.334$
Low$density$lipoprotein$
mmol/L!
0.99$(0.90,$1.08)$ 0.779$ 0.96$(0.87,$1.06)$ 0.415$ 0.525$
*Did not fulfil proportional odds (PO) assumption 
LVEF – left ventricular ejection fraction, NYHA – New York Heart Association functional class, BP –blood pressure, CABG/PCI – coronary artery bypass 
grafting/ percutaneous coronary intervention, ICD – implantable cardioverter defibrillator, MRA – Mineralocorticoid receptor antagonists, ACE – 
angiotensin converting enzyme, ARB – angiotensin II receptor blocker, TSH – thyroid stimulating hormone, NT-proBNP – N-terminal of the prohormone 
brain natriuretic peptide, CRP – – high-sensitivity C-reactive protein. 
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7.3.1.3 Model including co-enzyme Q10 
Given the controversy surrounding the role of ubiquinone as a potential 
treatment for reduction in symptom severity in patients with heart failure, I 
decided to include serum co-enzyme Q10 levels as a covariate in the model to 
analyse if there was any association between them and symptom severity at 
baseline. The results are shown next. 
Of the 3830 patients analysed, 980 (25%) had a baseline coenzyme Q10 value and 
678 were included in the multivariate model described above (the others were 
excluded mostly due to missing NT-proBNP values). 
A histogram of baseline co-enzyme Q10 can be seen below. 
Figure 7-1 Distribution of baseline co-enzyme Q10 
 
The distribution of co-enzyme Q10 across symptom group can be seen in 
TablesTable 7-2 andTable 7-3. P values were obtained by performing a Kruskal 
Wallis test. Both median and mean values of co-enzyme Q10 are lower in the high 
symptom group for both fatigue and dyspnoea, lending some support to the 
notion that co-enzyme Q10 could be a potential treatment target for improving 
symptoms. (158, 160, 248)  
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Table 7-2 Distribution of co-enzyme Q10 across fatigue groups 
Fatigue( n( Mean( SD( Median( p25( p75( p(
0/1( 250$ 0.83$ 0.40$ 0.76$ 0.59$ 0.98$ $
2( 397$ 0.85$ 0.43$ 0.77$ 0.58$ 1.03$ $
3/4( 333$ 0.74$ 0.37$ 0.67$ 0.51$ 0.89$ $
Total( 980$ 0.81$ 0.41$ 0.73$ 0.56$ 0.97$ <0.001$
$
Table 7-3 Distribution of co-enzyme Q10 across dyspnoea groups 
Dyspnoea(( n( Mean( SD( Median( p25( p75( p(
0/1( 143$ 0.80$ 0.36$ 0.72$ 0.57$ 0.97$ $
2( 443$ 0.85$ 0.42$ 0.76$ 0.60$ 1.00$ $
3/4( 394$ 0.77$ 0.40$ 0.68$ 0.51$ 0.96$ $
Total( 980$ 0.81$ 0.41$ 0.73$ 0.56$ 0.97$ 0.003$
 
Results of the multivariate model including co-enzyme Q10 are summarised in 
Table 7-4 below. Co-enzyme Q10 was not significantly associated with fatigue or 
dyspnoea on exertion. It could be argued however that a tendency can be seen 
where co-enzyme Q10 is associated with fatigue as the effect size is rather large 
(OR 0.60, 95% CI 0.38-0.93) and the p value is small (p=0.02). For this reason I 
decided to run an equality test (in the same manner as the preceding section) 
between the odds ratio for fatigue and the one for dyspnoea, getting a non-
significant test result (p value=0.34 for the null hypothesis of 
ORfatigue=ORdyspnoea for co-enzyme Q10). 
Table 7-4 Multivariable analyses including co-enzyme Q10 
( Fatigue( Dyspnoea(
Variable( OR((95%(CI)( P(value( OR((95%(CI)( P(value(
Age$p/10$years! 1.10$(0.87,$1.40)$ 0.424$ 1.27$(0.87,$1.66)$ 0.077$
Female! 1.99$(1.29,$3.07)$ 0.002$ 2.16$(1.31,$3.58)$ 0.003$
LVEF! 1.15$(0.09,$15.28)$ 0.916$ 0.36$(0.02,$5.95)$ 0.474$
NYHA$III/IV*$! $ $ $ $
*fatigue/dyspnoea!2!vs.!1!! 3.22$(2.10,$14.94)$ <0.001$ 10.97$(5.38,$22.40)$ <0.001$
*fatigue/dyspnoea!3!vs.1!! 5.63$(3.79,$8.38)$ <0.001$ 22.91$(14.46,$36.29)$ <0.001$
Overweight*! $ $ 1.45$(0.97,$2.16)$ 0.067$
*fatigue!2!vs.!1!! 0.69$(0.45,$1.05)$ 0.082$ $ $
*fatigue!3!vs.1!! 1.11$(0.73,$1.67)$ 0.628$ $ $
Obese*! 0.77$(0.50,$1.20)$ 0.253$ $ $
*dyspnoea!2!vs.!1!! $ $ 1.57$(0.81,$3.04)$ 0.180$
*dyspnoea!3!vs.1!! $ $ 0.71$(0.40,$1.26)$ 0.240$
Systolic$BP$p/10$mmHg! 0.96$(0.87,$1.05)$ 0.370$ 1.09$(0.98,$1.21)$ 0.124$
Heart$rate$p/10$beats/min*! $ $ 1.07$(0.90,$1.27)$ 0.460$
*fatigue!2!vs.!1!! 1.28$(1.05,$1.54)$ 0.013$ $ $
*fatigue!3!vs.1!! 0.91(0.77,$1.10)$ 0.350$ $ $
Years$w/heart$failure! 1.04$(1.01,$1.07)$ 0.019$ 1.00$(0.96,$1.03)$ 0.795$
Myocardial$Infarction! 1.43$(1.01,$2.03)$ 0.044$ 1.70$(1.15,$2.05)$ 0.008$
History$of$Diabetes$ 0.91$(0.60,$1.36)$ 0.631$ 1.09$(0.68,$1.75)$ 0.710$
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Stroke! 1.69$(0.98,$2.92)$ 0.060$ 1.24$(0.67,$2.31)$ 0.490$
Hypertension! 1.09$(0.79,$1.52)$ 0.593$ 1.11$(0.77,$1.60)$ 0.577$
History$of$angina! 0.99$(0.69,$1.43)$ 0.972$ 0.79$(0.53,$1.19)$ 0.269$
Baseline$atrial$
fibrillation/flutter!
1.09$(0.67,$1.77)$ 0.717$ 0.99$(0.57,$1.71)$ 0.972$
Intermittent$Claudication! 1.07$(0.67,$1.71)$ 0.769$ 0.71$(0.43,$1.17)$ 0.181$
CABG/PCI! 1.25$(0.88,$1.76)$ 0.207$ 1.86$(1.26,$1.75)$ 0.002$
Pacemaker! 1.23$(0.77,$1.97)$ 0.382$ 1.06$(0.63,$1.77)$ 0.824$
ICD! 0.74$(0.36,$1.52)$ 0.593$ 0.75(0.34,$1.65)$ 0.476$
MRAs*! 1.21$(0.85,$1.73)$ 0.281$ 1.07$0.72,$1.59)$ 0.725$
Loop/thiazide! 0.72$(0.47,$1.12)$ 0.149$ 0.89$(0.55,$1.46)$ 0.661$
Beta\blocker*! $ $ 0.92$(0.61,$1.40)$ 0.705$
*fatigue!2!vs.!1!! 1.62$(1.05,$2.49)$ 0.030$ $ $
*fatigue!3!vs.1!! 0.88$(0.57,$1.34)$ 0.553$ $ $
Nitrate$ 1.00$(0.69,$1.88)$ 0.995$ 1.02$(0.68,$1.54)$ 0.910$
Insulin! 1.44$(0.73,$2.83)$ 0.296$ 1.84$(0.80,$4.24)$ 0.151$
Antiarrhythmic! 1.22$(0.70,$2.13)$ 0.490$ 0.65$(0.36,$1.18)$ 0.159$
ACE$inhibitor$or$ARB! 0.92$(0.51,$1.67)$ 0.785$ 0.91$(0.47,$1.03)$ 0.067$
Digoxin! 1.55$(1.07,$2.24)$ 0.020$ 1.30$(0.85,$1.97)$ 0.224$
Anticoagulant! 0.74$(0.52,$1.05)$ 0.097$ 0.70$(0.47,$1.03)$ 0.067$
TSH$mIU/L$ 0.94$(0.87,$1.02)$ 0.144$ 1.00$(0.94,$1.07)$ 0.878$
Log(NT\proBNP)*! 1.03$(0.87,$1.21)$ 0.748$ $ $
*dyspnoea!2!vs.!1! $ $ 0.87$(0.69,$1.09)$ 0.232$
*dyspnoea!3!vs.!1! $ $ 1.41$(1.15,$1.74)$ 0.001$
hs\CRP$mg/litre! $ $ 1.01$(0.99,$1.02)$ 0.320$
*fatigue!2!vs.!1!! 1.00$(0.98,$1.02)$ 0.905$ $ $
*fatigue!3!vs.1!! 1.02$(1.01,$1.03)$ 0.004$ $ $
Alanine$transaminase$IU/L! 1.00$(0.99,$1.01)$ 0.555$ 1.00$(0.99,$1.01)$ 0.983$
Creatine$kinase$p/50$IU/L! 0.83$(0.67,$1.03)$ 0.097$ 1.03$(.82,$1.30)$ 0.772$
Creatinine$mg/dL$ 1.00$(0.99,$1.01)$ 0.863$ 1.00$(0.99,$1.00)$ 0.580$
Low$density$lipoprotein$
mmol/L!
1.01$(0.84,$1.22)$ 0.890$ 0.87$(0.71,$1.07)$ 0.196$
Co\enzyme$Q10$mmol/L! 0.60$(0.39,$0.93)$ 0.023$ 0.93$(0.57,$1.53)$ 0.784$
*Did not fulfil proportional odds (PO) assumption 
LVEF – left ventricular ejection fraction, NYHA – New York Heart Association functional class, BP –blood pressure, 
CABG/PCI – coronary artery bypass grafting/ percutaneous coronary intervention, ICD – implantable cardioverter 
defibrillator, MRA – Mineralocorticoid receptor antagonists, ACE – angiotensin converting enzyme, ARB – 
angiotensin II receptor blocker, TSH – thyroid stimulating hormone, NT-proBNP – N-terminal of the prohormone 
brain natriuretic peptide, CRP – – high-sensitivity C-reactive protein. 
 
 
7.4 Summary of results and discussion 
I found that a limited number of variables (history of hypertension and coronary 
heart disease; NYHA functional class; and use of mineralocorticoid receptor 
antagonists) were independently associated with both fatigue and dyspnoea, 
with no variables clearly associated with only one of these symptoms. The lack 
of association with ejection fraction or NT-proBNP suggests that “peripheral” 
rather than “central” mechanisms may explain the origin of both symptoms. 
Beta-blocker use has been linked to fatigue (249, 250) and two case series 
(albeit they had no control group) (251, 252) and early clinical trials in patients 
with acute myocardial infarction (253, 254) have found an association between 
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beta blocker use and fatigue. I conversely found no association between beta-
blocker use and symptoms. This could be due to the fact that beta-blocker use 
was almost ubiquitous (74% of patients in CORONA reported use of beta 
blockers). A quantitative review of randomized trials (255) that tested beta-
blockers in myocardial infarction, heart failure, and hypertension published in 
2002 found that the conventional wisdom that beta-blocker therapy is associated 
with a substantial risk of suffering fatigue is not supported by data from clinical 
trials. In their analysis, beta-blockers were associated with a small significant 
annual increase in risk of reported fatigue (18 per 1000 patients; 95% CI, 5-30), 
equivalent to 1 additional report of fatigue for every 57 patients treated per 
year with beta-blockers. Hjalmarson et al examined the effects of metoprolol 
succinate on symptoms and quality of life among patients in the MERIT-HF trial 
and found that it had an overall beneficial effect on patient well being, they 
report only a 0.3% net increase in fatigue between metoprolol succinate and 
placebo. (256) Another more recent study looking at the correlates of fatigue in 
patients who had a stroke (257) found no association between fatigue and beta-
blocker use.  The risk of fatigue with beta-blocker use should be put in the 
context of the documented benefits of these medications. 
My results show that co-enzyme Q10 was not a significant correlate of fatigue, 
however it is very important to note that a lot of information was lost due to 
missing data on said covariate. Although the results do not change with 
imputation for missing data, findings from such analyses should be interpreted 
cautiously due to the strong assumptions underlying imputation methods 
(specifically that the data are missing at random), which are probably not 
fulfilled as the missing values of co-enzyme Q10 are missing according to centre 
(i.e. some centres did not measure co-enzyme Q10 levels as centres had to be 
near a laboratory because samples were sent fresh on ice). 
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8 Symptoms as predictors of outcome: CORONA 
randomisation visit 
In this chapter I will present the results of analyses examining the association 
between symptom severity at baseline and the risk of a number of 
cardiovascular outcomes after adjustment for other risk factors in CORONA. The 
relationship is examined using traditional methods of survival analyses. As a 
result, I aim to determine if higher symptom burden at baseline is associated 
with a higher risk of certain cardiovascular outcomes. I will compare how two of 
the pivotal symptoms of heart failure (i.e. fatigue and dyspnoea) relate to such 
outcomes to examine if there is difference between them.  
8.1 Methods 
I tested the prognostic value of each symptom in relation to the composite 
outcome of cardiovascular death or hospitalisation due to worsening heart 
failure (heart failure) using Cox proportional-hazard regression models 
(described in Methods chapter). Cardiovascular death or hospitalisation due to 
worsening heart failure (rather than the pre-specified primary outcome of 
CORONA) was used in the present analysis as it better reflects the disease-
specific morbidity and mortality related to heart failure (and the primary 
endpoint of CORONA was recommended by regulatory authorities to reflect the 
treatment intervention used i.e. a statin). (234, 235) Other outcomes analysed 
were the components of the composite (cardiovascular death and heart failure) .  
As mentioned in section 4.2.2, the adjusted analyses used a previously published 
CORONA risk model for all cause mortality.  The covariates included were: age, 
sex, NYHA class, LVEF, body mass index (BMI), systolic blood pressure, heart 
rate, smoking, MI, CABG or PCI, aortic aneurysm, hypertension, diabetes, 
baseline atrial fibrillation/flutter (AF), stroke, intermittent claudication, 
pacemaker and ICD implantations, apoA-1, apoB, creatinine, alanine 
aminotransferase, creatine kinase, thyroid stimulating hormone, high-sensitivity 
C-reactive protein, and log NT-proBNP. (228) A logarithmic transformation of NT-
proBNP was performed. Linearity and proportional hazard assumptions were 
assessed for all continuous model covariates. 
Kaplan-Meier cumulative event curves are presented by symptom category and 
compared with log-rank tests. 
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8.2 Results 
Of the 3830 patients analysed, 1568 (40.9%) had a heart failure hospitalisation or 
cardiovascular death with a median survival time of 389 days (IQR 163.5-690). 
961 (25.1%) patients had a cardiovascular death with a median survival time of 
507 days (IQR 240-793). 1040 patients were hospitalised due to worsening heart 
failure; median “survival” time was of 349 days (IQR 134-664). (see Table 8-1) 
For the 2262 patients who did not have a CV death or heart failure 
hospitalisation, median survival time was of 1071 days (IQR 914-1176). 
8.2.1 Unadjusted outcomes 
Patients with a higher symptom severity were significantly more likely to die from 
any cause (fatigue group 3 n=618 [38%] vs. group 1 n=136 [24%], HR 1.72, 95% 
CI 1.43-2.07; dyspnoea group 3 n=662 [37%] vs. group 1 n=77 [23%], HR 1.81, 
95% CI 1.43-2.29) and from cardiovascular causes (fatigue group 3 n=503 [31%] 
vs. group 1 n=109 [20%] HR 1.75, 95% CI 1.42-2.15; dyspnoea group 3 n=540 
[31%] vs. group 1 n=63 [19%], HR 1.81, 95% CI 1.39-2.35). Those with greater 
symptom severity were also more likely to be hospitalized for worsening heart 
failure (fatigue group 3 n=554 [34%] vs. group 1 n=109 [20%], HR 2.07, 95% CI 
1.68-2.54; dyspnoea group 3 n=611 [35%] vs. group 1 n=49 [15%], HR 2.88, 95% 
CI 2.16-3.86); log rank p<0.01 for all outcomes (see Table 8-1 and Table 8-2: 
Figure 8-1 and Figure 8-2). 
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Table 8-1 Clinical outcomes according to baseline symptom severity 
! Fatigue! Dyspnoea!
! 0/1! 2! 3/4! 1! 2! 3/4!
! (n=552)! (n=1647)! (n=1630)! (n=338)! (n=1722)! (n=1770)!
n!(%)! ! ! ! ! ! !
Cardiovascular!death!or!heart!failure!
hospitalisation!
67/109!
(31.9)!
207/377!
(35.5)!
254/554!
(49.6)!
47/49!
(28.4)!
216/380!
(34.6)!
265/611!
(49.5)!
Cardiovascular!death! 109!
(19.8)!
349!
(21.2)!
503!
(30.9)!
63!
(18.6)!
358!
(20.8)!
540!
(30.5)!
Heart!failure!hospitalisation! 109!
(19.8)!
377!
(22.9)!
554!
(34.0)!
49!
(14.5)!
380!
(22.1)!
611!
(34.5)!
AllCcause!death! 136!
(24.6)!
451!
(27.4)!
618!
(37.9)!
77!
(22.8)!
466!
(27.1)!
662!
(37.4)!
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Table 8-2 Hazard ratio for symptom severity and clinical outcomes: Unadjusted analysis 
! Fatigue! Dyspnoea!
! 2!vs.!1! 3!vs.!1! 2!vs.!1! 3!vs.!1!
! HR!(95%!CI)! P!value! HR!(95%!CI)! P!value! HR!(95%!CI)! P!value! HR!(95%!CI)! P!value!
Cardiovascular!
death!or!heart!
failure!
hospitalisation!
1.16!
(0.98,!1.37)!
0.079! 1.87!
(1.59,!2.20)!
<0.001! 1.28!
(1.03,!1.59)!
0.024! 2.12!
(1.71,!2.62)!
<0.001!
Cardiovascular!
death!
1.10!
(0.89,!1.36)!
0.393! 1.75!
(1.42,!2.15)!
<0.001! 1.14!
(0.87,!1.48)!
0.353! 1.81!
(1.39,!2.35)!
<0.001!
Heart!failure!
hospitalisation!
1.21!
(0.98,!1.50)!
0.080! 2.07!
(1.68,!2.54)!
<0.001! 1.60!
(1.19,!2.16)!
0.002! 2.88!
(2.16,!3.86)!
<0.001!
AllCcause!death! 1.14!
(0.94,!1.38)!
0.188! 1.72!
(1.43,!2.07)!
<0.001! 1.21!
(0.95,!1.54)!
0.128! 1.81!
(1.43,!2.29)!
<0.001!
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Figure 8-1 Kaplan Meier curves for outcomes according to fatigue severity 
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Figure 8-2 Kaplan Meier curves for outcomes according to dyspnoea severity 
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8.2.2 Adjusted outcomes 
Adjustment for the other variables associated with worse clinical outcomes 
listed in the Methods section of this chapter weakened the relationship between 
symptom severity and all outcomes. (Group 3 vs. Group 1): fatigue - 
cardiovascular death HR 1.06 (95% CI 0.79, 1.41), p=0.72 and heart failure 
hospitalisation HR 1.10 (0.84, 1.44), p= 0.50; dyspnoea - cardiovascular death HR 
1.13 (0.78, 1.64) p=0.52 and heart failure hospitalisation HR 1.35 (0.93, 1.95), 
p=0.11. A total of 2718 (71%) patients were included in the complete-case 
analyses, with missing NT-proBNP values being the main reason for missing data 
in the regression, as stated previously (1112 patients had missing NT-proBNP 
values). (Table 8-3) 
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Table 8-3 Hazard ratio for symptom severity and clinical outcomes: Multivariable analysis 
! Fatigue! Dyspnoea!
! 2!vs.!1! 3!vs.!1! 2!vs.!1! 3!vs.!1!
! HR!(95%!CI)! P!value! HR!(95%!CI)! P!value! HR!(95%!CI)! P!value! HR!(95%!CI)! P!value!
Cardiovascular!
death!or!heart!
failure!
hospitalisation!
0.98!
(0.80,!1.21)!
0.884! 1.10!
(0.88,!1.38)!
0.401! 1.05!
(0.81,!1.36)!
0.719! 1.09!
(0.82,!1.45)!
0.547!
Cardiovascular!
death!
0.94!
(0.72,!1.23)!
0.674! 1.06!
(0.79,!1.41)!
0.719! 1.09!
(0.78,!1.52)!
0.609! 1.13!
(0.78,!1.64)!
0.516!
Heart!failure!
hospitalisation!
0.99!
(0.76,!1.28)!
0.925! 1.10!
(0.84,!1.44)!
0.496! 1.19!
(0.85,!1.67)!
0.317! 1.35!
(0.93,!1.95)!
0.113!
AllCcause!death! 1.05!
(0.83,!1.34)!
0.671! 1.11!
(0.86,!1.45)!
0.422! 1.21!
(0.90,!1.64)!
0.214! 1.18!
(0.84,!1.65)!
0.333!
Adjusted for: age, sex, NYHA class, LVEF, body mass index (BMI), systolic blood pressure, heart rate, smoking, MI, CABG or PCI, aortic aneurysm, 
hypertension, diabetes, baseline atrial fibrillation/flutter (AF), stroke, intermittent claudication, pacemaker and ICD implantation, ApoA-1, ApoB, 
creatinine, alanine aminotransferase, creatine kinase, thyroid stimulating hormone, high-sensitivity C-reactive protein, and log NT-proBNP. 
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8.2.2.1 Including randomised treatment 
My analysis was of the relationship between fatigue and dyspnoea at baseline 
(before randomisation to placebo or rosuvastatin) and outcomes, which would 
not have been confounded by treatment group allocation. Whether or not 
rosuvastatin affected fatigue after randomisation is not directly relevant to this 
analysis. However, an effect of rosuvastatin could be relevant to my analysis of 
the relationship between change in fatigue from baseline and subsequent 
outcomes, which will be analysed in Chapter 9. Creatine kinase was measured as 
a safety outcome in CORONA and showed no increase with rosuvastatin. 
Consequently, I do not think that statin therapy confounded analysis of the 
association between fatigue and clinical outcomes, nevertheless, including 
randomised treatment in the multivariable adjustment made little difference to 
the findings as can be seen from Table 8-4 below. 
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Table 8-4 Hazard ratio for symptom severity and clinical outcomes including randomised treatment 
! Fatigue! Dyspnoea!
! 2!vs.!1! 3!vs.!1! 2!vs.!1! 3!vs.!1!
! HR!(95%!CI)! P!value! HR!(95%!CI)! P!value! HR!(95%!CI)! P!value! HR!(95%!CI)! P!value!
Cardiovascular!
death!or!heart!
failure!
hospitalisation!
0.98!
(0.80,!1.21)!
0.879! 1.09!
(0.87,!1.37)!
0.428! 1.05!
(0.81,!1.36!
0.711! 1.08!
(0.81,!1.44)!
0.598!
Cardiovascular!
death!
0.94!
(0.72,!1.23)!
0.674! 1.06!
(0.79,!1.42)!
0.717! 1.09!
(0.78,!1.53)!
0.608! 1.13!
(0.78,!1.64)!
0.514!
Heart!failure!
hospitalisation!
0.98!
(0.76,!1.27)!
0.907! 1.09!
(0.83,!1.43)!
0.541! 1.19!
(0.85,!1.67)!
0.315! 1.33!
(0.92,!1.92)!
0.135!
AllCcause!death! 1.05!
(0.83,!1.34)!
0.670! 1.11!
(0.86,!1.45)!
0.424! 1.21!
(0.90,!1.64)!
0.214! 1.18!
(0.84,!1.65)!
0.337!
Adjusted for: age, sex, NYHA class, LVEF, body mass index (BMI), systolic blood pressure, heart rate, smoking, MI, CABG or PCI, aortic aneurysm, 
hypertension, diabetes, baseline atrial fibrillation/flutter (AF), stroke, intermittent claudication, pacemaker and ICD implantation, ApoA-1, ApoB, 
creatinine, alanine aminotransferase, creatine kinase, thyroid stimulating hormone, high-sensitivity C-reactive protein, log NT-proBNP, and 
randomised treatment 
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8.2.2.2 Parsimonious model  
To address a potential problem of over-fitting the model, I decided to run a 
model including only the top 10 predictive variables (based on chi-square) to the 
adjusted model (covariates selected from CORONA model with death and heart 
failure hospitalisation as outcome). Running this more parsimonious model made 
no difference to my overall results: (Group 3 vs. Group 1): fatigue-cardiovascular 
death HR 1.15 (95% CI 0.86, 1.52), p=0.34; dyspnoea- cardiovascular death HR 
1.21 (0.84, 1.75), p=0.31: fatigue- heart failure hospitalisation HR 1.13 (0.86, 
1.48), p=0.37; dyspnoea- heart failure hospitalisation HR 1.44 (1.00, 2.08), p=0.05. 
See Table 8-5. 
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Table 8-5 Hazard ratio for symptom severity and clinical outcomes for 10 strongest predictors 
! Fatigue! Dyspnoea!
! 2!vs.!1! 3!vs.!1! 2!vs.!1! 3!vs.!1!
! HR!(95%!CI)! P!value! HR!(95%!CI)! P!value! HR!(95%!CI)! P!value! HR!(95%!CI)! P!value!
Cardiovascular!
death!or!heart!
failure!
hospitalisation!
1.02!
(0.83,!1.25)!
0.874! 1.15!
(0.93,!1.44)!
0.202! 1.09!
(0.85,!1.42)!
0.483! 1.16!
(0.88,!1.55)!
0.294!
Cardiovascular!
death!
0.98!
(0.75,!1.28)!
0.892! 1.15!
(0.86,!1.52)!
0.344! 1.13!
(0.81,!1.58)!
0.469! 1.21!
(0.84,!1.75)!
0.307!
Heart!failure!
hospitalisation!
1.02!
(0.78,!1.31)!
0.903! 1.13!
(0.86,!1.48)!
0.371! 1.25!
(0.89,!1.76)!
0.193!
!
1.44!
(1.00,!2.08)!
0.051!
AllCcause!death! 1.08!
(0.85,!1.36)!
0.526! 1.18!
(0.92,!1.52)!
0.200! 1.25!
(0.92,!1.68)!
0.152! 1.24!
(0.89,!1.73)!
0.197!
Adjusted for: age, sex, NYHA class, LVEF, heart rate, diabetes, baseline atrial fibrillation/flutter (AF), randomised treatment, ApoA-1, and log NT-
proBNP (covariates selected from CORONA model with death and heart failure hospitalisation as outcome: 10 strongest predictors selected on a 
basis of chi-square) 
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8.2.3 Summary of results and discussion 
I found that the baseline level of symptoms was strongly associated with heart 
failure hospitalisation and fatal outcomes. However, this association was lost 
after adjustment for other well-known prognostic variables, including NYHA 
class, LVEF and NT-proBNP. This remains true for all the sensitivity analyses 
performed on symptoms from randomisation visit. Including randomised 
treatment or running a more parsimonious model did not change the results.  
Additionally, my findings from randomisation visit contradict those from the 
studies that I found which looked at fatigue and dyspnoea at baseline 
independently from NYHA class (see sections 2.3.3 and 3.3.3). In COMET (258) 
fatigue was associated with heart failure hospitalisation in multivariate analyses, 
and dyspnoea was associated with both death and hospitalisation. Madigan et al 
(204) found that dyspnoea on index hospitalisation for heart failure was 
associated with an increased risk for re-hospitalisation; they did include NT-
proBNP in their multivariate analyses and did not investigate fatigue. 
As can be seen in Chapter 5, my previously published work (85) looking at the 
same cohort of patients at a different time point showed slightly different 
results. So why did I get different results? Firstly, in such paper I chose to analyse 
the visit prior to randomisation (which is the main analysis time point in this 
thesis) for the reasons mentioned earlier in section 5.2. As I have shown, 
symptoms differed substantially between these two visits, and there were a large 
number of events in those patients who reported different levels of symptoms 
between these two visits. Secondly, and most importantly, although the hazard 
ratios vary slightly between analyses from the two time points, the point 
estimates generally go in the same direction and are of similar magnitude, and 
the 95% confidence intervals overlap. In recent years, emphasis has been put 
onto presenting confidence intervals and giving them due notice, as even precise 
p values convey no information about the sizes or directions of the differences 
between two groups (non-significant p value will only indicate that there as no 
difference between groups, or that the sample size was too small to detect a 
difference). (259) Confidence intervals cover a wide range of plausible 
population means, with the best estimate of the true effect being more likely to 
be near the middle of the confidence interval. (260, 261) This does not exclude 
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values in the extremes of the confidence intervals; it just makes them less likely.  
In this way, confidence intervals provide a range of possibilities for the true 
population value, rather than an “arbitrary dichotomy based solely on statistical 
significance” as Altman (260) points out. Actually, this year, a scientific journal 
passed a motion to ban p values from their publications, arguing that reporting 
such statistics support  “lower-quality research”. (262) 
Having said that, it is also important to note that for the published paper a 
significance level of 5% was considered, while for this thesis a 1% significance 
level is considered 
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9 Change in symptom severity and clinical 
outcomes 
In this chapter I will examine change in symptom severity from baseline to 6 
month visit in CORONA, classifying patients as showing a decrease (reduction in 
score), an increase (an increase in score) or no change (unchanged score) in 
symptoms. I will analyse the relationship between change in symptoms and 
subsequent clinical outcomes. 
9.1 Background 
It is well known that patients with heart failure frequently report worsening of 
symptoms for hours/days before presenting to hospital. (130, 263-265) Similarly, 
the prognostic importance of NYHA classification is well known and as well as 
the prognostic significance of signs and symptoms combined. (5, 266-268) 
However, the relationship between individual symptoms (as opposed to NYHA 
class which envelopes all symptoms without discriminating among them in the 
overall classification-see 1.2.1) and particularly change in symptom severity and 
clinical outcomes has seldom been analysed. (18, 85, 258)  
The association between symptom severity at baseline and outcomes has been 
reported in chapter 5; in this chapter the focus will be twofold. First, I will 
analyse which baseline characteristics are associated with change in symptoms 
at 6 months and then I will analyse the relationship between change in symptoms 
(baseline to 6 months) and subsequent clinical outcomes (from 6 months to end of 
study). 
9.2 Methods 
The data source and CORONA trial have been described in chapter 4, as well as 
the scale and methods used to measure symptom severity. Symptoms in CORONA 
were measured at baseline, 6 weeks and 12 weeks after randomisation and every 
three months thereafter. 
I examined change in symptoms from baseline to the 6-month visit by classifying 
patients as showing a decrease (reduction in score), an increase (an increase in 
score) or no change (unchanged score) in symptoms. Baseline characteristics are 
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presented according to change in symptom severity (i.e. unchanged, decrease or 
increase) and were compared using a chi2 test for categorical variables or ANOVA 
for continuous variables (a Kruskall Wallis test was used when the assumption of 
normality was not met). To analyse the correlates of change in symptoms I used 
a multinomial logistic regression. The multivariate model was adjusted for age, 
sex, LVEF, NYHA class, weight status as per baseline BMI (i.e. obese, 
overweight), systolic blood pressure, baseline heart rate, years with heart 
failure, history of myocardial infarction, history of diabetes, history of stroke, 
hypertension, history of angina, baseline atrial fibrillation/flutter, intermittent 
claudication, history of CABG or PCI, pacemaker, implantable cardioverter 
defibrillator, treatment with a mineralocorticoid receptor antagonist, 
loop/thiazide diuretic, beta-blocker, nitrate, insulin, antiarrhythmic drug, ACE-
inhibitor or ARB, digoxin, anticoagulant, thyroid stimulating hormone, N-
terminal prohormone of brain natriuretic peptide (NT-proBNP), high-sensitivity 
C-reactive protein, alanine aminotransferase, creatine kinase, creatinine and 
low-density lipoprotein and baseline symptom severity. Baseline symptom 
severity was added to the multivariate model to ensure that the results would be 
independent of average symptom levels. A logarithmic transformation of NT-
proBNP was performed (see 4.2 for rationale). Baseline body mass index was 
categorized to ease interpretation and to fit with the usual World Health 
Organization classification. (247) 
I tested the prognostic value of each category of change in symptom severity in 
relation to the composite outcome of cardiovascular death or hospitalisation due 
to worsening heart failure using Cox proportional-hazard regression models 
(described in Methods chapter). As in a previous chapter, other outcomes 
analysed were the components of the composite (cardiovascular death and heart 
failure hospitalisation individually) and all-cause death.  
The multivariate analysis was adjusted for: age, sex, NYHA class, LVEF, body 
mass index (BMI), systolic blood pressure, heart rate, smoking, MI, CABG or PCI, 
aortic aneurysm, hypertension, diabetes, baseline atrial fibrillation/flutter (AF), 
stroke, intermittent claudication, pacemaker and ICD implantations, ApoA-1, 
ApoB, creatinine, alanine aminotransferase, creatine kinase, thyroid stimulating 
hormone, high-sensitivity C-reactive protein, and log NT-proBNP. (228) The 
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group with unchanged symptom status was used as reference. (See section 8.1 
for rationale) 
Additionally, I investigated how time between visits was associated with change 
in symptom severity over time. That is, I wanted to figure out if greater time 
between visits was associated with a higher likelihood of reporting some change, 
either an increase or decrease, in symptom severity. 
Only patients with a follow-up observation for symptom status at 6 months were 
included in the model. Of the 3830 patients who had a LVEF≤35% at baseline, 
282 (7%) did not have a 6-month visit; of these 282 patients 216 (77%) died 
before visit 6. Given that such a large proportion of patients who did not have a 
6-month visit died, the interpretation of the results must be interpreted 
cautiously as the prognostic relevance of change in symptom severity only 
reflects the association between this change in a cohort of survivors. 
9.2.1 Predictors of change in symptom severity 
9.2.1.1 Unadjusted outcomes 
Of the 3830 patients in this analysis, 3547 (93%) had both a baseline and 6-month 
measure of fatigue and 3548 (93%) had a 6-month measure for dyspnoea. Of 
these 3547, 625 (17.6%) reported a decrease, 459 (12.9%) an increase and 2463 
(69.4%) no change in fatigue over that period. Of the 3548 patients who had a 6-
month measure for dyspnoea, 2507 (70.7%) reported no change, 667 (18.8%) 
reported a decrease and 374 (10.5%) reported an increase in dyspnoea over that 
period. (Table 9-1) 
Table 9-1 Cross-tabulation between change in symptoms at 6 months 
 
! Dyspnoea! !
Fatigue! Unchanged! Decrease! Increase! Total!
Unchanged! 2107%(59.4%)% 231%(6.5%)% 125%(3.5%)% 2463%(69.4%)%
Decrease! 203%(5.7%)% 397%(11.2%)% 25%(0.7%)% 625%(17.6%)%
Increase! 197%(5.5%)% 39%(1.1%)% 223%(6.3%)% 459%(12.9%)%
Total! 2507%(70.7%)% 667%(18.8%)% 373%(10.5%)% 3547%
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Most of the patients reported no change in symptom severity after 6 months, 
however of the 459 patients who reported worse fatigue at 6 months than at 
baseline, 85 (2% of the 3547 patients who had an observation for 6 months) 
reported a worsening of 2 or more categories (e.g. going from 0 to 2, or from 1 
to 3 or higher) – see Table 9-2. 
Table 9-2 Cross tabulation between fatigue level at baseline and 6-month visit 
! Fatigue!at!68month!visit! !
Fatigue!at!
Baseline! 0! 1! 2! 3! 4! Total!
0!
124%
(3.5%)%
21%
(0.6%)%
31%
(0.9%)%
13%
(0.4%)%
5%
(0.1%)%
194%
(5.5%)%
1!
27%
(0.8%)%
195%
(5.5%)%
85%
(2.4%)%
18%
(0.5%)%
5%
(0.1%)%
330%
(9.3%)%
2!
39%
(1.1%)%
133%
(3.8%)%
1,150%
(32.4%)%
219%
(6.2%)%
13%
(0.4%)%
1,554%
(43.8%)%
3!
21%
(0.6%)%
39%
(1.1%)%
308%
(8.7%)%
949%
(26.8%)%
49%
(1.4%)%
1,366%
(38.5%)%
4!
5%
(0.1%)%
11%
(0.3%)%
14%
(0.4%)%
28%
(0.8%)%
45%
(1.3%)%
103%
(2.9%)%
Total!
216%
(6.1%)%
399%
(11.3%)%
1,588%
(44.8%)%
1,227%
(34.6%)%
117%
(3.3%)% 3,547%
 
For dyspnoea, 374 (11%) patients reported worsening dyspnoea after 6 months, 
with 23 (<1% of the total 3548) worsening 2 or more categories - see Table 9-3.  
Table 9-3 Cross tabulation between dyspnoea level at baseline and 6-month visit 
! Dyspnoea!at!68month!visit! !
Dyspnoea!at!
Baseline! 0! 1! 2! 3! 4! Total!
0!
1%
(0.03%)%
0%
(0.0%)%
0%
(0.0%)%
0%
(0.0%)%
0%
(0.0%)%
1%
(0.03%)%
1!
18%
(0.5%)%
208%
(5.9%)%
80%
(2.3%)%
14%
(0.4%)%
3%
(0.1%)%
323%
(9.1%)%
2!
15%
(0.4%)%
163%
(4.6%)%
1214%
(34.2%)%
221%
(6.2%)%
6%
(0.2%)%
1619%
(45.6%)%
3!
17%
(0.5%)%
37%
(1.0%)%
367%
(10.3%)%
1057%
(29.8%)%
50%
(1.4%)%
1528%
(43.1%)%
4!
0%
(0.0%)%
8%
(0.2%)%
9%
(0.3%)%
33%
(0.9%)%
27%
(0.8%)%
77%
(2.2%)%
Total!
51%
(1.4%)%
416%
(11.7%)%
1670%
(47.1%)%
1325%
37.3%)%
86%
(2.4%)% 3,548%
 
Correlates of change in fatigue and dyspnoea: People in the lower symptom 
severity groups (no symptoms or on heavy exertion) were more likely to report 
an increase in symptom severity at 6 months (38.8% vs.13% no change or 4.3% a 
decrease), likewise, patients who were on higher NYHA class at baseline were 
more likely to report a decrease (51.1%) or no change (57.9%) in symptom 
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severity at 6 months. Lower systolic blood pressure was associated with an 
increase in both fatigue and dyspnoea at 6 months (p value <0.01 for both).  
Correlates of change in fatigue: People who did reported some change in fatigue 
severity were more likely to be treated with digitalis  (31.9% no change vs. 37.3% 
decrease or 36.6% increase), while people who had a no change or an increase in 
fatigue severity were more likely to be treated with nitrates (22.1% vs. 31% no 
change or 28.5% increase). 
Correlates of change dyspnoea: Patients who reported no change in fatigue 
severity were more likely to have a past history of angina (73.1% vs. 66.1% 
decrease or 69% increase) while history of intermittent claudication was 
associated with an increase (17.9% vs. 12% no change or 12.3% decrease) in 
dyspnoea. 
Baseline characteristics according to change in symptom severity are 
summarised in Table 9-4 below. 
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Table 9-4 Baseline characteristics according to change in symptom severity. 
! ! Change!in!fatigue! Change!in!dyspnoea!
!
All!patients!
(n=3548)!
Unchanged!
(n=2463)!
Decrease!
(n=625)!
Increase!
(n=429)! P!value!
Unchanged!
(n=2507)!
Decrease!
(n=667)!
Increase!
(n=374)! P!value!
Group!1!
!
Group!2!
!
Group!3!
!
!319!(13.0%)!
!
1150!(46.7%)!
!
994!(40.4%)!
27!(4.3%)!
!
172!(27.5%)!
!
426!(68.2%)!
178!(38.8%)!!
!
232!(50.5%)!
!!
49!(10.7%)!! <0.0001!
209!(8.3%)!
!
1214!(48.4%)!
!
1084!(43.2%)!
18!(2.7%)!
!
178!(26.7%)!
!
471!(70.6%)!
97!(25.9%)!!
!
227!(60.7%)!
!!
50!(13.4%)! <0.0001!
Age! 72.94!±!7.10! 72.94!±!7.15! 72.48!±!6.91! 73.57!±!7.04! 0.0454! 72.90!±!7.16! 72.66!±!7.00! 73.71!±!6.86! 0.0635!
Female! 757!(21.3%)! 526!(21.4%)! 137!(21.9%)! 94!(20.5%)! 0.8487! 548!(21.9%)! 132!(19.8%)! 77!(20.6%)! 0.4765!
Race! !
! ! ! !
! ! ! !
Caucasian!
Black!
Asian!
Other!
3492!(98.4%)!
11!(0.3%)!
31!(0.9%)!
14!(0.4%)!
2427!(98.5%)!
7!(0.3%)!
19!(0.8%)!
10!(0.4%)!
610!(97.6%)!
3!(0.5%)!
9!(1.4%)!
3!(0.5%)!
455!(99.1%)!!
0!(0.0%)!!
3!(0.7%)!!
1!(0.2%)!! 0.4739!
2470!(98.5%)!
6!(0.2%)!
20!(0.8%)!
11!(0.4%)!
653!(97.9%)!
3!(0.4%)!
8!(1.2%)!
3!(0.4%)!
369!(98.7%)!!
2!(0.5%)!!
3!(0.8%)!!
0!(0.0%)! 0.6624!
NYHA!III/IV! 1813!(51.1%)! 1258!(51.1%)! 362!(57.9%)! 193!(42.0%)! 0.0001! 1250!(49.9%)! 421!(63.1%)! 142!(38.0%)! 0.0001!
LVEF!(%)! 28.67!±!5.63! 28.78!±!5.62! 28.57!±!5.63! 28.22!±!5.68! 0.1356! 28.77!±!5.56! 28.60!±!5.89! 28.10!±!5.64! 0.0916!
Systolic!BP!mm/Hg! 124.23!±!17.49! 129.55!±!16.60! 127.21!±!16.70! 127.55!±!17.45! 0.0014! 129.64!±!16.52! 127.05!±!16.71! 126.98!±!18.03! 0.0001!
Heart!Rate!bpm! 74.66!±!10.97! 71.41!±!11.31! 71.45!±!11.05! 72.23!±!11.82! 0.3617! 71.55!±!11.20! 71.52!±!11.42! 71.35!±!12.09! 0.9523!
BMI!kg/m2! 26.14!±!4.44! 27.04!±!4.38! 26.92!±!4.57! 26.83!±!4.40! 0.5928! 27.06!±!4.37! 26.93!±!4.57! 26.66!±!4.41! 0.2389!
!BMI<25!kg/m2! 1324!(34.7%)! 206!(37.5%)! 547!(33.4%)! 571!(35.1%)! ! 132!(39.2%)! 590!(34.4%)! 602!(34.0%)! !
!BMI!≥25!and!<30!
kg/m2! 1665!(43.6%)! 243!(44.2%)! 716!(43.7%)! 706!(43/4%)! ! 144!(42.7%)! 738!(43.1%)! 783!(44.3%)! !
!BMI!≥30!kg/m2! 830!(21.7%)! 101!(18.4%)! 377!(23.0%)! 351!(21.6%)! 0.1794! 61!(18.1%)! 386!(22.5%)! 383!(21.7%)! 0.2773!
Years!with!heart!
failure! 4.79!±!5.28! 4.28!±!4.62! 4.29!±!4.83! 4.08!±!4.63! 0.6913! 4.26!±!4.59! 4.19!±!4.83! 4.30!±!4.81! 0.9293!
Current!Smoker! 28!(9.9%)! 228!(9.3%)! 53!(8.5%)! 40!(8.7%)! 0.8035! 227!(9.1%)! 66!(9.9%)! 28!(7.5%)! 0.4296!
MI! 179!(63.5%)! 1518!(61.6%)! 350!(56.0%)! 263!(57.3%)! 0.0158! 1539!(61.4%)! 373!(55.9%)! 220!(58.8%)! 0.0327!
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Angina! 196!(69.5%)! 1792!(72.8%)! 422!(67.5%)! 317!(69.1%)! 0.0179! 1833!(73.1%)! 441!(66.1%)! 258!(69.0%)! 0.0010!
CABG/PCI! 65!(23.0%)! 661!(26.8%)! 186!(29.8%)! 140!(30.5%)! 0.1354! 680!(27.1%)! 194!(29.1%)! 113!(30.2%)! 0.3322!
Hypertension! 167!(59.2%)! 1488!(60.4%)! 388!(62.1%)! 264!(57.5%)! 0.3126! 1512!(60.3%)! 409!(61.3%)! 220!(58.8%)! 0.7307!
Diabetes! 103!(36.5%)! 687!(27.9%)! 187!(29.9%)! 131!(28.5%)! 0.6005! 697!(27.8%)! 191!(28.6%)! 118!(31.6%)! 0.3193!
Baseline!atrial!
fibrillation/!flutter! 74!(26.2%)! 557!(22.6%)! 154!(24.6%)! 110!(24.0%)! 0.5096! 572!(22.8%)! 164!(24.6%)! 85!(22.7%)! 0.6158!
Stroke! 46!(16.3%)! 297!(12.1%)! 86!(13.8%)! 49!(10.7%)! 0.2917! 290!(11.6%)! 90!(13.5%)! 52!(13.9%)! 0.2238!
Intermittent!
Claudication! 46!(16.3%)! 301!(12.2%)! 81!(13.0%)! 68!(14.8%)! 0.3010! 301!(12.0%)! 82!(12.3%)! 67!(17.9%)! 0.0056!
Pacemaker! 26!(9.2%)! 311!(12.6%)! 67!(10.7%)! 50!(10.9%)! 0.3023! 289!(11.5%)! 92!(13.8%)! 47!(12.6%)! 0.2660!
ICD! 8!(2.8%)! 76!(3.1%)! 25!(4.0%)! 13!(2.8%)! 0.4523! 75!(3.0%)! 26!(3.9%)! 13!(3.5%)! 0.4760!
Cholesterol!
mmol/litre! 5.06!±!1.24! 5.37!±!1.06! 5.33!±!1.00! 5.34!±!1.10! 0.5799! 5.38!±!1.06! 5.30!±!1.01! 5.32!±!1.10! 0.1868!
ApoB:ApoA]1!ratio! 0.87!±!0.27! 0.87!±!0.24! 0.88!±!0.25! 0.87!±!0.24! 0.8710! 0.87!±!0.24! 0.87!±!0.25! 0.87!±!0.25! 0.9441!
ApoB!g/L! 1.21!±!0.32! 1.28!±!0.30! 1.26!±!0.28! 1.26!±!0.30! 0.3901! 1.28!±!0.30! 1.25!±!0.29! 1.26!±!0.30! 0.1248!
ApoA]1!g/L! 1.43!±!0.31! 1.50!±!0.27! 1.49!±!0.29! 1.49!±!0.29! 0.5006! 1.51!±!0.27! 1.49!±!0.29! 1.49!±!0.30! 0.3489!
TSH!mIU/L! 2.53!±!3.00! 2.17!±!4.05! 2.32!±!6.99! 2.07!±!1.88! 0.6376! 2.24!±!5.20! 2.02!±!2.23! 2.11!±!1.76! 0.5004!
ALT!IU/L! 19.16!±!67.41! 17.71!±!41.75! 15.84!±!11.56! 18.12!±!28.03! 0.4766! 17.67!±!40.84! 16.89!±!22.64! 17.66!±!29.05! 0.8860!
LDL!mmol/L! 3.29!±!1.01! 3.56!±!0.93! 3.55!±!0.87! 3.52!±!0.94! 0.6752! 3.57!±!0.93! 3.51!±!0.89! 3.52!±!0.94! 0.1921!
Creatinine!μmol/L! 122.81!±!31.45! 116.20!±!27.92! 115.78!±!27.83! 117.55!±!28.77! 0.5586! 115.71!±!27.88! 116.49!±!27.98! 120.02!±!28.88! 0.0210!
NT]proBNP]]
pmol/litre!(median!
386.9![181.2,!
847.8]!
183.5![82.5,!
374.4]!
195.4![88.0,!
383.5]!
198.1![99.0,!
426.6]! 0.0721!
172.8![79.7,!
359.7]!
214.3![93.8,!
413.5]!
245.6![125.0,!
438.5]! 0.0001!
hs]!CRP!mg/litre!
(median)! 5.7![2.4,!13.7]! 3.2![1.5,!6.7]! 3.7![1.6,!8.0]! 3.7![1.6,!7.9]! 0.0336! 3.3![1.6,!7.0]! 3.4![1.5,!7.5]! 3.7![1.5,!7.3]! 0.6365!
Co]enzyme!Q10!!
mmol/L!(median)! 0.7![0.5,!0.9]! 0.8![0.6,!1.0]! 0.7![0.5,!0.9]! 0.7![0.6,!1.0]! 0.0753! 0.8![0.6,!1.0]! 0.7![0.5,!0.9]! 0.7![0.6,!1.0]! 0.0085!
Creatine!Kinase!
UI/L!!(median)!!
39.5![28.0,!
60.0]!
46.0![33.0,!
66.0]! 44.0![32.0,!60.0]! 43.0![32.0,!61.0]! 0.0394! 46.0![33.0,!66.0]! 43.0![32.0,!60.0]! 45.0![32.0,!62.0]! 0.0297!
eGFR!
ml/min/1.73m2! 53.95!±!15.39! 55.93!±!15.43! 56.64!±!15.19! 55.45!±!15.32! 0.4204! 56.19!±!15.31! 56.45!±!15.36! 53.90!±!15.63! 0.0187!
Loop/thiazide!
diuretics! 264!(93.6%)! 2146!(87.1%)! 542!(86.7%)! 411!(89.5%)! 0.3117! 2178!(86.9%)! 583!(87.4%)! 339!(90.6%)! 0.1235!
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ACE!inhibitor!or!
ARB! 248!(87.9%)! 2293!(93.1%)! 580!(92.8%)! 426!(92.8%)! 0.9514! 2322!(92.6%)! 622!(93.3%)! 356!(95.2%)! 0.1852!
MRAs! 123!(43.6%)! 978!(39.7%)! 261!(41.8%)! 191!(41.6%)! 0.5377! 1006!(40.1%)! 265!(39.7%)! 160!(42.8%)! 0.584!
Digitalis! 118!(41.8%)! 786!(31.9%)! 233!(37.3%)! 168!(36.6%)! 0.0124! 824!(32.9%)! 239!(35.8%)! 124!(33.2%)! 0.3506!
Anticoagulant! 104!(36.9%)! 924!(37.5%)! 224!(35.8%)! 181!(39.4%)! 0.4804! 925!(36.9%)! 256!(38.4%)! 148!(39.6%)! 0.5238!
Beta]blockers! 189!(67.0%)! 1866!(75.8%)! 464!(74.2%)! 327!(71.2%)! 0.1117! 1898!(75.7%)! 488!(73.2%)! 272!(72.7%)! 0.2369!
Nitrate! 98!(34.8%)! 764!(31.0%)! 138!(22.1%)! 131!(28.5%)! 0.0001! 761!(30.4%)! 169!(25.3%)! 103!(27.5%)! 0.0313!
Insulin! 32!(11.3%)! 185!(7.5%)! 46!(7.4%)! 40!(8.7%)! 0.6445! 189!(7.5%)! 50!(7.5%)! 32!(8.6%)! 0.7785!
Antiarrhythmic! 46!(16.3%)! 305!(12.4%)! 70!(11.2%)! 58!(12.6%)! 0.6902! 307!(12.2%)! 80!(12.0%)! 46!(12.3%)! 0.9828!
LVEF!–!left!ventricular!ejection!fraction,!NYHA!–!New!York!Heart!Association!functional!class,!BP!–blood!pressure,!CABG/PCI!–!coronary!artery!bypass!grafting/!percutaneous!coronary!
intervention, ICD – implantable cardioverter defibrillator, MRA – Mineralocorticoid receptor antagonists, ACE – angiotensin converting enzyme, ARB – angiotensin II receptor blocker, TSH – thyroid stimulating 
hormone, NT-proBNP – N-terminal of the prohormone brain natriuretic peptide, CRP – – high-sensitivity C-reactive protein. 
Mean and standard deviation (SD) for continuous variables (median and interquartile range [IQR] when appropriate) and percentage for categorical variables are presented.
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Descriptive statistics for number of days from randomisation to the 6-month visit 
according to change in symptom severity are summarised in Table 9-5 and Table 
9-6. There was no difference in the time between visits (randomisation and 6 
months) among those who reported an increase, decrease or unchanged 
symptom severity. 
Table 9-5 Days from randomisation to visit 6 according to change in fatigue 
! Mean! SD! Median! P25! P75!
No!change! 181.5! 10.2! 182! 176! 184!
Decrease! 181.2! 12.2! 182! 175! 184!
Increase! 182.9! 13.4! 182! 177! 187!
 
Table 9-6 Days from randomisation to visit 6 according to change in dyspnoea 
! Mean! SD! Median! P25! P75!
No!change! 181.6! 10.7! 182! 176! 184!
Decrease! 181.3! 11.1! 182! 176! 184!
Increase! 182.9! 12.8! 182! 177! 186!
 
9.2.1.2 Adjusted outcomes 
Correlates of change of both fatigue and dyspnoea (see Tables Table 9-7 and 
Table 9-8): Higher symptom severity at baseline was strongly associated with a 
higher risk of reporting a decrease of symptom severity at 6 months (fatigue: 
group 2 vs. 1 RR 2.02, 95% CI 1.23-3.25; 3 vs. 1 RR 11.01, 95% CI 6.35-19.05; 
dyspnoea: group 2 vs. 1 RR 1.23, 95% CI 1.22-4.07; 3 vs. 1 RR 11.49, 95% CI 5.97-
22.07), with the opposite being true with higher symptom severity at baseline 
was associated with a lower risk of reporting an increase in symptoms after 6 
months. History of angina at baseline was significantly associated with a lower 
risk of reporting a decrease in symptoms (fatigue RR 0.72, 95% CI 0.56-0.92; 
dyspnoea RR 0.63, 95% CI 0.50-0.80; p value <0.01 for both). History of coronary 
intervention (CABG/PCI) was associated with decrease in symptom severity 
(fatigue RR 1.47, 95% CI 1.13-1.90; dyspnoea RR 1.42, 95% CI 1.11-1.81). On the 
other hand, intermittent claudication was associated with a higher risk of 
reporting an increase in symptoms (fatigue RR 1.68. 95% CI 1.17-2.42; dyspnoea 
RR 2.18, 95% CI 1.50-3.16). Similarly, NYHA III/IV at baseline was associated with 
a higher risk of reporting worse symptoms at 6 months (fatigue RR 1.63, 95% CI 
1.20-2.20; dyspnoea 1.86, 95% CI 1.29-2.67), as well as higher NT-proBNP values 
(fatigue RR 1.20, 95% CI 1.02-1.86; dyspnoea RR 1.32, 95% CI 1.12-1.54) 
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Correlates of change in fatigue (see Table 9-7): Higher systolic blood pressures 
were associated with a 12% lower risk for higher fatigue over 6 months. Patients 
on treatment with digitalis were more likely to report a decrease in fatigue over 
6 months (RR 1.38, 95% CI 1.07-1.76, p value=0.01). 
Table 9-7 Correlates of change in fatigue severity 
! Decrease!in!fatigue! Increase!in!fatigue!
!
!
RR! 95%!CI! P!value! RR! 95%!CI! P!value!
Fatigue!2!vs.!1! 2.06! 1.23,!3.45! 0.006! 0.26! 0.19,!0.36! <0.001!
Fatigue!3!vs.!1! 11.01! 6.35,!19.05! <0.001! 0.04! 0.02,!0.06! <0.001!
Age! 0.98! 0.97,!1.00! 0.032! 1.01! 0.99,!1.03! 0.203!
Female! 0.91! 0.69,!1.21! 0.521! 1.06! 0.75,!1.50! 0.738!
LVEF!%! 0.31! 0.04,!2.27! 0.248! 0.48! 0.05,!4.92! 0.536!
NYHA!III/IV! 0.45! 0.33,!0.61! <0.001! 1.63! 1.20,!2.20! 0.002!
Overweight! 0.84! 0.64,!1.09! 0.183! 1.24! 0.91,!1.69! 0.167!
Obese! 0.97! 0.70,!1.33! 0.834! 1.14! 0.77,!1.69! 0.510!
Systolic!BP!p/10!mmHg! 0.93! 0.86,!1.00! 0.045! 0.88! 0.80,!0.96! 0.003!
Heart!rate!p/10!beats/min! 0.97! 0.88,!1.08! 0.618! 1.13! 1.00,!1.28! 0.053!
Years!w/heart!failure! 0.99! 0.97,!1.02! 0.489! 1.00! 0.98,!1.03! 0.816!
Myocardial!Infarction! 0.78! 0.62,!0.99! 0.044! 0.84! 0.63,!1.12! 0.231!
History!of!Diabetes! 1.21! 0.92,!1.58! 0.167! 0.99! 0.71,!1.39! 0.958!
Stroke! 1.10! 0.80,!1.51! 0.573! 1.04! 0.69,!1.58! 0.847!
Hypertension*! 1.09! 0.85,!1.39! 0.493! 1.17! 0.88,!1.56! 0.274!
Baseline!atrial!
fibrillation/flutter! 0.94! 0.68,!1.28!! 0.687! 0.81! 0.55,!1.19! 0.285!
History!of!angina*! 0.72! 0.56,!0.92! 0.010! 1.05! 0.78,!1.42! 0.731!
Intermittent!Claudication! 0.96! 0.69,!1.33! 0.784! 1.68! 1.17,!2.42! 0.005!
CABG/PCI! 1.47! 1.13,!1.90! 0.004! 1.13! 0.83,!1.54! 0.426!
Pacemaker! 0.78! 0.54,!1.11! 0.169! 0.64! 0.42,!0.97! 0.037!
ICD! 1.26! 0.69,!1.33! 0.449! 0.53! 0.24,!1.20! 0.128!
MRAs*! 0.93! 0.73,!1.17! 0.527! 1.23! 0.93,!1.63! 0.138!
Loop/thiazide! 0.85! 0.60,!1.22! 0.382! 1.25! 0.81,!1.94! 0.315!
Beta[blocker! 0.90! 0.69,!1.17! 0.422! 0.73! 0.54,!0.99! 0.046!
Nitrate! 0.67! 0.51,!0.87! 0.003! 0.98! 0.72,!1.33! 0.889!
Insulin! 0.84! 0.52,!1.35! 0.480! 1.23! 0.72,!2.13! 0.446!
Antiarrhythmic! 0.83! 0.57,!1.21! 0.328! 1.30! 0.87,!1.96! 0.198!
ACE!inhibitor!or!ARB! 0.81! 0.53,!1.25! 0.346! 0.90! 0.72,!1.33! 0.889!
Digoxin! 1.38! 1.07,!1.76! 0.012! 1.38! 1.02,!1.86! 0.035!
Anticoagulant! 0.91! 0.70,!1.18! 0.480! 1.05! 0.77,!1.43! 0.751!
TSH!mIU/L! 1.02! 1.00,!1.04! 0.124! 1.01! 0.98,!1.04! 0.689!
Log(NT[proBNP)! 0.95! 0.85,!1.06! 0.392! 1.20! 1.04,!1.38! 0.012!
hs[CRP!mg/litre! 1.01! 1.00,!1.01! 0.159! 1.00! 0.99,!1.01! 0.899!
Alanine!transaminase!IU/L! 1.00! 0.99,!1.00! 0.394! 1.00! 1.00,!1.00! 0.521!
Creatine!kinase!p/50! 0.87! 0.74,!1.03! 0.106! 0.79! 0.64,!0.96! 0.019!
Creatinine!μmol/L! 1.00! 1.00,!1.00! 0.994! 1.00! 0.99,!1.00! 0.159!
Low!density!lipoprotein!
mmol/L! 0.96! 0.85,!1.09! 0.529! 0.95! 0.82,!1.10! 0.485!
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Correlates of change in dyspnoea (see Table 9-8): Older age was associated with 
a 2% reduced risk of reporting a decrease in dyspnoea (RR 0.98, 95% CI 0.96-
1.00, p value=0.01). 
Table 9-8 Correlates of change in dyspnoea severity 
! Decrease!in!dyspnoea! Increase!in!dyspnoea!
!
!
RR! 95%!CI! P!value! RR! 95%!CI! P!value!
Dyspnoea!2!vs.!1! 2.23! 1.22,!4.07! 0.009! 0.25! 0.18,!0.37! <0.001!
Dyspnoea!3!vs.!1! 11.49! 5.97,!22.07! <0.001! 0.04! 0.02,!0.06! <0.001!
Age! 0.98! 0.96,!1.00! 0.013! 1.01! 0.99,!1.03! 0.336!
Female! 0.92! 0.70,!1.21! 0.571! 1.08! 0.74,!1.56! 0.698!
LVEF!%! 1.02! 0.15,!7.07! 0.987! 0.27! 0.02,!3.38! 0.310!
NYHA!III/IV! 0.52! 0.38,!0.73! <0.001! 1.86! 1.29,!2.67! 0.001!
Overweight! 0.82! 0.64,!1.06! 0.126! 1.04! 0.74,!1.45! 0.840!
Obese! 0.95! 0.70,!1.28! 0.723! 1.02! 0.67,!1.56! 0.932!
Systolic!BP!p/10!mmHg! 0.95! 0.88,!1.01! 0.124! 0.90! 0.82,!0.99! 0.034!
Heart!rate!p/10!
beats/min! 0.92! 0.83,!1.02! 0.111! 0.96! 0.83,!1.10! 0.564!
Years!w/heart!failure! 0.99! 0.96,!1.01! 0.243! 1.00! 0.97,!1.04! 0.764!
Myocardial!Infarction! 0.77! 0.62,!0.97! 0.028! 0.90! 0.66,!1.23! 0.512!
History!of!Diabetes! 0.97! 0.74,!1.26! 0.823! 1.23! 0.87,!1.76! 0.246!
Stroke! 1.13! 0.82,!1.55! 0.450! 1.39! 0.93,!2.07! 0.113!
Hypertension*! 1.17! 0.92,!1.48! 0.196! 1.23! 0.90,!1.69! 0.192!
Baseline!atrial!
fibrillation/flutter! 0.84! 0.62,!1.14!! 0.254! 1.00! 0.66,!1.50! 0.984!
History!of!angina*! 0.63! 0.50,!0.80! <0.0001! 1.04! 0.75,!1.45! 0.799!
Intermittent!Claudication! 0.83! 0.60,!1.15! 0.270! 2.18! 1.50,!3.16! <0.0001!
CABG/PCI! 1.42! 1.11,!1.81! 0.006! 0.96! 0.68,!1.34! 0.802!
Pacemaker! 1.08! 0.78,!1.50! 0.622! 1.11! 0.72,!1.71! 0.634!
ICD! 1.37! 0.79,!2.40! 0.264! 1.06! 0.48,!2.33! 0.884!
MRAs*! 0.79! 0.63,!0.99! 0.044! 1.19! 0.88,!1.61! 0.257!
Loop/thiazide! 0.83! 0.59,!1.16! 0.279! 1.21! 0.75,!1.98! 0.437!
Beta[blocker! 0.85! 0.66,!1.09! 0.196! 0.74! 0.53,!1.04! 0.083!
Nitrate! 0.80! 0.62,!1.03! 0.083! 1.07! 0.77,!1.49! 0.689!
Insulin! 0.96! 0.61,!1.51! 0.849! 0.97! 0.52,!1.78! 0.909!
Antiarrhythmic! 0.92! 0.65,!1.31! 0.652! 0.88! 0.55,!1.41! 0.587!
ACE!inhibitor!or!ARB! 1.15! 0.74,!1.76! 0.535! 1.76! 0.92,!3.37! 0.088!
Digoxin! 1.22! 0.96,!1.55! 0.105! 1.22! 0.88,!1.70! 0.223!
Anticoagulant! 1.01! 0.79,!1.30! 0.910! 0.94! 0.66,!1.32! 0.732!
TSH!mIU/L! 0.95! 0.90,!1.01! 0.088! 1.00! 0.97,!1.03! 0.989!
Log(NT[proBNP)! 1.07! 0.96,!1.19! 0.200! 1.32! 1.12,!1.54! 0.001!
hs[CRP!mg/litre! 1.00! 0.99,!1.01! 0.987! 1.00! 0.99,!1.01! 0.898!
Alanine!transaminase!
IU/L! 1.00! 0.99,!1.00! 0.378! 1.00! 1.00,!1.00! 0.527!
Creatine!kinase!p/50! 0.87! 0.74,!1.02! 0.092! 0.85! 0.69,!1.04! 0.122!
Creatinine!μmol/L! 1.00! 1.00,!1.01! 0.359! 1.00! 0.99,!1.01! 0.854!
Low!density!lipoprotein!!
mmol/L! 0.96! 0.85,!1.08! 0.469! 0.97! 0.83,!1.15! 0.755!
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9.2.2 Change in symptom severity and outcomes 
9.2.2.1 Unadjusted outcomes 
Those reporting an increase in fatigue were significantly more likely to die from 
any cause than those reporting no change or decrease in fatigue severity (CV 
death – HR 1.50 95% CI [1.24, 1.82]; all-cause death-HR 1.45 95% CI [1.22, 1.72]). 
Increase in fatigue severity from baseline to six months was also associated with 
hospitalisation due to worsening heart failure (HR 1.42 95% CI [1.17, 1.72]) and 
the composite of cardiovascular death or heart failure hospitalisation (HR 1.42 
95% CI [1.21, 1.65]). (Table 9-9 and Table 9-10 and Figure 9-1)  
Similarly to fatigue, increase in dyspnoea was associated with fatal outcomes 
(CV death-HR 1.52 95% CI [1.24, 1.87]; all death-HR 1.40 95% CI [1.16, 1.69]), 
heart failure hospitalisation (HR 1.64 95% CI [1.35, 2.01]) and the composite 
outcome of CV death or heart failure hospitalisation HR 1.55 95% CI [1.31, 
1.83]). (Table 9-10 and Figure 9-2) 
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Table 9-9 Numbers of events by change in symptoms at 6 months 
! Fatigue( Dyspnoea(
! Unchanged(
(n=2463)(
Decrease(
(n=625)(
Increase(
(n=459)(
P( Unchanged(
(n=2507)(
Decrease(
(n=667)(
Increase(
(n=374)(
P(
Cardiovascular(
death/Heart(
failure(
hospitalisation( 300/541!(34.2%)! 64/126!(30.4%)! 70/128!(43.1%)! <0.001! 310/542!(34.0%)! 69/137!(30.9%)! 55/116!(45.7%)! <0.001!
(
Cardiovascular(
death(( 502!(20.4%)! 115!(18.4%)! 130!(28.3%)! <0.001! 521!(20.8%)! 117!(17.5%)! 109!(29.2%)! <0.001!
Heart(failure(
hospitalisation( 541!(22.0%)! 126!(20.2%)! 128!(27.9%)! 0.007! 542!(21.6%)! 137!(20.5%)! 116!(31.0%)! <0.001!
AllHcause(death((
( 639!(25.9%)! 153!(24.5%)! 160!(34.9%)! <0.001! 664!(26.5%)! 160!(24.0%)! 128!(34.3%)! 0.001!
 
Table 9-10 Unadjusted HR for change in symptom severity and outcomes 
! CV(Death/HF(hospitalisation(
HR((95%CI)(
P( Cardiovascular(death(
HR((95%CI)(
P( HF(hospitalisation(
HR((95%CI)(
P( AllHcause(death((
HR((95%CI)(
P(
Change(in(fatigue(
Decrease( 0.88!(0.75,!1.03)! 0.114! 0.91!(0.74,!1.11)( 0.339! 0.91!(0.75,!1.10)( 0.331! 0.94!(0.79,!1.13)! 0.522!
Increase( 1.42!(1.21,!1.65)! <0.001! 1.50!(1.24,!1.82)( <0.001! 1.42!(1.17,!1.72)( <0.001! 1.45!(1.22,!1.72)! <0.001!
Change(in(dyspnoea(
Decrease( 0.90!(0.77,!1.05)! 0.173! 0.85!(0.69,!1.03)! 0.103! 0.94!(0.78,!1.13)! 0.503! 0.91!(0.76,!1.08)! 0.274!
Increase( 1.55!(1.31,!1.83)! <0.001! 1.52!(1.24,!1.87)! <0.001! 1.64!(1.35,!2.01)! <0.001! 1.40!(1.16,!1.69)! <0.001!
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Figure 9-1 Kaplan Meier curves for clinical outcomes according to change in fatigue severity 
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Figure 9-2 Kaplan Meier curves for clinical outcomes according to change in dyspnoea severity 
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9.2.2.2 Adjusted outcomes 
A total of 2525 (71.2%) patients were included in the complete-case analyses. 
Adjustment for other variables (including NT-proBNP) seemed to strengthen the 
relationship between change in symptom severity and death (Table 9-11). 
Compared with those exhibiting no change in symptoms, those with an increase 
in either symptom had a higher hazard ratio for all outcomes (and the adjusted 
hazard ratio for these outcomes was lower in patients reporting a decrease in 
either fatigue or dyspnoea). Patients with an increase in dyspnoea had a 
significantly higher risk of the composite outcome of cardiovascular death or 
heart failure hospitalisation (HR 1.83 [95%CI 1.47, 1.97]) and the components of 
this composite (CV death HR 1.49 [95%CI 1.12, 1.97]; HF hospitalisation HR 2.39 
[95%CI 1.84, 3.09]). The corresponding findings for increase in fatigue were: CV 
death or heart failure hospitalisation - HR 1.56 (1.27, 1.93); CV death- HR 1.48 
(1.13, 1.92); and HF hospitalisation- HR 1.78 (1.38, 2.28). 
Similarly, when compared with those reporting no change in symptom severity, 
patients with a decrease in symptom severity had lower risks for all outcomes, 
particularly for dyspnoea. Patients with a decrease in dyspnoea had 
approximately a 27% decrease in the risk of the composite outcome of CV death 
of HF hospitalisation (HR 0.73 95% CI [0.60, 0.88]) and similar rates for the 
components of the composite outcome (CV death HR 0.69 95% CI [0.53, 0.88; HF 
hospitalisation HR 0.72, 95% CI [0.57, 0.9]), with similar findings for fatigue. 
(Table 9-11) 
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Table 9-11 Adjusted HR for change in symptom severity and outcomes 
! CV#Death/HF#hospitalisation#
HR#(95%CI)#
P# Cardiovascular#death#
HR#(95%CI)#
P# HF#hospitalisation#
HR#(95%CI)#
P# All@cause#death##
HR#(95%CI)#
P#
Change#in#fatigue#
Decrease# 0.74%(0.61,%0.90)% 0.002% 0.73%(0.56,%0.94)# 0.016% 0.75%(0.59,%0.95)# 0.019% 0.74%(0.59,%0.93)% 0.009%
Increase# 1.56%(1.27,%1.93)% <0.001% 1.48%(1.13,%1.92)# 0.004% 1.78%(1.38,%2.28)# <0.001% 1.45%(1.15,%1.82)% 0.002%
Change#in#dyspnoea#
Decrease# 0.73%(0.60,%0.88)% 0.001% 0.69%(0.53,%0.88)% 0.003% 0.72%(0.57,0.91)% 0.005% 0.75%(0.60,%0.93)% 0.008%
Increase# 1.83%(1.47,%2.29)% <0.001% 1.49%(1.12,%1.97)% 0.006% 2.39%(1.84,%3.09)% <0.001% 1.33%(1.03,%1.72)% 0.029%
Adjusted for: age, sex, NYHA class, LVEF, body mass index, systolic blood pressure, heart rate, smoking, myocardial infarction, CABG or PCI, aortic 
aneurysm, hypertension, diabetes, baseline atrial fibrillation/flutter, stroke, intermittent claudication, pacemaker and cardioverter-defibrillator 
implantations, ApoA-1, ApoB, creatinine, alanine aminotransferase, creatine kinase, thyroid stimulating hormone, high-sensitivity C-reactive protein, and 
log NT-proBNP and baseline symptom severity. 
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10 Impact of rosuvastatin on change in symptom 
severity 
In this chapter I will examine whether treatment with 10 mg rosuvastatin had an 
impact on change in symptom severity from baseline to 6-month visit. 
10.1 Results 
Compared to placebo, a small excess of patients (n=57 +3.1%) on rosuvastatin 
treatment reported an increase in fatigue over six months, and 21 (-1.4%) fewer 
reported improvement, most reported no change 1224 (68.6%) rosuvastatin and 
1196 (70.3%) placebo-treated patients (p value= 0. 021). (Figure 10-1) 
Figure 10-1 Change in fatigue severity according to randomised treatment. 
 
For dyspnoea a similar trend is seen. When compared to placebo, a small excess 
of patients (n=14 +0.4%) on statin treatment reported an increase of symptom 
severity over six months, while fewer patients (n=7 -0.6%) reported an 
improvement of dyspnoea. Same as with fatigue, most patients reported no 
change: 1265 (70.9%) rosuvastatin and 1242 (70.5%) placebo-treated patients (p 
value= 0.885). (Figure 10-2) 
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Figure 10-2 Change in dyspnoea severity according to randomised treatment 
 
Including randomised treatment in the multivariable model did not change the 
results obtained in the previous analysis. An increase in symptom severity at 6 
months continued to be associated with fatal outcomes and hospitalisation due 
to worsening heart failure, and a decrease in symptom severity continued to be 
protective of any outcome (Table 10-1). Treatment with rosuvastatin was not a 
significant predictor of any of the outcomes analysed at the significance level 
that we are considering. 
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Table 10-1 Adjusted HR for change in symptom severity and outcomes: -including randomised treatment 
! CV#Death/HF#hospitalisation#
HR#(95%CI)#
P# Cardiovascular#death#
HR#(95%CI)#
P# HF#hospitalisation#
HR#(95%CI)#
P# All@cause#death##
HR#(95%CI)#
P#
Change#in#fatigue#
Decrease# 0.73%(0.60,%0.89)% 0.002% 0.73%(0.56,%0.95)# 0.017% 0.74%(0.58,%0.94)# 0.014% 0.74%(0.59,%0.93)% 0.009%
Increase# 1.58%(1.29,%1.95)% <0.001% 1.47%(1.13,%1.91)# 0.004% 1.82%(1.42,%2.34)# <0.001% 1.44%(1.14,%1.82)% 0.002%
Change#in#dyspnoea#
Decrease# 0.73%(0.60,%0.88)% 0.001% 0.69%(0.53,%0.88)% 0.003% 0.72%(0.57,%0.91)% 0.005% 0.75%(0.60,%0.93)% 0.008%
Increase# 1.84%(1.48,%2.30)% <0.001% 1.48%(1.12,%1.97)% 0.007% 2.41%(1.86,%3.12)% <0.001% 1.33%(1.03,%1.72)% 0.030%
Adjusted for: age, sex, NYHA class, LVEF, body mass index, systolic blood pressure, heart rate, smoking, myocardial infarction, CABG or PCI, aortic 
aneurysm, hypertension, diabetes, baseline atrial fibrillation/flutter, stroke, intermittent claudication, pacemaker and cardioverter-defibrillator 
implantations, ApoA-1, ApoB, creatinine, alanine aminotransferase, creatine kinase, thyroid stimulating hormone, high-sensitivity C-reactive protein, and 
log NT-proBNP, baseline symptom severity and randomised treatment 
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10.2 Summary of results  
I found that a limited number of variables (lower symptom severity at baseline, 
higher NT-proBNP, intermittent claudication and NYHA class III/IV) were 
independently associated with a higher risk of worsening symptoms after 6 
months, while history of angina was inversely associated with an increase in 
symptoms. Statin treatment was not associated with change in symptoms over 
time, however a trend is evident where a small proportion statin-treated 
patients are more likely to report worsening of fatigue. The results I obtained 
from this cohort mirror the results from my previously published paper looking at 
the impact of statin treatment on fatigue in patients with heart failure which 
was done at the same time point (randomisation visit). (269) In said publication 
the entire spectrum of LVEF (n=5010) was analysed.  
Although most patients reported no change in symptoms over time, worsening 
symptoms were associated with an increased risk of adverse outcomes (both 
fatal and non-fatal), while a decrease in symptoms over time was associated 
with a lower risk of adverse outcomes. Treatment with rosuvastatin was not a 
significant predictor of any of the outcomes analysed. 
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11  Analyses on PARADIGM-HF 
In this section I will present results from analyses performed on 8399 patients 
enrolled in the PARADIGM-HF trial.  
11.1 Symptoms on effort 
Of the 8399 patients randomised in PARADIGH-HF, 8382 had an observation for 
fatigue on effort at randomisation visit, out of which, 4343 (51.8%) reported 
having fatigue on effort, while 8383 had record for dyspnoea at randomisation, 
with 7207 (86%) reporting dyspnoea on effort and only 309 (3.7%) dyspnoea at 
rest. Due to small numbers, dyspnoea on rest was not analysed. 
Overall, 4068 (48.5%) of the patients reported some level of fatigue and 
dyspnoea, while only 901 (11%) reported not having either fatigue or dyspnoea 
on effort. Table 11-1 
Table 11-1 Cross-tabulation between symptoms on effort at randomisation: PRADIGM-HF 
! Dyspnoea!
Fatigue! No!Dyspnoea! Dyspnoea!on!effort! Total!
No!fatigue! 901$(10.8%)$ 3138$(37.4%)$ 4093$(48.2%)$
Fatigue!on!effort! 275$(3.3%)$ 4068$(48.5%)$ 4343$(51.8%)$
Total! 1176$(14.0%)$ 7206$(86.0%)$ 8382(100%)3$
 
  
                                         
3 Percentages in brackets represent cell percentages (i.e. 8382 is the denominator). 
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Table 11-2  
Table 11-3 show the distribution of fatigue and dyspnoea within each NHYA 
class. 
Table 11-2 Tabulation between fatigue and NYHA class at baseline 
Fatigue!status! ! ! ! ! NYHA!class!at!baseline! !
$ I$ II$ III$ IV$ Total$
No$fatigue$ 348$
(8.6%)$
3242$
(80.3%)$
445$(11.0%)$ 4$$
(0.1%)$
4039$
Fatigue$on$effort$ 41$(0.9%)$ 2673$
(61.2%)$
1573$(36.2%)$ 56$(1.3%)$ 4343$
Total$ 389$
(4.6%)$
5915$
(70.6%)$
2018$(24.1%)$ 60$(0.7%)$ 8382$
 
Table 11-3 Tabulation between dyspnoea and NYHA class at baseline 
Dyspnoea!status! ! ! ! ! NYHA!class!at!baseline! !
$ I$ II$ III$ IV$ Total$
No$dyspnoea$ 271$
(23.0%)$
835$
(71.0%)$
67$(5.7%)$ 3$(0.3%)$ 1176$
Dyspnoea$on$effort$ 118$(1.6%)$ 5081$
(70.5%)$
1951$
(27.1%)$
57$(0.8%)$ 7207$
Total$ 389$(4.6%)$ 5915$
(70.6%)$
2018$
(24.1%)$
60$(0.7%)$ 8383$
 
11.2 Correlates of symptoms on effort 
Baseline characteristics according to symptom status at randomisation are 
summarised in Table 11-4.  
11.2.1.1 Unadjusted outcomes 
In summary, patients who had symptoms on effort (fatigue or dyspnoea) were 
more likely to be older (on average 1 year older than those without symptoms), 
Caucasian (fatigue 72%; dyspnoea 68%), female (fatigue 25% vs. 19%; dyspnoea 
22% vs. 19%), were less likely to have an implanted cardioverter defibrillator 
(fatigue 14% vs. 16%; dyspnoea 14% vs. 20%), were more likely to be NYHA class 
III/IV (fatigue 37% vs. 11%; dyspnoea 28% vs. 6%), had slightly higher systolic 
blood pressures (both systolic and diastolic) and LVEF. They also had a longer 
history with heart failure (more than one year since diagnosis), were more likely 
to have a history of COPD (fatigue 15% vs. 11%; dyspnoea 13% vs. 10%), renal 
disease (fatigue 20% vs. 15%; dyspnoea 18% vs. 14%), hypertension (fatigue 73% 
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vs. 68%; dyspnoea 71% vs. 67%), stable angina (fatigue 28% vs. 14%; dyspnoea 23% 
vs. 14%), myocardial infarction (fatigue 45% vs. 41%; dyspnoea 44% vs. 37%). 
Patients with symptoms were also more likely to have a history of atrial 
fibrillation or to have atrial fibrillation on baseline ECG and more commonly had 
heart failure of ischaemic aetiology (fatigue 63% vs. 57%; dyspnoea 61% vs. 54%). 
Not surprisingly, higher Kansas City Cardiomyopathy Questionnaire summary 
scores were associated with no symptoms at randomisation. Patients treated 
with anticoagulants, diuretics or digoxin were more likely to be symptomatic. 
Patients who reported fatigue on effort were heavier (approximately 2 kg 
heavier or 1 unit in BMI than those without fatigue), had slightly higher heart 
rate, and were more likely to be current smokers or have a prior hospitalisation 
due to heart failure (65% vs. 60%). They were also more likely to have a history 
of unstable angina (13% vs. 10%) or stroke (10% vs. 8%). Patients who reported 
drinking 1-2 alcoholic drinks per day (vs. less than one drink a day) were also 
more likely to report fatigue on effort. Higher NT-ProBNP levels were also 
associated with fatigue on effort, as was use of aspirin, MRAs and digoxin.  
Patients who reported having dyspnoea on effort were less likely to have a 
history of asthma (4% vs. 5%).  
133 
 
Table 11-4 Baseline characteristics according to symptom status 
!
All!patients! No!fatigue!on!
effort! Fatigue!on!effort!
!
No!dyspnoea!on!
effort!
Dyspnoea!on!
effort!
!
!
(n=8399)! (n=4039)! (n=4343)!! p!value! (n=1176)! (n=7206)! p!value!
Age! 63.79&±&11.39& 63.41&±&11.41& 64.16&±&11.34& 0.003& 61.67&±&11.78& 64.15&±&11.28& <0.001&
Race! &
& &
<0.001& & & <0.001&
Caucasian! 5544&(66.0%)& 2415&(59.8%)& 3119&(71.8%)&&
&
625&(53.1%)& 4909&(68.1%)&& &
Black! 428&(5.1%)& 279&(6.9%)& 147&(3.4%)&&
&
124&(10.5%)& 302&(4.2%)&& &
Asian! 1509&(18.0%)& 844&(20.9%)& 661&(15.2%)&&
&
324&(27.6%)& 1182&(16.4%)&& &
Other! 918&(80.9%)& 501&(12.4%)& 416&(9.6%)&&
&
103&(8.8%)& 814&(11.3%)&& &
Region! &
& &
<0.001& & & <0.001&
North!America! 602&(7.2%)& 284&(7.0%)& 316&(7.3%)&&
&
148&(12.6%)& 452&(6.3%)&& &
Latin!America! 1433&(17.1%)& 933&(23.1%)& 498&(11.5%)&&
&
206&(17.5%)& 1225&(17.0%)&& &
Western!Europe! 2051&(24.45)& 1185&(29.3%)& 861&(19.8%)&&
&
341&(29.0%)& 1705&(23.7%)&& &
Central!Europe! 2826&(33.7%)& 804&(19.9%)& 2019&(46.5%)&&
&
159&(13.5%)& 2664&(37.0%)&& &
AsiaMPacific! 1487&(17.7%)& 833&(20.6%)& 649&(14.9%)&&
&
322&(27.4%)& 1161&(16.1%)&& &
Female! 1832&(21.8%)& 750&(18.6%)& 1082&(24.9%)& <0.001& 221&(18.8%)& 1611&(22.4%)& 0.006&
ICD!(including!CRT)! 1243&(14.8%)& 651&(16.2%)& 590&(13.6%)& <0.001& 230&(19.6%)& 1011&(14.0%)& <0.001&
Weight!(kg)! 80.65&±&19.08& 79.56&±&18.59& 81.65&±&19.49& <0.001& 79.79&±&19.41& 80.78&±&19.03& 0.099&
Body!mass!index!(kg/m2)! 28.17&±&5.52& 27.84&±&5.33& 28.47&±&5.68& <0.001& 27.85&±&5.57& 28.22&±&5.51& 0.036&
BMI!<25!kg/m2! 2421&(28.9%)& 1229&(30.5%)& 1188&(27.4%)& & 366&(31.2%)& 2052&(28.5%)& &
BMI!≥25!and!<30!kg/m2! 13249&(38.7%)& 1607&(39.8%)& 1635&(37.7%)& & 453&(38.6%)& 2789&(38.7%)& &
BMI!≥!30!kg/m2! 2719&(32.4%)& 1198&(29.7%)& 1515&(34.9%)& <0.001& 354&(30.2%)& 2359&(32.8%)& 0.099&
NYHA!class! &
& &
<0.001& & & <0.001&
I! 389&(4.6%)& 348&(8.6%)& 41&(0.9%)&&
&
271&(23.0%)& 118&(1.6%)&& &
II! 5919&(70.6%)& 3242&(80.3%)& 2673&(61.5%)&&
&
835&(71.0%)& 5081&(70.5%)&& &
III! 2018&(24.1%)& 445&(11.0%)& 1573&(36.2%)&&
&
67&(5.7%)& 1951&(27.1%)&& &
IV! 60&(0.72%)& 4&(0.1%)& 56&(1.3%)&&
&
3&(0.3%)& 57&(0.8%)&& &
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Heart!rate!(bmp)! 72.35&±&12.01& 71.65&±&11.78& 73.03&±&12.19& <0.001& 71.72&±&11.90& 72.47&±&12.03& 0.048&
Systolic!blood!pressure!
(mm/Hg)!
121.38&±&15.32&
120.73&±&15.87& 122.00&±&14.76& <0.001& 119.69&±&15.75& 121.66&±&15.23& <0.001&
Diastolic!blood!pressure!
(mm/Hg)!
73.59&±&10.08&
72.96&±&10.23& 74.19&±&9.90& <0.001& 72.69&±&10.46& 73.74&±&10.01& <0.001&
Pulse!pressure!(mm/Hg)! 42.80&±&12.47& 47.77&±&12.89& 47.81&±&12.07& 0.880& 47.01&±&12.99& 47.92&±&12.38& 0.020&
Current!smoker! 1208&(14.4%)& 536&(13.3%)& 669&(15.4%)& 0.005& 163&(13.9%)& 1043&(14.5%)& 0.580&
LVEF!(%)! 29.49&±&6.22& 29.13&±&6.26& 29.82&±&6.16& <0.001& 28.32&±&6.49& 29.68&±&6.15& <0.001&
Medical(history( ! ! ! ! ! ! !
Prior!heart!failure!
hospitalisation! 5274&(62.8%)& 2426&(60.1%)& 2838&(65.3%)& <0.001& 764&(65.0%)& 4501&(62.5%)& 0.098&
Time!since!diagnosis!of!heart!failure&
& &
0.003& & & 0.003&
≤1!year! 2523&(30.0%)& 1283&(31.8%)& 1234&(28.4%)&&
&
403&(34.3%)& 2115&(29.3%)&& &
1M5!years!! 3232&(38.5%)& 1502&(37.2%)& 1721&(39.6%)&&
&
425&(36.1%)& 2798&(38.8%)&& &
≥5!years! 2644&(31.5%)& 1254&(31.0%)& 1388&(32.0%)&&
&
348&(29.6%)& 2294&(31.8%)&& &
Asthma! 314&(3.7%)& 157&(3.9%)& 156&(3.6%)& 0.476& 61&(5.2%)& 252&(3.5%)& 0.005&
COPD! 1080&(12.9%)& 445&(11.0%)& 632&(14.6%)& <0.001& 113&(9.6%)& 964&(13.4%)& <0.001&
Cancer! 413&(4.95)& 204&(5.1%)& 208&(4.8%)& 0.580& 47&(4.0%)& 365&(5.1%)& 0.116&
Renal!disease! 1453&(17.3%)& 592&(14.7%)& 853&(19.6%)& <0.001& 167&(14.2%)& 1279&(17.7%)& 0.003&
Hypertension! 5940&(70.75)& 2746&(68.0%)& 3183&(73.3%)& <0.001& 783&(66.6%)& 5147&(71.4%)& <0.001&
Diabetes! 2896&(34.5%)& 1386&(34.3%)& 1516&(34.9%)& 0.570& 376&(32.0%)& 2527&(35.1%)& 0.039&
Unstable!angina! 970&(11.6%)& 401&(9.9%)& 565&(13.0%)& <0.001& 120&(10.2%)& 846&(11.7%)& 0.127&
Stable!angina! 1794&(21.4%)& 569&(14.1%)& 1219&(28.1%)& <0.001& 166&(14.1%)& 1622&(22.5%)& <0.001&
Myocardial!Infarction! 3634&(43.35)& 1662&(41.1%)& 1963&(45.2%)& <0.001& 440&(37.4%)& 3185&(44.2%)& <0.001&
PCI! 1801&(21.4%)& 892&(22.1%)& 903&(20.8%)& 0.150& 280&(23.8%)& 1515&(21.0%)& 0.031&
CABG! 1303&(15.5%)& 617&(15.3%)& 682&(15.7%)& 0.589& 171&(14.5%)& 1128&(15.7%)& 0.3291&
History!of!AF! 3091&(36.8%)& 1297&(32.1%)& 1787&(41.1%)& <0.001& 346&(29.4%)& 2738&(38.0%)& <0.001&
AF!on!baseline!ECG! 2036&(24.2%)& 803&(19.9%)& 1229&(28.3%)& <0.001& 201&(17.1%)& 1831&(25.4%)& <0.001&
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Stroke! 735&(8.6%)& 306&(7.6%)& 418&(9.6%)& <0.001& 86&(7.3%)& 639&(8.9%)& 0.079&
Ischaemic!aetiology! 5036&(60.0%)& 2298&(56.9%)& 2725&(62.7%)& <0.001& 639&(54.3%)& 4385&(60.8%)& <0.001&
TIA! 272&(3.2%)& 117&(2.9%)& 152&(3.5%)& 0.118& 28&(2.4%)& 241&(3.3%)& 0.082&
Coronary!heart!disease! 4585&(54.6%)& 2012&(49.8%)& 2563&(59.0%)& <0.001& 540&(45.9%)& 4036&(56.0%)& <0.001&
Clinically!significant!valvular!
heart!disease! 604&(7.2%)& 267&(6.6%)& 336&(7.7%)& 0.046& 79&(6.7%)& 524&(7.3%)& 0.496&
Abdominal!aortic!aneurism! 110&(1.3%)& 51&(1.3%)& 58&(1.3%)& 0.769& 14&(1.2%)& 95&(1.3%)& 0.721&
Renal!artery!stenosis! 34&(0.4%)& 16&(0.4%)& 17&(0.4%)& 0.973& 6&(0.5%)& 27&(0.4%)& 0.491&
Intermittent!claudication! 392&(4.7%)& 167&(4.1%)& 224&(5.2%)& 0.0265& 42&(3.6%)& 350&(4.9%)& 0.053&
Lower!limb!revascularisation!! 148&(1.8%)& 74&(1.8%)& 74&(1.7%)& 0.656& 21&(1.8%)& 127&(1.8%)& 0.955&
Lower!limb!stenosis!
documented!by!imaging! 236&(2.8%)& 107&(2.6%)& 129&(3.0%)& 0.375& 31&(2.6%)& 205&(2.8%)& 0.689&
KCCQ!clinical!summary!score! 75&±&19.32& 82.09&±&16.87& 70.50&±&19.71& <0.001& 84.33&±&16.93& 74.68&±&19.34& <0.001&
1M2!drinks!(alcohol)!per!day! 983&(11.7%)& 511&(12.7%)& 470&(10.8%)& 0.009& 137&(11.6%)& 844&(11.7%)& 0.952&
Medication( ! ! ! ! ! ! !
ACE!inhibitors! 6532&(77.8%)& 3080&(76.3%)& 3436&(79.1%)& 0.002& 898&(76.4%)& 5619&(78.0%)& 0.220&
ARBs! 1892&(22.5%)& 969&(24.0%)& 922&(21.2%)& 0.003& 276&(23.5%)& 1615&(22.4%)& 0.420&
MRAs! 4671&(55.6%)& 2145&(53.15)& 2518&(58.0%)& <0.001& 643&(54.7%)& 4021&(55.8%)& 0.475&
BetaMblocker! 7811&(93.0%)& 3753&(92.9%)& 4043&(93.1%)& 0.7560& 1091&(92.8%)& 6706&(93.1%)& 0.730&
Digoxin! 2539&(30.2%)& 1124&(27.85)& 1414&(32.6%)& <0.001& 3169&(26.9%)& 2222&(30.8%)& 0.006&
Anticoagulant! 2685&(32.0%)& 1158&(28.7%)& 1523&(35.1%)& <0.001& 300&(25.5%)& 2381&(33.0%)& 0.0001&
Aspirin! 4349&(51.8%)& 2172&(53.8%)& 2166&(49.9%)& <0.001& 626&(53.2%)& 3713&(51.5%)& 0.276&
Adenosine!diphospate!
antagonist! 1260&(15.0%)& 608&(15.1%)& 649&(14.9%)& 0.888& 182&(15.5%)& 1075&(14.9%)& 0.618&
Lipid!lowering!! 4729&(56.3%)& 2307&(57.1%)& 2413&(55.6%)& 0.151& 640&(54.4%)& 4081&(56.6%)& 0.158&
Diuretics!! 6738&(80.2%)& 3145&(77.9%)& 3582&(82.5%)& <0.001& 835&(71.0%)& 5893&(81.8%)& <0.001&
ACE!inhibitors!or!ARB! 8379&(99.8%)& 4028&(99.7%)& 4334&(99.8%)& 0.542& 1168&(99.3%)& 7195&(99.8%)& 0.001&
Laboratories( ! ! ! ! ! ! !
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NTMproBNP!
Mpmol/litre!
(median)!
1615&[888,&3231]&
1557.5&[879.0,&
3024.0]&
1669.0&[903.0,&
3431.0]& 0.007&
1568.0&[888.0,&
3202.0]&
1620.0&[888.0,&
3234.0]& 0.806&
Haemoglobin!A1C!%! 6.5&±&1.4
&
6.5&±&1.4& 6.6&±&1.4& 0.042& 6.5&±&1.4& 6.6&±&1.4& 0.079&
Estimated!GFR!
(mL/min/1.73m^2)! 67.7&±&20.11& 68.04&±&20.15& 67.40&±&20.04& 0.149& 68.61&±&19.98& 67.56&±&20.11& 0.095&
Creatinine!(umol/L)! 99.31&±&26.32& 99.97&±&25.88& 98.64&±&26.71& 0.021& 100.12&±&25.26& 99.15&±&26.49& 0.241&
Haemoglobin!g/L! 139.4&±&16.0& 139.5&±&16.0& 139.3&±&16.0& 0.623& 139.0&±&16.3& 139.4&±&16.0& 0.392&
LVEF – left ventricular ejection fraction, NYHA – New York Heart Association functional class, BMI – body mass index BP – blood pressure, CABG/PCI – coronary artery bypass grafting/ 
percutaneous coronary intervention, ICD – implantable cardioverter defibrillator, LDL – low density lipoprotein, NT-proBNP – N-terminal of the prohormone brain natriuretic peptide, hs-CRP – 
high-sensitivity C-reactive protein, TSH – thyroid stimulating hormone, ACE – angiotensin converting enzyme, ARB – angiotensin II receptor blocker, MRA – Mineralocorticoid receptor 
antagonist. 
Mean and standard deviation (SD) for continuous variables and percentage for categorical variables are presented. 
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11.2.2 Multivariate analysis 
All available baseline characteristics were included in the model (except for 
troponin as >75% of the patients were missing a baseline troponin value). A 
logistic regression adjusted for all variables in Table&11(5 was run for fatigue and 
then again for dyspnoea. Caucasian race and the region of Western Europe were 
used as reference.  
A total of 7,326 patients were included in the analysis mostly due to missing 
Kansas City Cardiomyopathy clinical summary scores (776 missing observations) 
and haemoglobin levels at randomisation (274 missing observations). 
Correlates with both fatigue and dyspnoea on effort: People from Central 
Europe were more likely than those from Western Europe to report symptoms on 
effort (fatigue OR 2.41 95% CI [2.07, 2.81]; dyspnoea OR 2.19 [1.72, 2.80]). 
Again, not surprisingly, higher KCCQ summary scores were associated with a 
lower risk of reporting symptoms (2% lower risk for both fatigue and dyspnoea). 
Similarly, higher NYHA class was associated with a higher risk of reporting 
symptoms on effort, with the association being stronger for dyspnoea than for 
fatigue. 
Correlates with fatigue only: Female sex was associated with a 33% higher risk 
of reporting fatigue on effort (95% CI 1.09-1.63; p value <0.01). People from 
Latin America were 35% less likely to report fatigue than those from Western 
Europe (95% CI 0.52-0.81, p value <0.01); the were also less likely to have a 
history of hypertension (OR 0.82 [0.72, 0.93]) but more likely to have a history 
of stable angina (OR 1.48 [1.28, 1.71]. People with a normal BMI (<25 kg/m2) 
were less likely to report fatigue on effort. 
Correlates with dyspnoea only: Only diuretic use was uniquely associated with 
dyspnoea (OR 1.56, 95% CI [1.29, 1.87] p value<0.01. 
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Table&11(5&Correlates&of&symptoms&
& Fatigue&on&effort& Dyspnoea&on&effort&
& OR&(95%&CI)& p&value& OR&(95%&CI)& &
Age&p/10&years& 0.99&(0.93,1.06)& 0.802& 1.00&(0.94,&1.13)& 0.482&
Female& 1.33&(1.09,&1.63)& 0.005& 1.10&(0.81,&1.49)& 0.542&
Race% & & & &
Black& 0.81&(0.61,1.06)& 0.126& 0.61&(0.47,&0.90)& 0.009&
Asian& 1.28&(0.69,&2.35)& 0.429& 1.99&(0.72,&5.48)& 0.182&
Other& 1.88&(1.49,&2.36)& <0.001& 1.31&(0.95,&1.80)& 0.094&
Region%
& &
&
North&America& 1.67&(1.34,&2.08)& <0.001& 0.61&(0.46,&0.80)& <0.001&
Latin&America& 0.65&(0.52,&0.81)& <0.001& 1.39&(1.05,&1.83)& 0.020&
Central&Europe& 2.41&(2.07,&2.81)& <0.001& 2.19&(1.72,&2.80)& <0.001&
Asia(Pacific& 1.27&(0.69,&2.35)& 0.450& 0.65&(0.23,&1.79)& 0.323&
Pacemaker& 1.06&(0.85,&1.32)& 0.614& 1.10&(0.77,&1.57)& 0.584&
ICD/CRT& 0.84&(0.65,&1.08)& 0.168& 0.71&(0.48,&1.03)& 0.074&
Weight&(kg)& 1.00&(1.00,&1.01)& 0.321& 1.00&(0.99,&1.01)& 0.922&
BMI&(kg/m2)& 0.98&(0.96,&1.01)& 0.142& 0.98&(0.95,&1.01)& 0.152&
KCCQ&clinical&summary&
score& 0.98&(0.97,&0.98)& <0.001& 0.98&(0.98,&0.99)& <0.001&
1(2&drinks&per&day& 0.96&(0.82,&1.13)& 0.659& 1.12&(0.88,&1.43)& 0.341&
NYHA%functional%class% % % % %
NYHA&II& 4.45&(3.10,&6.38)& <0.001& 12.11&(9.26,&15.85)& <0.001&
NYHA&III& 11.38&(7.77,&16.66)& <0.001& 37.68&(25.60,&55.52)& <0.001&
NYHA&IV& 33.46&(9.69,&115.53)& <0.001& 22.14&(5.11,&95.92)& <0.001&
Heart&rate&p/10&bpm& 1.00&(0.95,&1.04)& 0.853& 0.98&(0.92,&1.05)& 0.662&
SBP&p/10&mmHg& 0.98&(0.95,&1.02)& 0.414& 1.04&(0.98,&1.09)& 0.209&
Current&smoker& 1.18&(1.01,&1.37)& 0.040& 0.93&(0.74,&1.17)& 0.530&
LVEF&(%)& 1.00&(0.99,&1.01)& 0.969& 1.01&(1.00,&1.02)& 0.093&
Prior&HF&hospitalisation& 1.01&(0.91,&1.13)& 0.813& 0.74&(0.63,&0.87)& <0.001&
Years%since%HF%diagnosis% % % %
1(5&years&& 0.97&(0.85,&1.10)& 0.618& 1.04&(0.86,&1.26)& 0.690&
>5&years&& 0.90&(0.78,&1.04)& 0.141& 1.00&(0.81,&1.23)& 0.990&
Past%medical%history% % % %
Asthma& 0.85&(0.64,&1.11)& 0.225& 0.72&(0.50,&1.02)& 0.068&
COPD& 1.02&(0.87,&1.20)& 0.775& 1.31&(1.01,&1.70)& 0.043&
Cancer& 1.06&(0.83,&1.37)& 0.655& 1.64&(1.13,&2.40)& 0.010&
Renal&disease& 1.20&(1.03,&1.40)& 0.021& 0.95&(0.75,&1.20)& 0.648&
Hypertension& 0.82&(0.72,&0.93)& 0.002& 0.90&(0.74,&1.08)& 0.241&
Diabetes& 0.91&(0.79,&1.04)& 0.167& 1.18&(0.96,&1.45)& 0.109&
Unstable&angina& 1.08&(0.91,&1.28)& 0.386& 0.90&(0.69,&1.16)&& 0.414&
Stable&angina& 1.48&(1.28,&1.71)& <0.001& 1.07&(0.85,&1.34)& 0.582&
Myocardial&infarction& 1.04&(0.89,&1.21)& 0.650& 1.19&(0.94,&1.50)& 0.143&
Coronary&revascularisation& 0.99&(0.86,&1.15)& 0.933& 0.77&(0.61,&0.96)& 0.019&
History&of&AF& 0.90&(0.76,&1.07)& 0.250& 0.98&(0.76,&1.26)& 0.874&
AF&on&baseline&ECG& 1.13&(0.93,&1.37)& 0.203& 1.04&(0.78,&1.40)& 0.770&
Stroke& 1.02&(0.84,&1.23)& 0.849& 0.94&(0.70,&1.26)& 0.686&
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11.3 Symptoms as predictors of outcome: PARADIGM-HF 
I tested the prognostic value of each symptom in relation to the composite 
outcome of cardiovascular death or hospitalisation due to worsening heart 
failure (heart failure) using Cox proportional-hazard regression models 
(described in Methods chapter). Cardiovascular death or hospitalisation due to 
worsening heart failure was the primary composite endpoint for PARADIGM-HF. I 
also analysed the components of the composite (cardiovascular death and heart 
failure hospitalisation individually) and all-cause death. I used two different 
models: one similar to the one used in the CORONA analyses (with all available 
variables in PARADIGM) and another model which is currently being developed 
for the composite endpoint of cardiovascular death or heart failure 
hospitalisation (J. Simpson- BHF Cardiovascular Research Centre, University of 
Glasgow).  
Ischaemic&aetiology&of&HF& 0.85&(0.72,&1.01)& 0.072& 0.84&(0.65,&1.07)& 0.162&
TIA& 1.24&(0.92,&1.65)& 0.154& 1.46&(0.92,&2.33)& 0.109&
Coronary&heart&disease& 1.14&(0.96,&1.34)& 0.127& 1.25&(0.98,&1.59)& 0.072&
Valvular&heart&disease& 1.08&(0.88,&1.32)& 0.462& 1.12&(0.84,&1.51)& 0.441&
Abdominal&aortic&aneurysm& 0.94&(0.60,&1.45)& 0.773& 0.87&(0.47,&1.62)& 0.660&
Renal&artery&stenosis& 0.60&(0.26,&1.37)& 0.225& 0.72&(0.22,&2.36)& 0.591&
Intermittent&claudication& 1.03&(0.80,&1.31)& 0.833& 1.01&(0.70,&1.48)& 0.941&
Medication%% % % % %
ARB/ACE& 1.50&(0.52,&4.33)& 0.451& 4.11&(1.31,&12.88)& 0.015&
MRAs& 1.13&(1.01,&1.26)& 0.029& 1.00&(0.85,&1.18)& 0.994&
Beta(blocker& 0.99&(0.79,&1.22)& 0.898& 0.96&(0.69,&1.33)& 0.805&
Digoxin& 1.14&(1.01,&1.30)& 0.039& 1.10&(0.91,&1.33)& 0.327&
Diuretics& 0.94&(0.82,&1.08)& 0.357& 1.56&(1.29,&1.87)& <0.001&
Anticoagulant& 1.10&(0.95,&1.28)& 0.208& 1.07&(0.85,&1.33)& 0.570&
Aspirin& 0.92&(0.82,&1.05)& 0.217& 0.97&(0.81,&1.17)& 0.776&
Adenosine&diphospate&
antagonist& 1.03&(0.88,&1.20)& 0.748& 1.10&(0.86,&1.39)& 0.449&
Lipid&lowering& 0.94&(0.84,&1.07)& 0.356& 1.19&(0.99,&1.43)& 0.064&
Laboratories% & & & &
eGFR&(mL/min/1.73m^2)& 1.00&(0.99,&1.01)& 0.707& 1.00&(0.99,&1.01)& 0.496&
Creatinine&μmol/L& 1.00&(1.00,&1.01)& 0.838& 1.00&(0.99,&1.01)& 0.576&
Log(NT(proBnp)& 0.97&(0.92,&1.03)& 0.313& 0.91&(0.84,&1.00)& 0.044&
Haemoglobin&A1C& 1.03&(0.99,&1.08)& 0.172& 1.00&(0.93,&1.07)& 0.918&
Haemoglobin& 1.00&(1.00,&1.00)& 0.954& 1.00&(1.00,&1.01)& 0.245&
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The model similar to the one used in the CORONA cohort was adjusted for the 
following variables: sex, age, NYHA class, LVEF, systolic blood pressure, heart 
rate, smoking status, baseline BMI, coronary intervention (CABG/PCI), history of 
myocardial infarction, history of aortic aneurism, history of hypertension, 
stroke, diabetes, intermittent claudication, pacemaker or cardioverter 
defibrillator implantation, atrial fibrillation at baseline ECG, serum creatinine 
and a logarithmic transformation of NT-proBNP; thyroid stimulating hormone, hs-
CRP, CK, ALT Apo-A1 and Apo-B were not available in PRADIGM-HF, hence were 
not included in the model. 
The model under development for PARADIGM-HF was adjusted for the following 
covariates: age, sex, race, region, systolic blood pressure, heart rate, NYHA 
class, LVEF, prior HF hospitalisation, time since diagnosis of HF, history of 
myocardial infarction, diabetes, coronary intervention, haemoglobin levels, 
serum creatinine, albumin levels, haemoglobin A1C levels, potassium levels, 
beta-blocker use, randomised treatment, the interaction between prior heart 
failure hospitalisation and region, and NT-proBNP. Continuous variables were 
dichotomised to allow for non-linear relationships with outcomes. 
Kaplan-Meier cumulative event curves are presented by symptom category and 
compared with log-rank tests. 
11.3.1.1 Unadjusted outcomes 
Of the 8399 patients analysed, 2031 (24.2%) had a heart failure hospitalisation or 
cardiovascular death with a median survival time of 345 days (IQR 168-599). (see 
Table 11-6) For the 6368 patients who did not have a composite outcome of 
cardiovascular death or heart failure hospitalisation median survival time was 
853 days (IQR 614-1096). 
Patients who reported symptoms on effort were more likely to die from any 
cause (CV death: fatigue HR 1.18 95% CI[1.06, 1.32]; dyspnoea HR 1.35 [1.13, 
1.61]. All cause death: fatigue HR 1.15 [1.05, 1.28]; dyspnoea HR 1.25 [1.07, 
1.46]). Symptoms on effort were also associated with to a higher risk of the 
primary composite outcome (fatigue HR 1.18 [1.18, 1.29]; dyspnoea 1.19 [1.05, 
1.37]). (Table 11-6 Table 11-7 and Figure 11-1 and Figure 11-2) 
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Table 11-6 Clinical outcomes according to presence of symptoms 
& Fatigue&on&effort&
(n=4343)&
Dyspnoea&on&effort&
(n=7207)&
n&(%)& Number&of&events&& p&value& Number&of&events&& p&value&
CV&death/HF&
composite&
1125&(25.9)& <0.001& 1782&(24.7)& 0.007&
Heart&failure&
hospitalisation&
651&(15.0)& 0.043& 1043&(14.5)& 0.138&
CV&death& 698&(16.1)& 0.002& 1114&(15.5)& 0.001&
All&cause&death& 855&(19.7)& 0.002& 1365&(18.9)& 0.004&
 
Table 11-7 Hazard ratio for symptoms and clinical outcomes: Unadjusted analysis 
& Fatigue&on&effort& Dyspnoea&on&effort&
& HR&(95%&CI)& P&value& HR&(95%&CI)& P&value&
CV&death/HF&
composite&
1.18&(1.08,&1.29)& <0.001& 1.19&(1.05,&1.37)& 0.008&
Heart&failure&
hospitalisation&
1.13&(1.02,&1.28)& 0.025& 1.15&(0.97,&1.37)& 0.106&
CV&death& 1.18&(1.06,&1.32)& 0.003& 1.35&(1.13,&1.61)& 0.001&
All&cause&death& 1.15&(1.05,&1.28)& 0.004& 1.25&(1.07,&1.46)& 0.005&
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Figure 11-1 Kaplan Meier curves for outcomes according to presence or absence of fatigue on effort 
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Figure 11-2 Kaplan Meier curves for outcomes according to presence or absence of dyspnoea on effort 
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11.3.2 Multivariate analysis 
Adjustment for other variables mentioned in section 11.3 of this chapter (for 
both multivariate models) weakened the relationship between the presence of 
symptoms and all outcomes. A total of 8008 (95%) patients were included in the 
analyses, 274 patients were omitted mainly due to missing haemoglobin value. 
(Table 11-8 Table 11-9) 
Only dyspnoea on effort remained predictive of cardiovascular death (HR 1.28 
95% CI 1.06-1.50) in the model currently under development for PARADIGM-HF. 
Table 11-8 Hazard ratio for symptoms and clinical outcomes: Multivariable analysis using 
model similar to CORONA 
! Fatigue! Dyspnoea!
! HR!(95%!CI)! P!value! HR!(95%!CI)! P!value!
Cardiovascular!death!or!heart!
failure!hospitalisation!
1.04!
(0.95,!1.15)!
0.393! 1.13!
(0.97,!1.30)!
0.109!
Cardiovascular!death! 1.03!
(0.91,!1.16)!
0.689! 1.24!
(1.03,1.51)!
0.026!
Heart!failure!hospitalisation! 1.02!
(0.90,!1.15)!
0.737! 1.12!
(0.93,!1.35)!
0.246!
AllCcause!death! 1.03!
(0.92,!1.15)!
0.609! 1.16!
(0.98,!1.37)!
0.083!
Adjusted for: age, sex, NYHA class, LVEF, body mass index (BMI), systolic blood 
pressure, heart rate, smoking, MI, CABG or PCI, aortic aneurysm, hypertension, diabetes, 
baseline atrial fibrillation/flutter (AF), stroke, intermittent claudication, pacemaker and ICD 
implantations, creatinine, and log NT-proBNP. 
  
147 
 
Table 11-9 Hazard ratio for symptoms and clinical outcomes: Multivariable analysis 
PRADIGM-HF model 
! Fatigue! Dyspnoea!
! HR!(95%!CI)! P!value! HR!(95%!CI)! P!value!
Cardiovascular!death!or!heart!
failure!hospitalisation!
1.05!
(0.95,!1.16)!
0.313! 1.20!
(1.04,!1.38)!
0.012!
Cardiovascular!death! 1.06!
(0.93,!1.20)!
0.377! 1.28!
(1.06,!1.54)!
0.009!
Heart!failure!hospitalisation! 1.03!
(0.91,!1.17)!
0.662! 1.24!
(1.03,!1.50)!
0.020!
AllCcause!death! 1.05!
(0.94,!1.17)!
0.423! 1.20!
(1.02,!1.42)!
0.028!
Adjusted for: age, sex, race, region, NYHA class, LVEF, systolic blood pressure, heart rate, 
MI, clinically significant valvular heart disease, prior heart failure hospitalisation, time 
since diagnosis of heart failure, coronary artery intervention, haemoglobin A1C, 
haemoglobin, albumin, potassium, beta-blocker use at randomisation diabetes, the 
interaction between previous heart failure hospitalisation and region; randomised 
treatment and NT-proBNP. 
 
11.3.3 Summary of findings 
Some of the univariate associations with symptoms on effort such as LVEF, 
systolic and diastolic blood pressures, although statistically significant, could be 
considered clinically irrelevant. For example, patients with symptoms on effort 
had an average of 1.6 mmHg higher systolic blood pressure than those with no 
symptoms on effort, and had a LVEF of approximately 1% higher. These findings 
reflect the ability to show that even small differences are statistically significant 
when studying large numbers of patients. It is also important to note that these 
associations were attenuated towards the null in multivariable analysis. Same as 
with the results from CORONA, fatigue and dyspnoea on effort do not differ much 
in relation to their predictors (NYHA class and KCCQ summary scores), however in 
the analyses run in PARADIGM-HF, female sex was independently associated with 
fatigue and not dyspnoea, which coincides with much of the available literature 
(see section 2.3.2). On the other hand, I did not find haemoglobin levels to be 
associated with symptoms on effort in this cohort. 
Additionally, I found that symptoms at baseline were associated with outcomes in 
univariate analyses, but that association is lost after adjustment for other well-
known prognostic variables like NT-proBNP. This is true for the two models run. 
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12 Overall summary of findings and discussion 
Although dyspnoea is the best recognised symptomatic manifestation of heart 
failure, fatigue is also a prototypal symptom limiting exercise in this condition. 
(5, 78, 270) For example, in one community-based survey more than half (59%) 
of 540 patients with chronic heart failure reported being moderately to 
extremely troubled by fatigue and few (9%) had not experienced this symptom at 
all. Of those reporting fatigue, 53% experienced the symptom at least once a 
day. (271) Similar conclusions have been reported in other studies (272, 273) and 
my results reflect analogous findings. 
12.1 Prevalence and correlates of symptoms 
I found the symptom of fatigue to be almost ubiquitous in CORONA (which 
included only patients with symptoms -i.e. those in NYHA functional class II or 
greater and with dyspnoea at baseline- and a reduced LVEF) and highly prevalent 
in PARADIGM-HF. Overall, in CORONA only 5% of patients reported no fatigue and 
9% reported fatigue only on severe exertion, while in PARADIGM-HF 52% reported 
fatigue on effort and 86% reported dyspnoea on effort. For the vast majority in 
CORONA, fatigue was present on slight (43%) or moderate (43%) exertion. 
12.1.1 Origin of symptoms: central vs. peripheral hypothesis 
While a number of studies have tried to identify correlates of fatigue and 
dyspnoea in patients with heart failure, the results have been conflicting. I 
found both symptoms were associated with a number of variables and these 
variables were very similar for both symptoms (history of hypertension, angina 
and myocardial infarction; NYHA functional class; use of mineralocorticoid 
receptor antagonists). This suggests that the pathophysiological basis of both 
symptoms may be similar and, as discussed earlier, my findings lend some 
support to a “peripheral” (muscle) rather than “central” (haemodynamic) 
explanation for both dyspnoea and fatigue in heart failure. Although no 
information on haemodynamic measures was available, I would argue that NT-
proBNP and LVEF provide a reasonable surrogate for central haemodynamic 
measures. Given the fact that both the clinical trial cohorts used in this thesis 
included ambulatory patients it would have been very difficult to obtain “hard” 
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(i.e. PCWP, LVEDP) measurements as they would require interventions like the 
insertion of a central venous catheter or a right heart catheterisation. 
12.1.2 Correlates of symptoms: two sides of the same coin? 
The association between history of coronary heart disease and greater fatigue 
and dyspnoea is noteworthy. Angina commonly occurs simultaneously with other 
heart failure symptoms, and previous studies have shown that there is a 
significant association between chest pain and both greater fatigue and greater 
dyspnoea. (131, 274) The strength of the associations previously reported is 
greater for dyspnoea than fatigue (274), however, I found that history of angina 
was significantly associated with moderate fatigue or dyspnoea (not with severe 
symptoms).  
The deleterious impact of hypertension on quality of life has been documented 
previously (275-277) but the reasons for this remain unclear. Fatigue has 
previously been associated with hypertension in patients with HF. (131) It has 
been hypothesized that this association could be attributable to the 
hypertension itself, drug treatment and “labelling effect” after diagnosis, but 
again, the results are conflicting. (278, 279) I found that hypertension was 
significantly associated with increased fatigue at baseline. 
The association between treatment with a MRA and greater fatigue and 
dyspnoea in CORONA likely reflects confounding by indication, with use of this 
class of treatment at the start of CORONA recruitment restricted to patients 
with more advanced heart failure. MRA use is therefore probably a marker of 
unmeasured severity of heart failure.  
12.1.2.1 Coenzyme Q10 as a potential treatment 
There has been much interest in the potential role of coenzyme Q10 as a 
therapeutic agent in heart failure (155-157), nonetheless I found no association 
between plasma coenzyme Q10 level and symptoms. However, plasma and 
muscle coenzyme Q10 levels are poorly correlated and it would be interesting to 
analyze muscle coenzyme Q10 levels and its relationship to symptoms in heart 
failure. (280) It is important to call attention to the fact that I had relatively few 
patients with a coenzyme Q10 level and results from this sensitivity analysis 
should be taken cautiously, as I have discussed in the relevant section.  
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12.1.2.2 Statins and fatigue 
Recently there has been some controversy surrounding statin treatment and 
changes in fatigue severity, with some authors stating that statins have a 
deleterious impact on energy and exertional fatigue (153, 281), while some 
other groups advocate for the safety and tolerability of statin treatment, 
specifically in patients with heart failure (152, 153, 269, 281). I did not find a 
statistically significant association between statin treatment and either change 
in symptom severity or outcomes. I found little evidence supporting the idea 
that statins could have a deleterious effect on symptom severity in this cohort of 
patients with heart failure. Albeit I must acknowledge that a slight trend can be 
seen with a small number of patients treated with rosuvastatin reporting a 
worsening of fatigue over six months, with questionable clinical significance as 
the cohort where I studied this association could represent a more vulnerable 
group to the adverse effects of statins (i.e. older patients with systolic heart 
failure). 
12.1.2.3 CORONA vs. PARADIGM-HF 
Although my results from CORONA and PARADIGM-HF differ regarding the 
correlates of symptoms, specifically for dyspnoea, most predictors of fatigue are 
common to both cohorts (with the exception of MRAs which were not associated 
with symptoms in PARADIGM-HF). This could be due to the fact the symptoms in 
PARADIGM-HF were measured as a dichotomous variable (no symptoms vs. 
symptoms on effort), potentially leading to a loss of information. Additionally, 
86% of the patients in PARADIGM-HF reported having dyspnoea on effort, which 
makes it difficult to tease out specific predictors of this symptom in this cohort. 
Symptoms in PARADIGM-HF appear to be much milder than in CORONA, this could 
be due to the fact that patients in PARADIGM-HF were on average 9 years 
younger than those in CORONA (mean age 64 vs. 73). They also had lower mean 
systolic blood pressures (122 mmHg vs.129 mmHG). Additionally, PARADIGM-HF 
randomised patients with NYHA class I, while patients in CORONA had to be 
NYHA class II or higher. Patients in PARADIGM-HF were largely treated with 
evidence-based medicine as well (93% were on beta-blockers, 80% were on 
diuretics,78% were on ACE inhibitors, 22% on angiotensin receptor blockers, and 
57% were on MRAs).  
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Also of interest are the things that I found were not significantly associated with 
either fatigue or dyspnoea. A higher NT-proBNP level might have been expected 
to correlate with dyspnoea, especially if higher natriuretic peptide levels relate 
to higher left ventricular filling pressures, which in turn cause dyspnoea. This 
lack of association lends indirect support to the muscle hypothesis, which states 
that dyspnoea might have its origins in heart failure as much in abnormal muscle 
as in congested lungs. It is noteworthy that although in CORONA about one third 
of the patients were missing values for NT-proBNP, in PARADIGM-HF virtually no 
observations were missing (only 14 patients did not have an NT-proBNP value; 
less than 0.2%), making the findings more robust. Likewise, the lack of 
relationship between ejection fraction and fatigue suggests that symptom does 
not have a haemodynamic origin related to diminished cardiac output and 
skeletal muscle blood flow (although the relationships between ejection 
fraction, cardiac output, systemic vascular resistance and regional distribution 
of arterial flow are complex). Additionally, it is well known that skeletal muscle 
metabolism is often abnormal in HF and muscle wasting may develop. (76, 90, 
113) Exercise capacity in patients with HF is dependent on both muscle function 
and bulk (282) and a correlation between serum CK level and lean body mass has 
been demonstrated by others. (283) Nevertheless I found no association between 
CK and fatigue or dyspnoea in CORONA (PARADIGM-HF did not measure CK). 
Additionally, I found that beta-blocker use was not associated with fatigue, 
although a meta-analysis in 2002 reported that beta-blocker use was associated 
with a small significant annual increase in risk of reported fatigue (18 per 1000 
patients; 95% CI 5-30). (255) Although I am aware that a lack of evidence for 
association does not necessary equal no association I believe my results to be 
robust as confidence intervals are generally narrow and point estimates are 
similar in direction and magnitude in both cohorts analysed. As discussed above, 
the only surrogates for central haemodynamics available would be NT-proBNP 
and LVEF, neither of which showed an association with symptom severity. 
It is also noteworthy that although both symptoms vary slightly in their 
correlates, the direction and magnitude of the associations are very similar. A 
clear trend can be seen for all covariates. This perhaps supports the view that 
these two symptoms are different expressions of the same underlying disease 
mechanism or mechanisms. (80, 84) It could be argued that the only real 
difference lies in NYHA class, where there seems to be a stronger association for 
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dyspnoea than for fatigue. This association should also be interpreted with care, 
as it could be due to the fact that in CORONA the range of plausible values for 
fatigue was wider than for dyspnoea (because some level of dyspnoea was an 
inclusion criterion). In other words, after grouping, 18% of the patients with 
fatigue 0/1 were in NYHA III/IV, while only 7.4% of the patients with the lower 
levels of dyspnoea were classified as NYHA III/IV, making more dyspnoeic 
patients more likely to be in worse NYHA class. This lends support to the notion 
that fatigue and dyspnoea share a common pathophysiological background. It is 
common for the same patient to complain of fatigue or dyspnoea depending on 
the type of exercise being performed. (138, 284) It is possible that patients have 
trouble distinguishing between fatigue and dyspnoea, and as my results show, 
the two symptoms tend to overlap with 75% of patients reporting the same levels 
of dyspnoea and fatigue.  
My results from CORONA are supported by my findings from PARADIGM-HF, the 
largest, most contemporary heart failure clinical trial, where patients were 
largely treated with evidence based medicine and where virtually no data was 
missing. So why is my main analysis on CORONA and not PARADIGM-HF? The data 
from PARADIGM-HF became available to me a little less than one year ago, with 
it being ready to analyse only until late in my studies, where I could not focus on 
this trial population. Additionally, symptoms in PARADIGM-HF were measured as 
a dichotomous variable (as mentioned earlier), which leads to a loss of valuable 
information regarding severity of symptoms and how it relates to outcome. 
Having said this, I believe that neither cohort is better for the purpose of this 
thesis, but that results both provide important insights into the two pivotal 
symptoms of heart failure. If I were required to choose one, I would probably go 
for CORONA mostly because symptoms were measured in an ordinal scale. As I 
have mentioned before the fact that symptoms were dichotomised in PARADIGM-
HF deducts from their importance and possibly lead to investigators and patients 
under-reporting subtle changes. As I have shown in this thesis, symptoms can 
change in short periods of time and the change in symptoms is associated to 
outcome -something that I will analyse in the future using PARADIGM-HF. 
However, just asking patients to report whether they have or have not got 
symptoms on effort may have made it difficult for them to describe the ordinal 
character of symptoms; for these reasons I would be prefer CORONA over 
PARADIGM-HF. 
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12.2 Symptoms as predictors of outcome 
Except for dyspnoea, which remained a significant predictor of the composite 
outcome of HF hospitalisation or cardiovascular death, as well as for it’s 
individual components, symptoms at randomisation were not predictive of 
outcome, although as have mentioned before, a trend is evident both from the 
univariate analyses and from the direction and magnitude of the point estimates 
(hazard ratios) and it could be argued that symptoms of baseline show a 
tendency to be associated with adverse clinical outcomes. Results from both 
cohorts (CORONA and PARADIGM-HF) showed the same trend. 
The only other large trial that I know of which analysed fatigue independently to 
NYHA class in an ambulatory setting (not hospitalised patients) was the 
Carvedilol Or Metoprolol European Trial (COMET) which used a 5 point scale, 
although this was labelled differently (1 asymptomatic; 2 walking up stairs at 
normal pace; 3 walking at normal pace on a flat surface; 4 walking slowly on a 
flat surface or during washing or dressing; and 5 at rest). Few patients (<8%) 
were given the lowest or highest score on this scale although there was a more 
even distribution across the middle three scores in COMET compared with 
CORONA, presumably reflecting the different scale-labelling, different patient 
characteristics or both. For example, patients in CORONA were an average of 10 
years older than those in COMET and more likely to have a history of myocardial 
infarction, hypertension or diabetes, and to be treated with beta-blockers at 
baseline; they were less likely to be treated with ACE inhibitors or diuretics. 
12.3 Change in symptoms: correlates and their 
importance as predictors of outcome 
First I must draw attention to the fact most patients who did not have a 6-month 
visit died before this visit, hence the analysis on change in symptoms should be 
interpreted with caution, as it is an analysis of the surviving cohort. Having said 
this, I found in the CORONA cohort of older patients with ischaemic heart failure 
also largely treated with evidence based medicine (93% were treated with 
ARB/ACE inhibitors, 74% with beta-blockers, and 88% were on loop/thiazide 
diuretics) symptoms were mostly unchanged over six months: 66-69% of the 
patients reported no change in symptoms severity for both fatigue and 
dyspnoea; it is also possible that symptoms varied within these two time points 
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but might have been the same when measured at the times analysed. Around 20-
22% of the patients reported an improvement of symptoms over time and 
worsening was reported in 9-13% of the patients. Given that symptoms can 
change rapidly, I wanted to analyse if patients who had longer periods of time 
between visits were more likely to report a change in symptoms, however there 
was no association with time between visits and how symptom severity changed 
after six months. 
Not surprisingly, the most important correlates of change in symptom severity 
were baseline symptoms, where a regression to the mean is evident, as patients 
with worse symptoms at baseline could not worsen after six months. This is 
partly why higher symptom severity at baseline was associated with a decrease 
in symptoms at six months and vice versa. As were higher Kansas City clinical 
questionnaire summary scores strongly associated with a decreased risk of 
reporting symptoms on effort; higher scores represent better health status. 
Fatigue and dyspnoea are quite subjective, and are commonly associated with 
other quality of life measures, this could be why intermittent claudication was 
significantly associated with an increase in symptoms, or it could be a surrogate 
for other cardiovascular risk factors and reflects “sicker” patients. A similar 
phenomenon might be occurring with NYHA class and its association to change in 
symptom severity, where patients with a worse functional class were more likely 
to report an increase in symptoms, this could be a reflection of worse overall 
health or could be associated with overall quality of life, or both. 
A worsening of either symptom over six months was associated with fatal 
outcomes and heart failure hospitalisation, even after adjusting for other well-
known prognostic factors like NT-proBNP. Additionally, decreasing symptom 
severity was shown to be protective of both fatal and non-fatal outcomes. This 
association between change in symptoms and clinical outcomes has been 
previously documented in a few studies (18, 85, 99, 100, 143, 258) and the 
results from this thesis, together with the results from my previously published 
work (18, 85, 285) provide support to this very important link between symptom 
change and clinical outcomes, though most previous studies have looked at 
hospitalised and not ambulatory patients. A small study by Moser et al (203) 
showed that variability in daily symptoms and not their severity was associated 
with adverse outcomes. My results show that the direction of such variation is 
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important, with improving symptoms being associated with a lower risk of 
adverse outcomes, while the opposite is also true, with worsening symptoms 
associated with higher risk of clinical adverse outcomes. While having 
measurements from only two time points the results imply a direction of the 
effect, it is possible that symptoms could have fluctuated in different directions, 
thus the importance of studying symptoms at different times, as I have shown in 
section 5.2 they can vary substantially in short periods of time. 
12.4 Limitations 
This study has several limitations. It was not a pre-specified analysis of the 
CORONA trial. The patients enrolled were older subjects with systolic heart 
failure of ischemic aetiology. 1181 patients (23.6%) were excluded from the 
analyses because patients with a LVEF >35% (and ≤40%) had to be in NYHA class 
III or IV and I wished to examine the predictive value of fatigue and dyspnoea in 
addition to NYHA functional class. However additional analyses including these 
patients gave similar results. While my findings are consistent with those of 
COMET and therefore probably can be generalized to most patients with heart 
failure and reduced ejection fraction, I do not know about the prevalence or 
prognostic importance of fatigue in patients with heart failure and preserved 
ejection fraction. Fatigue was not measured using a validated score although I 
do not know of any instrument has been fully validated in heart failure and is 
suitable for use in a large multinational trial. Because dyspnoea was an inclusion 
criterion in CORONA, the dyspnoea scale had only 4 possible points as opposed to 
5 for fatigue. Subjects were asked about symptoms over “the past few days” and 
investigators recorded these.  
The scale used in CORONA is not dissimilar to the Dyspnoea-Fatigue index (“Yale 
scale”), which is a validated instrument in heart failure although that instrument 
uses a 0-4 scale to assess three domains – “magnitude of task”, “magnitude of 
pace” and “functional limitation”. However, simple Likert-like sales such as the 
one I used are commonly employed to assess symptoms in clinical trials in heart 
failure and do seem to identify changes with treatment. Several studies 
comparing xamoterol with placebo, digoxin or both used a 5 point Likert scale to 
assess “tiredness” (and “breathlessness”) and demonstrated significant 
differences between active therapy and placebo. (286, 287) 
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The Diabetes Symptom Checklist (DSC) records a number of symptoms, including 
fatigue, on a 5-point scale ranging from 1 (not at all) to 5 (extremely). This scale 
was able to demonstrate a significant difference between two beta-blockers 
(carvedilol and metoprolol) in The Glycemic Effect in Diabetes Mellitus: 
Carvedilol–Metoprolol Comparison in Hypertensives (GEMINI) study of 
approximately 1200 patients randomised to metoprolol or carvedilol in a 3 to 2 
ratio. (288)  
On the other hand, it is widely accepted for dyspnoea to be measured with a 
visual analogue scale (289), or with a modification of the Borg scale for 
perceived exertion. (290) Both of these scales are similar to the scale used in 
CORONA to measure dyspnoea, and there is no evidence that either the visual 
analogue scale or the modified Borg scale are better at measuring dyspnoea. 
(289) 
So, as far as I can tell, simple scales such as the ones used in CORONA do detect 
the effect of therapies on symptoms and are also predictive of 
morbidity/mortality. 
A skeletal myopathy may occur in heart failure and this, in turn, may arise as a 
result of disturbed anabolic-catabolic imbalance. (76) Activation of metabolic or 
ergo-receptors in muscle may also lead to sympathetic nervous system activation 
which is known to be detrimental in heart failure. Severity of fatigue is also 
related to depressive symptoms (73, 162, 271) and depression is also an adverse 
prognostic finding in heart failure. Whether there is a mechanistic link between 
fatigue, muscle dysfunction and depression (e.g. autonomic dysfunction) is 
unknown. Depression, which is predictive of adverse events in patients with 
cardiovascular disease, was not measured in CORONA. (291) Fatigue in heart 
failure is also associated with anaemia, another adverse prognostic finding. (96) 
CORONA did not measure haemoglobin levels, iron indices or sodium levels and 
these may be relevant to both dyspnoea and fatigue. 
As I mentioned earlier, in CORONA about 30% of the patients were missing NT-
proBNP values and only 25% had an observation for coenzyme-Q10, and although 
my analyses on imputed data do not change my results, these results should be 
taken cautiously as multiple imputation has some strong assumptions that might 
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not hold, particularly for the analyses on the imputed coenzyme-Q10 where data 
are probably not missing at random. 
The multivariate model for CORONA was not adjusted for race or region 
(country), and there is historical evidence to support the notion that culture 
(hence race and/or country of origin) affects how symptoms are reported and 
experienced. (171, 172, 292, 293) These differences have been attributed to a 
variety of possible factors, including variation in translations of the quality of 
life questionnaires, clinicians’ differences in recommendation of one treatment 
or other, socioeconomic status, educational level, amongst others. More 
recently, other authors have found no association between the experience of 
symptoms and culture. (294, 295) However, I found an association between 
region/race and presence or absence of symptoms among patients in the 
PARADIGM-HF trial, where Caucasians and people from Western Europe were 
more likely to report symptoms on effort. These results could have been the 
result of confounding by unmeasured variables, such as socioeconomic status or 
educational levels, but this cannot be determined from the present data. These 
considerations do, however, warrant adjusting for race in CORONA. 
Another important limitation is the fact that in CORONA, subjects who were 
already on a statin, or considered by their own doctor to need (or have a 
contraindication to) a statin were not randomised. This means that patients who 
had a history of statin induced myopathy or serious hypersensitivity reactions to 
statins were excluded.  This would limit the validity of the multivariate analysis 
including statin treatment looking at the impact of symptoms and outcome and 
the impact of creatine kinase as a correlate of symptoms. 
For the analyses on change in symptom severity, I analysed only two time points 
as have discussed in the preceding section leading to potentially misleading 
results, as any variation within the two time points will not have been detected. 
Additionally, as mentioned before, analyses were run basically on survivors, as 
most of the patients who did not have a 6-month visit had died before this visit. 
Lower haemoglobin levels and anaemia have both been independently related to 
dyspnoea and fatigue, and currently it would be almost unthinkable to run a 
clinical trial in heart failure where haemoglobin levels are not measured. In 
CORONA, which randomised patients between the years 2003 and 2005, 
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haemoglobin levels were in fact not measured, leading to a potentially 
important oversight of relevant predictor of symptoms. Although haemoglobin 
levels were not associated with symptoms on effort in the PARADIGM-HF cohort 
(neither on univariate or multivariate analysis), it is important to note that 
haemoglobin levels were largely within a normal range in this cohort (in g/L 
range: 101-194, IQR: 129-195, mean 139, median 140), which may explain why 
no association was found. 
As with any results from clinical trials, the generalizability of my results is 
questionable as it is well known that patients who participate in clinical trials 
tend to have different prognosis than the “real-world” heart failure population.  
12.5 Conclusions 
Fatigue and dyspnoea in heart failure appear to be two sides of the same coin, 
having very similar (it could be argued identical) correlates and predicting 
clinical outcomes in the same manner and with associations of similar 
magnitude. My results provide evidence to support the notion that symptoms in 
heart failure have a peripheral or muscular, if not origin, strong component. 
This thesis shows that although baseline symptoms were not independently 
associated with outcome, a trend is evident and more studies are justified and 
needed to clarify this potential association. Importantly, worsening symptoms 
are an adverse prognostic development and, improvement of symptoms was 
associated with lower risk of adverse clinical outcomes. These findings suggest 
that closer attention should be paid to symptoms in clinical practice; more 
should be done to standardise their measurement, efforts to understand there 
origins intensified and better treatment strategies developed.  
Advising patients to keep a daily diary on their symptoms and keeping track of 
how they change might prove beneficial by making them aware of fluctuations 
which may pass unnoticed otherwise, and prompting them to seek medical 
attention if they notice their symptoms are fluctuating frequently. Patients 
should be made aware of how symptom variability could be associated with 
adverse clinical outcomes and should be advised notify medical personnel if they 
notice changes.  
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These results provide convincing evidence that early intervention not only to 
improve but also to prevent deterioration of functional status in patients with 
heart failure could prove beneficial, although this is a hypothesis that needs to 
be tested prospectively. 
12.6 Future work 
The next step for me is to try and validate the results I got from CORONA 
regarding change in symptom severity in PARADIGM-HF, where change in overall 
symptoms was recorded by the Kansas City cardiomyopathy questionnaire in 
every visit. I will then repeat the analyses in MERIT-HF and investigate if the 
findings from this thesis are valid in patients with heart failure with preserved 
ejection fraction by analysing data from I-PRESERVE. I am also interested in 
exploring if the results presented here differ between patients with and without 
AF. 
If changing symptoms are shown conclusively to be prognostic factors, this could 
warrant a longitudinal study similar to the one performed by Moser et al (203) to 
evaluate the impact of changing symptom severity on pre-specified clinical 
outcomes, or a cluster clinical trial where patients could be randomised to 
record symptoms daily vs. not recording them and evaluating the impact of 
symptom awareness on outcome. 
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Appendix 1: Search strategies fatigue 
Search strategies employed in the search of the literature regarding fatigue 
MEDLINE (OVID) 
exp cardiac output, low/ or exp cardiomyopathy, dilated/ or exp heart failiure/ 
or exp ventricular dysfunction/ 
(heart adj2 failure*).tw. 
(congestive adj2 heart).tw 
(cardiac adj2 failure*).tw. 
(heart adj2 decompensation*).tw. 
(myocardial adj2 failure*).tw. 
paroxysmal dyspnea*.tw. 
cardiac asthma.tw. 
cardiac edema*.tw. 
(congest* heart adj2 failure).tw. 
(left side* heart adj2 failure).tw. 
(right side* heart adj2 failure).tw. 
(congest* adj1 cardiomyopath*).tw. 
low cardiac output.tw. 
(left ventric* adj1 dysfunction).tw. 
(right ventric* adj1 dysfunction).tw. 
or/1-16 
exp asthenia/ or exp fatigue/ 
asthenia.tw. 
fatigue.tw. 
exhaustion.tw. 
(muscle adj2 fatigue).tw. 
tiredness.tw. 
lassitude.tw. 
or/18-24 
17 and 25 
limit 26 to (English language and humans) 
 
 
EMBASE (0VID) 
exp cardiac output, low/ or exp cardiomyopathy, dilated/ or exp heart failiure/ 
or exp ventricular dysfunction/ 
(heart adj2 failure*).tw. 
(congestive adj2 heart).tw 
(cardiac adj2 failure*).tw. 
(heart adj2 decompensation*).tw. 
(myocardial adj2 failure*).tw. 
paroxysmal dyspnea*.tw. 
cardiac asthma.tw. 
cardiac edema*.tw. 
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(congest* heart adj2 failure).tw. 
(left side* heart adj2 failure).tw. 
(right side* heart adj2 failure).tw. 
(congest* adj1 cardiomyopath*).tw. 
low cardiac output.tw. 
(left ventric* adj1 dysfunction).tw. 
(right ventric* adj1 dysfunction).tw. 
or/1-16 
exp asthenia/ or exp fatigue/ 
asthenia.tw. 
fatigue.tw. 
exhaustion.tw. 
(muscle adj2 fatigue).tw. 
tiredness.tw. 
lassitude.tw. 
or/18-24 
17 and 25 
limit 26 to (english language and humans) 
limit 27 to embase 
limit 28 to adult 
limit 29 to meta analysis 
29 not 30 
limit 31 to “reviews (maximizes sensitivity) 
31 not 32 
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Appendix 2: Search strategies dyspnoea 
Search strategies employed in the search of the literature regarding dyspnoea 
MEDLINE (OVID) 
exp cardiac output, low/ or exp cardiomyopathy, dilated/ or exp heart failiure/ 
or exp ventricular dysfunction/ 
(heart adj2 failure*).tw. 
(congestive adj2 heart).tw 
(cardiac adj2 failure*).tw. 
(heart adj2 decompensation*).tw. 
(myocardial adj2 failure*).tw. 
paroxysmal dyspnea*.tw. 
cardiac asthma.tw. 
cardiac edema*.tw. 
(congest* heart adj2 failure).tw. 
(left side* heart adj2 failure).tw. 
(right side* heart adj2 failure).tw. 
(congest* adj1 cardiomyopath*).tw. 
low cardiac output.tw. 
(left ventric* adj1 dysfunction).tw. 
(right ventric* adj1 dysfunction).tw. 
or/1-16 
exp Dyspnea, Paroxysmal/ or exp Dyspnea/ 
dyspn?ea.tw. 
breathlessness*.tw. 
(shortn* adj2 breath).tw. 
(breath* adj2 shortne*).tw. 
or/18-22 
17 and 23 
limit 24 to (English language and humans) 
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Appendix 3: Linearity assessment 
Log(NT-proBNP) distribution on patients with LVEF ≤35%: CORONA 
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Linearity assessment fatigue on patients with LVEF≤35%: CORONA 
 Fatigue Nl Check 
LVEF 
 
0.2049 
 
Weight 
 
0.5016 
SBP 
 
0.1125 
Heart Rate 
 
0.3525 
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Age 
 
0.3838 
BMI 
 
0.8101 
 
Years w/HF 
 
0.1767 
Log(BNP) 
 
0.0013 
CRP 
 
0.0217 
166 
 
TSH 
 
0.7054 
 
Cholesterol 
 
0.0618 
HDL 
 
0.7133 
LDL 
 
0.1254 
GFR 
 
0.5789 
167 
 
CK 
 
0.000 
ApoA 
 
0.0548 
ApoB 
 
0.2423 
TG 
 
0.7865 
ALT 
 
0.0094 
168 
 
Creat 
 
0.5261 
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Linearity assessment dyspnoea on patients with LVEF≤35%: CORONA 
 Dyspnoea Nl Check 
LVEF 
 
0.4374 
Weight 
 
0.6706 
SBP 
 
0.2552 
Heart Rate 
 
0.3307 
170 
 
Age 
 
0.1735 
BMI 
 
0.7686 
Years w/HF 
 
0.0014 
Log(BNP) 
 
0.1044 
CRP 
 
0.0004 
171 
 
TSH 
 
0.6277 
Cholesterol 
 
0.0066 
HDL 
 
0.0126 
LDL 
 
0.0282 
GFR 
 
0.1194 
172 
 
CK 
 
0.0005 
ApoA 
 
0.1634 
ApoB 
 
0.1785 
TG 
 
0.0923 
ALT 
 
0.0038 
173 
 
Creat 
 
0.2618 
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Appendix 4: Imputed data 
This appendix shows results from analyses run on imputed data. Running the 
models on imputed data made no difference to my overall results. 
Summary of imputed data 
! Complete! Incomplete! Imputed! Total!
Log(NTCproBNP)! 3664! 1347! 1347! 5011!
Baseline!BMI! 4997! 14! 14! 5011!
Obese! 5011! 0! 0! 5011!
Overweight! 5011! 0! 0! 5011!
Baseline!weight! 5008! 3! 3! 5011!
Baseline!systolic!
blood!pressure! 5010! 1! 1! 5011!
Baseline!diastolic!
blood!pressure! 5010! 1! 1! 5011!
hsCCRP! 5009! 2! 2! 5011!
TSH! 4987! 24! 24! 5011!
TG! 4985! 26! 26! 5011!
Cholesterol!! 4985! 26! 26! 5011!
HDL! 4985! 26! 26! 5011!
LDL! 4985! 26! 26! 5011!
apoB!! 4958! 53! 53! 5011!
apoA!! 4958! 53! 53! 5011!
ApoB_ApoA! 4958! 53! 53! 5011!
Co!–enzyme!Q10! 1191! 3820! 3820! 5011!
175 
 
Correlates of dyspnoea severity: imputed data 
 Fatigue Dyspnoea 
Variable OR (95% CI) P value OR (95% CI) P value 
Age p/10 years 1.03 (0.92, 1.14) 0.612 1.20 (1.07, 1.36)  0.002 
Female 1.46 (1.22, 1.75) <0.001 1.17 (0.96, 1.43) 0.124 
LVEF 1.86 (0.53, 6.55) 0.334 1.25 (0.31, 5.10) 0.753 
NYHA III/IV*      
*fatigue/dyspnoea 2 vs. 1  5.15 (4.08, 6.51) <0.001 13.43 (8.83, 20.41) <0.001 
*fatigue/dyspnoea 3 vs.1  13.82 (11.61, 16.44) <0.001 30.00 (24.74, 36.39) <0.001 
Baseline BMI kg/m2   1.02 (1.00, 1.04) 0.022 
*fatigue 2 vs. 1  1.03 (1.00, 1.05) 0.025   
*fatigue 3 vs.1  1.00 (0.98, 1.02) 0.895   
Systolic BP p/10 mmHg 0.96 (0.91, 1.00) 0.043 0.99 (0.94, 1.03) 0.550 
Heart rate p/10 beats/min 1.07 (1.00, 1.14) 0.048 1.16 (1.07, 1.24) <0.001 
Years w/heart failure 1.00 (0.99, 1.02) 0.740 1.00 (0.98, 1.02) 0.975 
Myocardial Infarction   1.39 (1.18, 1.64) <0.001 
*fatigue 2 vs. 1  1.68 (1.38, 2.06) <0.001   
*fatigue 3 vs.1  1.24 (1.05, 1.47) 0.012   
History of Diabetes 1.03 (0.86, 1.22) 0.772 1.11 (0.91, 1.35) 0.300 
Stroke 1.35 (1.09, 1.67) 0.005 1.02 (0.81, 1.29) 0.853 
Hypertension* 1.37 (1.18, 1.58) <0.001 1.17 (0.99, 1.37) 0.069 
History of angina* 1.31 (1.12, 1.53) 0.001   
* dyspnoea 2 vs. 1    1.54 (1.21, 1.98) 0.001 
* dyspnoea 3 vs. 1    0.95 (0.77, 1.28) 0.606 
Baseline atrial 
fibrillation/flutter 
  1.02 (0.82, 1.28) 0.839 
*fatigue 2 vs. 1  1.26 (0.91, 1.76) 0.167   
*fatigue 3 vs.1  0.99 (0.79, 1.24) 0.942   
Intermittent Claudication 1.07 (0.87, 1.32) 0.495 1.08 (0.86, 1.36) 0.494 
CABG/PCI 0.89 (0.76, 1.05) 0.166 0.92 (0.77, 1.10) 0.351 
Pacemaker 0.89 (0.72, 1.10) 0.289 1.19 (0.93, 1.53) 0.163 
ICD 0.67 (0.45, 0.97) 0.036 0.79 (0.52, 1.20) 0.275 
MRAs* 1.29 (1.11, 1.49) 0.001   
* dyspnoea 2 vs. 1    0.90 (0.69, 1.17) 0.421 
* dyspnoea 3 vs. 1    1.40 (1.16, 1.68) <0.001 
Loop/thiazide 0.97 (0.79, 1.20) 0.808   
* dyspnoea 2 vs. 1    1.38 (1.02, 1.87) 0.040 
* dyspnoea 3 vs. 1    0.91 (0.67, 1.22) 0.510 
Beta-blocker 1.07 (0.91, 1.25) 0.427 1.06 (0.89, 1.27) 0.505 
Nitrate 1.11 (0.95, 1.30) 0.183 1.25 (1.05, 1.49) 0.014 
Insulin 1.05 (0.78, 1.40) 0.754 0.94 (0.68, 1.30) 0.720 
Antiarrhythmic 1.15 (0.93, 1.43) 0.199 0.91 (0.72, 1.16) 0.450 
ACE inhibitor or ARB 0.97 (0.74, 1.25) 0.791 0.99 (0.73, 1.33) 0.941 
Digoxin   1.22 (1.02, 1.46) 0.026 
*fatigue 2 vs. 1  1.29 (1.01, 1.64) 0.041   
*fatigue 3 vs.1  1.22 (1.02, 1.45) 0.028   
Anticoagulant 0.90 (0.77,1.06) 0.218 0.89 (0.74, 1.06) 0.189 
TSH mIU/L 1.00 (0.99, 1.02) 0.721   
* dyspnoea 2 vs. 1    1.02 (0.93, 1.12) 0.615 
* dyspnoea 3 vs. 1    1.00 (0.98, 1.02) 0.893 
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Log(NT-proBNP) 1.07 (0.99, 1.15) 0.086 1.01 (0.93, 1.10) 0.739 
hs-CRP mg/litre 1.00 (1.00, 1.01) 0.070 1.00 (1.00, 1.01) 0.276 
Alanine transaminase 
IU/L 
1.00 (1.00, 1.00) 0.547 1.00 (1.00, 1.00) 0.636 
Creatine kinase p/50 IU/L 0.93 (0.85, 1.02) 0.146 0.95 (0.86, 1.06) 0.359 
Creatinine µmol/L 1.00 (1.00, 1.00) 0.149 1.00 (0.99, 1.00) 0.076 
Low density lipoprotein 
mmol/L 
1.00 (0.93, 1.08) 0.945 0.96 (0.88, 1.04) 0.318 
*Did not fulfil proportional odds (PO) assumption 
LVEF – left ventricular ejection fraction, NYHA – New York Heart Association functional class, BP –blood pressure, 
CABG/PCI – coronary artery bypass grafting/ percutaneous coronary intervention, ICD – implantable cardioverter 
defibrillator, MRA – Mineralocorticoid receptor antagonists, ACE – angiotensin converting enzyme, ARB – angiotensin II 
receptor blocker, TSH – thyroid stimulating hormone, NT-proBNP – N-terminal of the prohormone brain natriuretic peptide, 
CRP – high-sensitivity C-reactive protein. 
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Adjusted hazard ratio for symptom severity and clinical outcomes: imputed data 
 Fatigue Dyspnoea 
 2 vs. 1 3 vs. 1 2 vs. 1 3 vs. 1 
 HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
Cardiovascular 
death or heart 
failure 
hospitalisation 
1.02 
(0.85, 1.21) 
0.865 1.16 
(0.97, 1.40) 
0.111 1.12 
(0.89, 1.40) 
0.308 1.22 
(0.96, 1.56) 
0.103 
Cardiovascular 
death 
0.98 
(0.78, 1.22) 
0.827 1.13 
(0.89, 1.44) 
0.309 1.02 
(0.77, 1.35) 
0.884 1.13 
(0.83, 1.53) 
0.442 
Heart failure 
hospitalisation 
1.03 
(0.83, 1.28) 
0.762 1.20 
(0.95, 1.52) 
0.118 1.38 
(1.02, 1.87) 
0.039 1.60 
(1.15, 2.21) 
0.005 
All-cause death 1.02 
(0.84, 1.24) 
0.815 1.15 
(0.93, 1.42) 
0.208 1.09 
(0.85, 1.40) 
0.492 1.14 
(0.86, 1.50) 
0.359 
Adjusted for: age, sex, NYHA class, LVEF, body mass index (BMI), systolic blood pressure, heart rate, smoking, MI, CABG or PCI, aortic 
aneurysm, hypertension, diabetes, baseline atrial fibrillation/flutter (AF), stroke, intermittent claudication, pacemaker and ICD 
implantations, ApoA-1, ApoB, creatinine, alanine aminotransferase, creatine kinase, thyroid stimulating hormone, high-sensitivity C-
reactive protein, and log NT-proBNP. 
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Adjusted hazard ratio for symptom severity and clinical outcomes including randomised treatment: imputed data 
 Fatigue Dyspnoea 
 2 vs. 1 3 vs. 1 2 vs. 1 3 vs. 1 
 HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
Cardiovascular 
death or heart 
failure 
hospitalisation 
1.02 
(0.85, 1.21) 
0.864 1.16 
(0.96, 1.40) 
0.113 1.13 
(0.90, 1.41) 
0.296 1.22 
(0.96, 1.56) 
0.106 
Cardiovascular 
death 
0.98 
(0.78, 1.22) 
0.827 1.13 
(0.89, 1.44) 
0.310 1.02 
(0.77, 1.35) 
0.883 1.13 
(0.83, 1.53) 
0.443 
Heart failure 
hospitalisation 
1.03 
(0.83, 1.28) 
0.767 1.20 
(0.95, 1.51) 
0.125 1.38 
(1.02, 1.87) 
0.037 1.59 
(1.15, 2.21) 
0.005 
All-cause death 1.02 
(0.84, 1.25) 
0.812 1.15 
(0.93, 1.42) 
0.206 1.09 
(0.85, 1.40) 
0.488 1.14 
(0.84, 1.50) 
0.359 
Adjusted for: age, sex, NYHA class, LVEF, body mass index (BMI), systolic blood pressure, heart rate, smoking, MI, CABG or PCI, aortic 
aneurysm, hypertension, diabetes, baseline atrial fibrillation/flutter (AF), stroke, intermittent claudication, pacemaker and ICD 
implantations, ApoA-1, ApoB, creatinine, alanine aminotransferase, creatine kinase, thyroid stimulating hormone, high-sensitivity C-
reactive protein, log NT-proBNP and randomised treatment. 
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Adjusted HR for change in symptom severity and outcomes: imputed data 
 CV Death/HF hospitalisation 
HR (95%CI) 
P Cardiovascular death 
HR (95%CI) 
P HF hospitalisation 
HR (95%CI) 
P All-cause death  
HR (95%CI) 
P 
Change in fatigue 
Decrease 0.62 (0.54, 0.73) <0.001 0.57 (0.46, 0.70) <0.001 0.70 (0.59, 0.85) <0.001 0.61 (0.51, 0.73) <0.001 
Increase 1.45 (1.24, 1.70) <0.001 1.17 (0.95, 1.43) 0.137 1.83 (1.52, 2.20) <0.001 1.13 (0.94, 1.35) 0.187 
Change in dyspnoea 
Decrease 0.64 (0.55, 0.74) <0.001 0.53 (0.44, 0.65) <0.001 0.72 (0.60, 0.85) <0.001 0.59 (0.50, 0.71) <0.001 
Increase 1.60 (1.35, 1.89) <0.001 1.13 (0.91, 1.41) 0.269 2.29 (1.89, 2.77) <0.001 1.04 (0.85, 1.27) 0.710 
Adjusted for: age, sex, NYHA class, LVEF, body mass index, systolic blood pressure, heart rate, smoking, myocardial infarction, CABG or PCI, aortic 
aneurysm, hypertension, diabetes, baseline atrial fibrillation/flutter, stroke, intermittent claudication, pacemaker and cardioverter-defibrillator 
implantation, ApoA-1, ApoB, creatinine, alanine aminotransferase, creatine kinase, thyroid stimulating hormone, high-sensitivity C-reactive protein, and 
log NT-proBNP and baseline symptom severity. 
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Adjusted HR for change in symptom severity and outcomes including randomised treatment: imputed data 
 CV Death/HF hospitalisation 
HR (95%CI) 
P Cardiovascular death 
HR (95%CI) 
P HF hospitalisation 
HR (95%CI) 
P All-cause death  
HR (95%CI) 
P 
Change in fatigue 
Decrease 0.63 (0.54, 0.73) <0.001 0.57 (0.46, 0.70) <0.001 0.70 (0.58, 0.84) <0.001 0.61 (0.51, 0.73) <0.001 
Increase 1.44 (1.23, 1.69) <0.001 1.17 (0.95, 1.43) 0.135 1.85 (1.54, 2.22) <0.001 1.13 (0.95, 1.36) 0.176 
Change in dyspnoea 
Decrease 0.64 (0.55, 0.74) <0.001 0.53 (0.44, 0.65) <0.001 0.72 (0.60,0.85) <0.001 0.59 (0.50, 0.71) <0.001 
Increase 1.60 (1.35, 1.89) <0.001 1.13 (0.91, 1.41) 0.269 2.30 (1.89, 2.79) <0.001 1.04 (0.85, 1.27) 0.706 
Adjusted for: age, sex, NYHA class, LVEF, body mass index, systolic blood pressure, heart rate, smoking, myocardial infarction, CABG or PCI, aortic 
aneurysm, hypertension, diabetes, baseline atrial fibrillation/flutter, stroke, intermittent claudication, pacemaker and cardioverter-defibrillator 
implantation, ApoA-1, ApoB, creatinine, alanine aminotransferase, creatine kinase, thyroid stimulating hormone, high-sensitivity C-reactive protein, and 
log NT-proBNP, baseline symptom severity and randomised treatment. 
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Appendix 4: Entire spectrum of LVEF 
This appendix shows results from sensitivity analyses run on the entire cohort 
(entire spectrum of LVEF) available from CORONA.  
Tabulation between dyspnoea and NYHA class at baseline 
Dyspnoea status    NYHA class at baseline  
 II III IV Total 
0 1 
(0.02%) 
0 
(0.0%) 
0 
(0.0%) 
1 
(0.02%) 
1 317 
(6.3%) 
32 
(06%) 
0 
(0.0%) 
349 
(7.0%) 
2 1346 
(28.9%) 
620 
(12.4%) 
2 
(0.04%) 
1968 
(39.3%) 
3 182 
(3.6%) 
2380 
(47.5%) 
23 
(0.5%) 
2585 
(51.6%) 
4 11 
(0.2%) 
49 
(1.0%) 
48 
(1.0%) 
108 
(2.2%) 
Total 1857 
(37.1%) 
3081 
(61.5%) 
73 
(1.46%) 
5011 
(100%) 
 
Tabulation between fatigue and NYHA class at baseline 
Fatigue status    NYHA class at baseline  
 II III IV Total 
0 155 
(3.1%) 
75 
(1.5%) 
3 
(0.1%) 
233 
(4.7%) 
1 302 
(6.0%) 
61 
(1.2%) 
2 
(0.04%) 
365 
(7.3%) 
2 1160 
(23.2%) 
775 
(15.5%) 
5 
(0.1%) 
1940 
(38.7%) 
3 209 
(4.2%) 
2097 
(41.9%) 
31 
(0.6%) 
2337 
(46.7%) 
4 30 
(0.6%) 
73 
(1.5%) 
32 
(0.6%) 
135 
(2.7%) 
Total 1856 
(37.1%) 
3081 
(61.5%) 
73 
(1.5%) 
5010 
(100%) 
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Distribution of symptoms at baseline in all patients 
 
Distribution of symptoms at baseline after grouping: entire spectrum LVEF 
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The table below shows a cross tabulation between the merged groups of fatigue 
and dyspnoea at baseline for the entire cohort. Although there is some evidence 
of collinearity, 400 (8%) patients had more severe fatigue than dyspnoea while 
916 (18%) had more severe dyspnoea than fatigue at baseline. 3695 (74%) had 
the same symptom severity at baseline. 
Cross-tabulation between symptoms at baseline: entire spectrum of LVEF 
 Dyspnoea 
Fatigue 1 2 3/4 Total 
0/1 239 
(4.8%) 
267 
(5.3%) 
92 
(1.8%) 
598 
(11.9%) 
2 81 
(1.6%) 
1427 
(5.5%) 
432 
(8.6%) 
1940 
(38.7%) 
3/4 30 
(0.6%) 
273 
(5.5%) 
2169 
(43.3%) 
2472 
(49.3%) 
Total 350 
(7.0%) 
1967 
(39.3%) 
2693 
(53.8%) 
5010 
(100%) 
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Baseline characteristics according to symptom severity entire spectrum of LVEF 
 
 
All patients 
(n=5011) 
Fatigue 0/1 
(n=598) 
Fatigue 2 
(n=1940) 
Fatigue 3/4 
(n=2472) 
p 
value 
Dyspnoea 1 
(n=350) 
Dyspnoea 2 
(n=1968) 
Dyspnoea 3/4 
(n=2693) p value 
Age 72.7'±'7.1' 72.65'±'6.90' 72.69'±'7.04' 72.72'±'7.16' 0.8364 72.27'±'7.08' 72.51'±'7.03' 72.89'±'7.12' 0.0350'
Female 1180'(23.6%)' 95'(15.9%)' 377'(19.4%)' 708'(28.6%)' 0.0001 55'(15.7%)' 387'(19.7%)' 738'(27.4%)' 0.0001'
Race 
Caucasian 
Black 
Asian 
Other 
4939'(98.6%)'
13'(0.3%)'
38'(0.8%)'
21'(0.4%) 
589'(98.5%) 
3'(0.5%) 
3'(0.5%) 
3'(0.5%) 
1915'(98.7%) 
5'(0.3%) 
11'(0.6%) 
9'(0.5%) 
2435'(98.5%)' 
4'(0.2%)' 
24'(1.0%)' 
9'(0.4%)' 0.8007 
346'(98.9%) 
1'(0.3%) 
3'(0.9%) 
0'(0.0%)'
1940'(98.6%) 
7'(0.4%) 
10'(0.5%) 
11'(0.6%)'
2653'(98.5%)' 
5'(0.2%)' 
25'(0.9%)' 
10'(0.4%)'' 0.6540'
NYHA'III/IV 3154'(62.9%)' 141'(23.6%)' 780'(40.2%)' 2233'(90.3%)' 0.0001 32'(9.1%)' 622'(31.6%)' 2500'(92.8%)' 0.0001'
LVEF'(%) 30.8'±'0.6' 29.10'±'6.28' 30.20'±'6.19' 31.79'±'6.61' < 0.0001 28.66'±'6.06' 29.96'±'6.12' 31.80'±'6.63' < 0.0001'
Systolic'BP'
mm/Hg 129.3'±'16.5'
129.55'±'
17.33' 130.19'±'16.56'
128.50'±'
16.12' 0.0092 129.52'±'16.74' 130.04'±'16.64' 128.68'±'16.27' 0.0201'
Heart'Rate'bpm 71.7'±'11.2' 69.51'±'10.56' 71.13'±'11.45' 72.59'±'11.05' < 0.0001 68.80'±'11.04' 70.63'±'11.03' 72.78'±'11.20' < 0.0001'
BMI kg/m2 27.2'±4.5' 26.71'±'4.05' 27.16'±'4.48' 27.35'±'4.68' 0.0022 26.46'±'3.98' 27.05'±'4.46' 27.41'±'4.64' < 0.0001'
BMI <25 kg/m2 
BMI ≥25 and <30 
kg/m2 
BMI >=30 kg/m2 
1,637 (32.8%)'
'
2,181 (46.7%) 
1,179 (23.6%) 
217 (36.4%) 
265 (44.5%) 
114 (19.1%) 
626 (32.4%) 
846 (43.8%) 
459 (23.8%) 
794 (32.2%) 
1070 (43.3%)' 
605 (24.5%) 0.0192 
135 (38.7%) 
149 (42.7%) 
65 (18.6%) 
659 (33.7%) 
851 (43.5%) 
448 (22.9%) 
843 (31.3%) 
1181 (43.9%)' 
666 (24.8%) 0.0010'
Years'with'heart'
failure 4.2'±'4.6' 3.83'±'4.69' 4.08'±'4.61' 4.30'±'4.62' 0.0145 3.63'±'4.50' 4.07'±'4.60' 4.30'±'4.65' 0.0058'
Current'Smoker 430'(8.6%)' 72'(12.0%)' 167'(8.6%)' 191'(7.7%)' 0.0021 36'(10.3%)' 171'(8.7%)' 223'(8.3%)' 0.2556'
! Past!Medical!History 
MI 3004'(60.0%)' 307'(51.3%)' 1159'(59.7%)' 1537'(62.2%)' 0.0001 172'(49.1%)' 1173'(59.6%)' 1659'(61.6%)' 0.0001'
Angina 3638'(72.6%)' 369'(61.7%)' 1367'(70.5%)' 1901'(76.9%)' 0.0001 200'(57.1%)' 1394'(70.8%)' 2044'(75.9%)' 0.0001'
CABG/PCI 1298'(25(%)' 170'(28.4%)' 553'(28.5%)' 575'(23.3%)' 0.0002 88'(25.1%)' 584'(29.7%)' 626'(23.2%)' 0.0004'
Hypertension 3175'(63.4%)' 308'(51.5%)' 1160'(59.8%)' 1706'(69.0%)' 0.0001 180'(51.4%)' 1171'(59.5%)' 1824'(67.7%)' 0.0001'
Diabetes 1477'(29.5)' 142'(23.7%)' 541'(27.9%)' 793'(32.1%)' 0.0001 76'(21.7%)' 520'(26.4%)' 881'(32.7%)' 0.0001'
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Baseline'atrial'
fibrillation/'
flutter' 1194'(23.8%)' 94'(15.7%)' 436'(22.5%)' 664'(26.9%)' 0.0001 65'(18.6%)' 402'(20.4%)' 727'(27.0%)' 0.0001'
Stroke 624'(12.5%)' 49'(8.2%)' 215'(11.1%)' 360'(14.6%)' 0.0001 34'(9.7%)' 217'(11.0%)' 373'(13.9%)' 0.0012'
Intermittent'
Claudication 638'(12.7%)' 73'(12.2%)' 220'(11.3%)' 344'(13.9%)' 0.0436 35'(10.0%)' 225'(11.4%)' 377'(14.0%)' 0.0027'
Pacemaker 561'(11.2%)' 63'(10.5%)' 209'(10.8%)' 289'(11.7%)' 0.2926 26'(7.4%)' 206'(10.5%)' 329'(12.2%)' 0.0034'
ICD 136'(2.7%)' 25'(4.2%)' 55'(2.8%)' 56'(2.3%)' 0.0120 10'(2.9%)' 63'(3.2%)' 63'(2.3%)' 0.1398'
! Laboratory!measurements 
Cholesterol'
mmol/L' 5.35'±'1.08' 5.44'±'1.03' 5.37'±'1.05' 5.31'±'1.12' 0.0044' 5.45'±'1.05' 5.40'±'1.05' 5.30'±'1.11' 0.0002'
ApoB:ApoAZ1'
ratio' 0.87'±'0.25' 0.86'±'0.24' 0.86'±'0.24' 0.88'±'0.26' 0.0111' 0.86'±'0.24' 0.87'±'0.24' 0.88'±'0.26' 0.2533'
ApoB'g/L' 1.27'±'0.30' 1.28'±'0.28' 1.27'±'0.30' 1.27'±'0.31' 0.3391' 1.28'±'0.29' 1.28'±'0.29' 1.26'±'0.31' 0.0350'
ApoA'g/L' 1.50'±'0.28' 1.52'±'0.27' 1.52'±'0.28' 1.48'±'0.28'
<'
0.0001' 1.53'±'0.27' 1.51'±'0.28' 1.48'±'0.28' 0.0001'
TSH'mIU/L' 2.19'±'4.02' 2.04'±'2.59' 2.13'±'4.21' 2.28'±'4.16' 0.1095' 1.85'±'1.38' 2.18'±'4.37' 2.25'±'3.99' 0.1265'
ALT'IU/L' 17.33'±'37.79' 18.07'±'26.32' 17.33'±'36.01' 17.03'±'40.87' 0.5553' 19.87'±'31.22' 17.28'±'35.20' 17.04'±'40.32' 0.3138'
LDL'mmol/L' 3.55'±'0.94' 3.60'±'0.90' 3.56'±'0.92' 3.53'±'0.96' 0.0790' 3.63'±'0.93' 3.59'±'0.92' 3.51'±'0.95' 0.0007'
NTZproBNPZZ
pmol/litre'
(median)'
173.3'[73.0,'
368.2]'
65'(10.9%)' 230'(11.9%)' 329'(13.3%)' 0.0003' 143.1'[74.9,'
310.6]'
166.4'[70.9,'
348.1]'
183.5'[73.7,'
394.7]'
0.0069'
hsZCRP'mg/litre'
(median)'
3.5'[1.6,'7.4]' 140.4'[71.4,'
280.7]'
170.0'[70.9,'
359.7]'
186.6'[76.1,'
396.1]'
<'
0.0001'
2.4'[1.2,'5.5]' 3.2'[1.5,'6.7]' 3.9'[1.7,'8.3]' <'0.0001'
CoZenzyme'Q10'
mmol/L'
0.7'[0.6,'1.0]' 2.9'[1.3,'6.4]' 3.3'[1.5,'6.8]' 3.8'[1.6,'8.2]' 0.0006' 0.7'[0.6,'1.0]' 0.8'[0.6,'1.0]' 0.7'[0.5,'1.0]' 0.0149'
CK' 45.0'[32.0,'
65.0]'
50.0'[36.0,'
70.0]'
50.0'[36.0,'
70.0]'
42.0'[31.0,'
61.0]''
<0.000
1'
49.5'[34.0,'
73.0]'
48.0'[34.0,'
67.0]'
42.0'[31.0,'61.0]' <0.0001'
Creatinine' 115.32'±'28.08' 115.11'±' 115.57'±'27.70' 115.15'±' 0.8392' 115.73'±'27.65' 115.32'±'27.32' 115.27'±'28.69' 0.8167'
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μmol/L' 26.08' 28.83'
eGFR'
ml/min/1.73m2'
56.30'±'15.22' 57.02'±'14.94' 56.68'±'15.27' 55.83'±'15.25' 0.0312' 57.03'±'15.03' 56.89'±'15.10' 55.78'±'15.32' 0.0132'
! Medication 
Loop/thiazide'
diuretics 
4416'(88.1%)' 57.02'±'14.94' 56.68'±'15.27' 55.83'±'15.25' 0.0001 279'(79.7%)' 1676'(85.2%)' 2461'(91.4%)' 0.0001'
ACE inhibitor or 
ARB 
4599'(91.8%)' 495'(82.8%)' 1664'(85.8%)' 2256'(91.3%)' 0.0740 324'(92.6%)' 1822'(92.6%)' 2453'(91.1%)' 0.0781'
MRAs 1965'(39.2%)' 562'(94.0%)' 1778'(91.6%)' 2258'(91.3%)' 0.0001 122'(34.9%)' 645'(32.8%)' 1198'(44.5%)' 0.0001'
Digitalis 1648'(32.9%)' 187'(31.3%)' 666'(34.3%)' 1111'(44.9%)' 0.0001 85'(24.3%)' 594'(30.2%)' 969'(36.0%)' 0.0001'
Anticoagulant 1767'(35.3%)' 142'(23.7%)' 614'(31.6%)' 892'(36.1%)' 0.1979 136'(38.9%)' 709'(36.0%)' 922'(34.2%)' 0.0566'
BetaZblockers 3766'(75.2%)' 214'(35.8%)' 708'(36.5%)' 845'(34.2%)' 0.8379 261'(74.6%)' 1493'(75.9%)' 2012'(74.7%)' 0.6047'
Nitrate 1638'(32.7%)' 445'(74.4%)' 1471'(75.8%)' 1849'(74.8%)' 0.0001 65'(18.6%)' 526'(26.7%)' 1047'(38.9%)' 0.0001'
Insulin 403'(8.0%)' 133'(22.2%)' 538'(27.7%)' 967'(39.1%)' 0.0271 20'(5.7%)' 147'(7.5%)' 236'(8.8%)' 0.0216'
Antiarrhythmic 624'(12.5%)' 38'(6.4%)' 147'(7.6%)' 218'(8.8%)' 0.0570 42'(12.0%)' 245'(12.4%)' 337'(12.5%)' 0.8243'
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Correlates of symptoms 
Unadjusted outcomes 
Patients with higher levels of fatigue (i.e. fatigue on slight exertion or at rest) 
were more likely to be female, and to have lower systolic blood pressure than 
patients with lower levels of fatigue. They also had higher heart rates and higher 
LVEFs and were more likely to be in NYHA functional class III or IV. Patients with 
greater fatigue more frequently had a history of myocardial infarction, angina, 
hypertension, diabetes, or stroke, lower ApoA-1 levels and higher levels of NT-
proBNP and hsCRP. They were less likely to have a history of coronary 
intervention, smoke or have an ICD implanted. They were more likely to be 
treated with insulin. 
Patients with higher levels of dyspnoea (i.e. dyspnoea at rest or slight exertion) 
presented a generally similar pattern, although there was no association 
between level of dyspnoea and history of stroke, ICD or smoking status and they 
were more likely to have a longer time (in years) with heart failure. They also 
had lower lipid levels and lower eGFR levels.  
Both patients with higher levels fatigue and dyspnoea were more likely to be in 
atrial fibrillation/flutter at baseline and were more likely to be treated with 
diuretics and digitalis, nitrates or MRAs. 
Adjusted outcomes 
3624 (72%) patients were included in the model, mostly due to missing NT-
proBNP values. 
Running the model on the entire spectrum of LVEF did not substantially change 
the results obtained from running the analyses on patients with LVEF≤35%. 
Overall same correlates persevered, if anything, the associations seemed to 
grow a bit stronger (i.e. slightly narrower confidence intervals and smaller p 
values). When compared to my main analysis (i.e. patients with LVEF≤35%), the 
tendencies in associations persisted and nothing mayor was added by including 
the entire cohort. 
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Correlates of symptom severity: entire spectrum LVEF 
! Fatigue! Dyspnoea!
Variable! OR!(95%!CI)! P!value! OR!(95%!CI)! P!value!
Age p/10 years 0.94 (0.83, 1.05) 0.244 1.05 (0.93, 1.19)  0.446 
Female 1.53 (1.27, 1.84) <0.001 1.38 (1.12, 1.70) 0.002 
LVEF 2.57 (0.76, 8.65) 0.125 1.52 (0.40, 5.88) 0.537 
NYHA III/IV*      
*fatigue/dyspnoea 2 vs. 1  5.42 (4.24, 6.91) <0.001 17.26 (11.00, 27.08) <0.001 
*fatigue/dyspnoea 3 vs.1  13.38 (11.02, 16.23) <0.001 30.38 (24.44, 37.78) <0.001 
Overweight* 1.06 (0.89, 1.25) 0.519 1.20 (1.00, 1.45) 0.053 
Obese*   1.21 (0.96, 1.52) 0.109 
*fatigue 2 vs. 1  1.29 (0.96, 1.74) 0.095   
*fatigue 3 vs.1  0.94 (0.75, 1.17) 0.574   
Systolic BP p/10 mmHg 0.96 (0.91, 1.00) 0.055 0.95 (0.91, 1.00) 0.075 
Heart rate p/10 beats/min 1.05 (0.98, 1.12) 0.179 1.10 (1.01, 1.19) 0.020 
Years w/heart failure 1.01 (0.99, 1.02) 0.484 1.00 (0.98, 1.02) 0.808 
Myocardial Infarction   1.35 (1.14, 1.60) 0.001 
*fatigue 2 vs. 1  1.83 (1.46, 2.30) <0.001   
*fatigue 3 vs.1  1.31 (1.11, 1.55) 0.002   
History of Diabetes 1.07 (0.89, 1.28) 0.484 1.29 (1.05, 1.58) 0.016 
Stroke 1.32 (1.06, 1.64) 0.015 1.03 (0.81, 1.31) 0.835 
Hypertension* 1.49 (1.27, 1.75) <0.001 1.30 (1.09, 1.55) 0.003 
History of angina*     
* fatigue/dyspnoea 2 vs. 1  1.45 (1.15, 1.83) 0.002 1.59 (1.20, 2.11) 0.001 
* fatigue/dyspnoea 3 vs. 1  1.13 (0.94, 1.35) 0.209 1.02 (0.83, 1.26) 0.820 
Baseline atrial fibrillation/flutter   1.14 (0.90, 1.44) 0.290 
*fatigue 2 vs. 1  1.59 (1.16, 2.00) 0.004   
*fatigue 3 vs.1  1.10 (0.88, 1.38) 0.392   
Intermittent Claudication 1.10 (0.89, 1.36) 0.380 1.11 (0.88, 1.41) 0.368 
CABG/PCI 0.86 (0.72, 1.01) 0.071 0.87 (0.72, 1.05) 0.142 
Pacemaker 0.96 (0.76, 1.21) 0.719 1.15 (0.89, 1.50) 0.288 
ICD 0.79 (0.52, 1.19) 0.264 0.83 (0.53, 1.30) 0.415 
MRAs* 1.39 (1.19, 1.62) <0.001 1.25 (1.06, 1.49) 0.010 
Loop/thiazide 1.13 (0.90, 1.41) 0.292 1.17 (0.91, 1.49) 0.214 
Beta-blocker 1.10 (0.93, 1.31) 0.265 1.11 (0.91, 1.34) 0.296 
Nitrate 1.26 (1.07, 1.48) 0.006 1.36 (1.13, 1.64) 0.001 
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Insulin 0.91 (0.68, 1.22) 0.524 0.80 (0.57, 1.12) 0.199 
Antiarrhythmic 1.07 (0.85, 1.34) 0.583 0.86 (0.68, 1.11) 0.252 
ACE inhibitor or ARB 1.00 (0.77, 1.30) 0.997 1.13 (0.85, 1.53) 0.384 
Digoxin 1.17 (0.99, 1.39) 0.066 1.12 (0.93, 1.36) 0.230 
Anticoagulant 0.91 (0.77,1.08) 0.299 0.94 (0.78, 1.13) 0.490 
TSH mIU/L 1.00 (0.98, 1.02) 0.892 1.00 (0.98, 1.02) 0.904 
Log(NT-proBNP) 1.05 (0.98, 1.13) 0.165 1.00 (0.93, 1.09) 0.910 
hs-CRP mg/litre 1.00 (1.00, 1.01) 0.893 1.00 (0.99, 1.00) 0.853 
Alanine transaminase IU/L 1.00 (1.00, 1.00) 0.836 1.00 (1.00, 1.00) 0.636 
Creatine kinase p/50 IU/L 0.95 (0.86, 1.04) 0.252 0.94 (0.85, 1.04) 0.218 
Creatinine µmol/L 1.00 (0.99, 1.00) 0.124 1.00 (0.99, 1.00) 0.026 
Low density lipoprotein mmol/L 0.99 (0.91, 1.07) 0.759 0.95 (0.87, 1.03) 0.220 
*Did not fulfil proportional odds (PO) assumption 
LVEF – left ventricular ejection fraction, NYHA – New York Heart Association functional class, BP –blood pressure, CABG/PCI – coronary 
artery bypass grafting/ percutaneous coronary intervention, ICD – implantable cardioverter defibrillator, MRA – Mineralocorticoid receptor 
antagonists, ACE – angiotensin converting enzyme, ARB – angiotensin II receptor blocker, TSH – thyroid stimulating hormone, NT-proBNP 
– N-terminal of the prohormone brain natriuretic peptide, CRP – – high-sensitivity C-reactive protein. 
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Correlates of change in fatigue severity: entire spectrum of LVEF 
! Decrease!in!fatigue! Increase!in!fatigue!
!
!
RR! 95%!CI! P!value! RR! 95%!CI! P!value!
Fatigue(2(vs.(1( 2.02( 1.24,(3.30( 0.005( 0.26( 0.19,(0.34( <0.001(
Fatigue(3(vs.(1( 9.07( 5.44,(15.11( <0.001( 0.03( 0.02,(0.04( <0.001(
Age( 0.98( 0.97,(1.00( 0.029( 1.01( 0.99,(1.03( 0.184(
Female( 0.98( 0.78,(1.23( 0.873( 1.05( 0.77,(1.43( 0.763(
LVEF(%( 0.64( 0.13,(2.23( 0.575( 0.54( 0.07,(4.00( 0.553(
NYHA(III/IV( 0.52( 0.39,(0.68( <0.001( 1.71( 1.30,(2.26( <0.001(
Overweight( 0.94( 0.75,(1.18( 0.607( 1.22( 0.92,(1.63( 0.165(
Obese( 1.01( 0.77,(1.32( 0.941( 1.28( 0.90,(1.82( 0.171(
Systolic BP p/10 
mmHg 0.94( 0.88,(1.00( 0.040( 0.87( 0.81,(0.95( 0.001(
Heart rate p/10 
beats/min 0.97( 0.88,(1.06( 0.472( 1.11( 0.99,(1.25( 0.070(
Years w/heart failure 0.98( 0.96,(1.00( 0.098( 1.00( 0.97,(1.03( 0.970(
Myocardial Infarction 0.81( 0.66,(0.99( 0.039( 0.80( 0.62,(1.03( 0.086(
History of Diabetes 1.21( 0.96,(1.52( 0.098( 0.99( 0.73,(1.34( 0.949(
Stroke 1.05( 0.80,(1.39( 0.704( 0.99( 0.67,(1.44( 0.938(
Hypertension* 0.98( 0.79,(1.21( 0.839( 1.09( 0.85,(1.43( 0.485(
Baseline atrial 
fibrillation/flutter( 0.94( 0.72,(1.23(( 0.647( 0.80( 0.56,(1.14( 0.224(
History of angina* 0.81( 0.66,(1.01( 0.061( 1.12( 0.85,(1.47( 0.420(
Intermittent 
Claudication 1.01( 0.77,(1.33( 0.950( 1.69( 1.22,(2.36( 0.002(
CABG/PCI 1.45( 1.16,(1.80( 0.001( 1.04( 0.78,(1.38( 0.801(
Pacemaker 0.89( 0.66,(1.21( 0.475( 0.74( 0.50,(1.09( 0.129(
ICD 1.33( 0.78,(2.27( 0.300( 0.52( 0.23,(1.17( 0.114(
MRAs* 0.84( 0.69,(1.02( 0.085( 1.18( 0.92,(1.53( 0.199(
Loop/thiazide 0.81( 0.60,(1.29( 0.166( 1.27( 0.86,(1.89( 0.227(
Beta-blocker 0.80( 0.64,(1.00( 0.053( 0.66( 0.50,(0.87( 0.003(
Nitrate 0.68( 0.55,(0.85( <0.001( 1.06( 0.81,(1.39( 0.653(
Insulin 0.88( 0.60,(1.29( 0.519( 0.92( 0.56,(1.54( 0.763(
Antiarrhythmic 0.82( 0.60,(1.12( 0.211( 1.16( 0.80,(1.70( 0.421(
ACE inhibitor or ARB 0.89( 0.63,(1.26( 0.505( 0.84( 0.55,(1.29( 0.430(
Digoxin 1.29( 1.04,(1.61( 0.021( 1.39( 1.05,(1.83( 0.020(
Anticoagulant 0.99( 0.79,(1.23( 0.904( 0.93( 0.70,(1.24( 0.626(
TSH mIU/L 1.01( 0.99,(1.04( 0.354( 1.00( 0.98,(1.03( 0.744(
Log(NT-proBNP) 1.00( 0.91,(1.09( 0.949( 1.15( 1.02,(1.31( 0.023(
hs-CRP 1.00( 1.00,(1.01( 0.218( 1.00( 1.00,(1.01( 0.198(
Alanine transaminase 
IU/L 1.00( 0.99,(1.00( 0.568( 1.00( 1.00,(1.00( 0.612(
Creatine kinase p/50 0.93( 0.82,(1.07( 0.317( 0.84( 0.71,(1.01( 0.061(
Creatinine µmol/L 1.00( 1.00,(1.00( 0.559( 1.00( 0.99,(1.00( 0.225(
Low density lipoprotein 
mmol/L 0.93( 0.84,(1.03( 0.188( 0.90( 0.79,(1.03( 0.127(
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Correlates of change in dyspnoea severity: entire spectrum LVEF 
! Decrease!in!dyspnoea! Increase!in!dyspnoea!
!
!
RR! 95%!CI! P!value! RR! 95%!CI! P!value!
Dyspnoea(2(vs.(1( 2.43( 1.34,(4.43( 0.003( 0.25( 0.17,(0.36( <0.001(
Dyspnoea(3(vs.(1( 8.64( 4.59,(16.30( <0.001( 0.03( 0.02,(0.05( <0.001(
Age( 0.99( 0.97,(1.00( 0.038( 1.01( 0.99,(1.04( 0.163(
Female( 0.87( 0.70,(1.09( 0.239( 1.22( 0.88,(1.70( 0.240(
LVEF(%( 0.94( 0.21,(4.30( 0.941( 0.29( 0.03,(2.56( 0.265(
NYHA(III/IV( 0.68( 0.51,(0.91( 0.009( 1.93( 1.40,(2.69( <0.001(
Overweight( 0.93( 0.75,(1.15( 0.505( 0.99( 0.72,(1.35( 0.943(
Obese( 0.95( 0.73,(1.22( 0.669( 1.11( 0.76,(1.63( 0.577(
Systolic BP p/10 
mmHg 0.97( 0.91,(1.03( 0.280( 0.93( 0.85,(1.01( 0.091(
Heart rate p/10 
beats/min 0.92( 0.85,(1.01( 0.071( 1.01( 0.88,(1.14( 0.932(
Years w/heart failure 0.99( 0.97,(1.01( 0.151( 1.00( 0.97,(1.03( 0.845(
Myocardial Infarction 0.77( 0.64,(0.94( 0.009( 0.90( 0.68,(1.19( 0.457(
History of Diabetes 1.00( 0.80,(1.24( 0.977( 1.20( 0.87,(1.68( 0.262(
Stroke 1.05( 0.81,(1.37( 0.710( 1.32( 0.90,(1.92( 0.155(
Hypertension* 1.10( 0.90,(1.34( 0.367( 1.19( 0.89,(1.60( 0.241(
Baseline atrial 
fibrillation/flutter( 0.88( 0.68,(1.14(( 0.324( 1.02( 0.70,(1.49( 0.910(
History of angina* 0.72( 0.59,(0.89( 0.002( 1.10( 0.81,(1.50( 0.528(
Intermittent 
Claudication 0.83( 0.63,(1.09( 0.173( 1.99( 1.40,(2.81( <0.001(
CABG/PCI 1.45( 1.18,(1.78( 0.001( 1.04( 0.76,(1.42( 0.819(
Pacemaker 1.20( 0.91,(1.59( 0.203( 1.15( 0.77,(1.72( 0.502(
ICD 1.38( 0.83,(2.29( 0.218( 1.00( 0.46,(2.18( 0.999(
MRAs* 0.76( 0.63,(0.92( 0.005( 1.33( 1.00,(1.75( 0.047(
Loop/thiazide 0.82( 0.62,(1.09( 0.167( 1.29( 0.82,(2.03( 0.266(
Beta-blocker 0.82( 0.66,(1.02( 0.069( 0.72( 0.53,(0.98( 0.038(
Nitrate 0.78( 0.64,(0.96( 0.019( 1.13( 0.83,(1.52( 0.441(
Insulin 0.93( 0.64,(1.34( 0.684( 0.79( 0.45,(1.40( 0.432(
Antiarrhythmic 0.86( 0.64,(1.17( 0.340( 0.85( 0.55,(1.31( 0.449(
ACE inhibitor or ARB 1.14( 0.81,(1.61( 0.456( 1.53( 0.89,(2.63( 0.120(
Digoxin 1.17( 0.95,(1.44( 0.140( 1.15( 0.84,(1.55( 0.382(
Anticoagulant 1.06( 0.86,(1.31( 0.593( 0.91( 0.67,(1.24( 0.562(
TSH  0.94( 0.90,(0.99( 0.026( 1.00( 0.97,(1.03( 0.829(
Log(NT-proBNP) 1.10( 1.00,(1.20( 0.044( 1.26( 1.10,(1.45( 0.001(
hs-CRP 1.00( 1.00,(1.01( 0.596( 1.00( 1.00,(1.01( 0.275(
Alanine transaminase 
IU/L 1.00( 1.00,(1.00( 0.450( 1.00( 1.00,(1.00( 0.708(
Creatine kinase p/50 0.90( 0.79,(1.02( 0.099( 0.86( 0.71,(1.04( 0.129(
Creatinine µmol/L 1.00( 1.00,(1.00( 0.500( 1.00( 0.99,(1.00( 0.849(
Low density lipoprotein 
mmol/L 0.94( 0.85,(1.04( 0.222( 0.90( 0.77,(1.04( 0.147(
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Symptoms as predictors of outcome: entire spectrum of LVEF 
As can be seen in the following tables and figures, including all patients in the analyses made little difference to my results.  
Clinical outcomes according to baseline symptom severity: entire spectrum of LVEF 
 Fatigue Dyspnoea 
 0/1 2 3/4 1 2 3/4 
 (n=598) (n=1940) (n=2472) (n=350) (n=1968) (n=2693) 
n (%)       
Cardiovascular death or heart 
failure hospitalisation 
68/119 
(31.3) 
244/426 
(35.5) 
354/746 
(44.5) 
48/52 
(28.5) 
240/431 
(34.1) 
1378/808 
(44.0) 
Cardiovascular death 113 
(18.9) 
398 
(20.5) 
663 
(26.8) 
65 
(18.6) 
390 
(19.8) 
719 
(26.7) 
Heart failure hospitalisation 119 
(19.9) 
426 
(22.0) 
746 
(30.2) 
52 
(14.9) 
431 
(21.9) 
808 
(30.0) 
All-cause death 144 
(24.1) 
521 
(26.9) 
822 
(33.3) 
80 
(22.9) 
518 
(26.3) 
889 
(33.0) 
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Unadjusted hazard ratio for symptom severity and clinical outcomes: entire spectrum of LVEF 
 Fatigue Dyspnoea 
 2 vs. 1 3 vs. 1 2 vs. 1 3 vs. 1 
 HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
Cardiovascular 
death or heart 
failure 
hospitalisation 
1.14 
(0.97, 1.34) 
0.104 1.62 
(1.39, 1.90) 
<0.001 1.24 
(1.01, 1.54) 
0.041 1.77 
(1.45, 2.17) 
<0.001 
Cardiovascular 
death 
1.11 
(0.90, 1.36) 
0.341 1.53 
(1.26, 1.87) 
<0.001 1.08 
(0.83, 1.40) 
0.564 1.54 
(1.19, 1.99) 
0.001 
Heart failure 
hospitalisation 
1.14 
(0.93, 1.40) 
0.200 1.72 
(1.42, 2.09) 
<0.001 1.54 
(1.15, 2.05) 
0.003 2.32 
(1.75, 3.06) 
<0.001 
All-cause death 1.14 
(0.95, 1.37) 
0.171 1.49 
(1.25, 1.78) 
<0.001 1.16 
(0.92, 1.47) 
0.204 1.55 
(1.23, 1.94) 
<0.001 
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Kaplan Meier curves for clinical outcomes according to fatigue severity: entire spectrum of LVEF 
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Kaplan Meier curves for clinical outcomes according to dyspnoea severity: entire spectrum of LVEF 
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Adjusted outcomes 
A total of 3613 (72%) patients were included in the analyses, 1398 were omitted 
due mostly to missing NT-proBNP values as mentioned previously. 
As it is shown below, including the entire spectrum of LVEF did not modify the 
trends seen in the rest of the models. Although it seems to have weakened the 
relationship between symptom severity and death (both cardiovascular and all 
cause death), the confidence intervals in all the models tend to overlap and the 
hazard ratios all go in the same direction.  
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Hazard ratio for symptom severity and clinical outcomes: entire spectrum of LVEF 
 Fatigue Dyspnoea 
 2 vs. 1 3 vs. 1 2 vs. 1 3 vs. 1 
 HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
Cardiovascular 
death or heart 
failure 
hospitalisation 
0.99 
(0.81, 1.21) 
0.91- 1.11 
(0.90, 1.37) 
0.334 1.04 
(0.81, 1.35) 
0.730 1.09 
(0.83, 1.44) 
0.533 
Cardiovascular 
death 
0.98 
(0.76, 1.27) 
0.893 1.08 
(0.82, 1.43) 
0.568 1.11 
(0.79, 1.55) 
0.542 1.24 
(0.86, 1.78) 
0.249 
Heart failure 
hospitalisation 
0.95 
(0.74, 1.21) 
0.668 1.10 
(0.85, 1.42) 
0.469 1.17 
(0.84, 1.63) 
0.346 1.28 
(0.91, 1.84) 
0.158 
All-cause death 1.07 
(0.85, 1.34) 
0.565 1.11 
(0.87, 1.42) 
0.396 1.21 
(0.90, 1.63) 
0.212 1.24 
(0.89, 1.71) 
0.201 
Adjusted for: age, sex, NYHA class, LVEF, body mass index (BMI), systolic blood pressure, heart rate, smoking, MI, CABG or PCI, aortic 
aneurysm, hypertension, diabetes, baseline atrial fibrillation/flutter (AF), stroke, intermittent claudication, pacemaker and ICD implantations, 
ApoA-1, ApoB, creatinine, alanine aminotransferase, creatine kinase, thyroid stimulating hormone, high-sensitivity C-reactive protein, and log 
NT-proBNP 
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Change in symptom severity: entire spectrum of LVEF 
Baseline characteristics according to change in symptom severity: entire spectrum of LVEF 
! Fatigue! Dyspnoea!
!
Unchanged!
n=3253!
Decrease!
n=855!
Increase!
n=545! P!value!
Unchanged!
n=3306!
Decrease!
n=914!
Increase!
n=434,! P!value!
Age, 72.60,±,7.08, 72.24,±,6.96, 73.41,±,7.11, 0.1219, 72.53,±,7.08, 72.47,±,7.04, 73.72,±,6.93, 0.0105,
Female, 779,(23.9%), 206,(24.1%), 118,(21.7%), 0.3417, 806,(24.4%), 200,(21.9%), 97,(22.4%), 0.1331,
Race,
, , ,
0.7434,
, , ,
0.4876,
Caucasian, 3212,(98.7%), 836,(97.8%), 540,(99.1%),, 3263,(98.7%), 897,(98.1%), 428,(98.6%),,
Black, 7,(0.2%), 3,(0.4%), 1,(0.2%),,
,
6,(0.2%), 3,(0.3%), 3,(0.7%),,
,Asian, 21,(0.6%), 11,(1.3%), 3,(0.6%),,
,
22,(0.7%), 10,(1.1%), 3,(0.7%),,
,Other, 13,(0.4%), 5,(0.6%), 1,(0.2%),,
,
15,(0.5%), 4,(0.4%), 0,(0.0%),,
,NYHA,III/IV, 2037,(62.6%), 586,(68.5%), 271,(49.7%), 0.0003, 2032,(61.5%), 665,(72.8%), 197,(45.4%), 0.0224,
LVEF,(%), 31.08,±,6.40, 31.19,±,6.51, 29.83,±,6.43, 0.0007, 31.06,±,6.35, 31.23,±,6.66, 29.54,±,6.38, 0.0006,
Systolic,BP,
mm/Hg, 130.16,±,16.16, 128.43,±,16.38, 128.13,±,17.37, 0.0007, 130.18,±,16.03, 128.35,±,16.60, 127.87,±,18.13, 0.0003,
Heart,Rate,
bpm, 71.35,±,11.13, 71.35,±,11.06, 72.11,±,11.51, 0.2192, 71.43,±,11.04, 71.29,±,11.29, 71.83,±,11.82, 0.6877,
BMI kg/m2, 27.31,±,4.50, 27.27,±,4.69, 27.13,±,4.50, 0.4132, 27.35,±,4.50, 27.19,±,4.56, 26.97,±,4.75, 0.0726,
BMI <25kg/m2 1020,(31.4%), 283,(33.3%), 189,(34.8%),, 1027,(31.1%), 302,(33.2%), 163,(37.8%),,
BMI ≥25kg/m2 
and <30, 1449,(44.6%), 358,(42.1%), 232,(42.7%),, 1468,(44.5%), 398,(43.7%), 173,(40.1%),,
BMI ≥30kg/m2, 777,(23.9%), 209,(24.6%), 122,(22.5%),, 804,(24.4%), 210,(23.1%), 95,(22.0%),,
Years,with,
heart,failure, 4.17,±,4.59, 4.08,±,4.60, 3.97,±,4.49, 0.3301, 4.13,±,4.54, 4.08,±,4.68, 4.24,±,4.69, 0.7937,
Current, 290,(8.9%), 63,(7.4%), 43,(7.9%), 0.2089, 292,(8.8%), 74,(8.1%), 30,(6.9%), 0.1544,
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Smoker,
MI, 1996,(61.4%), 479,(56.0%), 306,(56.1%), 0.002, 2020,(61.1%), 508,(55.6%), 254,(58.5%), 0.0236,
Angina, 2402,(73.8%), 601,(70.3%), 384,(70.5%), 0.0257, 2452,(74.2%), 630,(68.9%), 306,(70.5%), 0.0051,
CABG/PCI, 815,(25.1%), 246,(28.8%), 158,(29.0%), 0.0114, 834,(25.2%), 256,(28.0%), 129,(29.7%), 0.0154,
Hypertension, 2084,(64.1%), 550,(64.3%), 316,(58.0%), 0.0243, 2103,(63.6%), 590,(64.6%), 258,(59.4%), 0.2629,
Diabetes, 930,(28.6%), 258,(30.2%), 155,(28.4%), 0.7569, 942,(28.5%), 266,(29.1%), 136,(31.3%), 0.2448,
Baseline,atrial,
fibrillation/,
flutter, 750,(23.1%), 215,(25.1%), 128,(23.5%), 0.4801, 764,(23.1%), 225,(24.6%), 104,(24.0%), 0.4409,
Stroke, 397,(12.2%), 111,(13.0%), 56,(10.3%), 0.4071, 385,(11.6%), 122,(13.3%), 57,(13.1%), 0.1662,
Intermittent,
Claudication, 391,(12.0%), 111,(13.0%), 80,(14.7%), 0.0755, 401,(12.1%), 109,(11.9%), 72,(16.6%), 0.0399,
Pacemaker, 373,(11.5%), 96,(11.2%), 58,(10.6%), 0.579, 348,(10.5%), 124,(13.6%), 55,(12.7%), 0.0219,
ICD, 84,(2.6%), 29,(3.4%), 13,(2.4%), 0.7607, 83,(2.5%), 30,(3.3%), 13,(3.0%), 0.2815,
Cholesterol,
mmol/L, 5.39,±,1.09, 5.31,±,1.01, 5.33,±,1.08, 0.0721, 5.40,±,1.08, 5.30,±,1.04, 5.30,±,1.08, 0.0055,
ApoB:ApoA[1,
ratio, 0.88,±,0.25, 0.87,±,0.25, 0.86,±,0.25, 0.1728, 0.88,±,0.25, 0.87,±,0.25, 0.86,±,0.25, 0.226,
ApoB,g/L, 1.28,±,0.30, 1.26,±,0.28, 1.26,±,0.30, 0.0264, 1.28,±,0.30, 1.25,±,0.29, 1.25,±,0.30, 0.0051,
ApoA,g/L, 1.51,±,0.27, 1.50,±,0.28, 1.50,±,0.29, 0.698, 1.51,±,0.27, 1.49,±,0.28, 1.50,±,0.30, 0.2693,
TSH,mIU/L, 2.17,±,3.71, 2.24,±,6.07, 2.08,±,1.91, 0.8207, 2.23,±,4.69, 1.99,±,2.12, 2.08,±,1.72, 0.1822,
ALT,IU/L, 17.29,±,40.10, 16.34,±,14.05, 17.89,±,26.26, 0.9771, 17.42,±,39.53, 16.66,±,20.63, 17.23,±,27.22, 0.7211,
LDL,mmol/L, 3.59,±,0.95, 3.53,±,0.89, 3.52,±,0.93, 0.0281, 3.60,±,0.94, 3.51,±,0.92, 3.49,±,0.93, 0.0017,
NT[proBNP[[
pmol/litre,
(median), 157.2,[65.9,,334.2],
178.8,[73.1,,
354.0],
174.6,[84.2,,
399.8], 0.0067,
150.4,[63.1,,
320.1],
188.0,[77.0,,
374.2],
239.5,[110.2,,
427.9], 0.0001,
hs[CRP,
mg/litre, 3.3,[1.5,,6.8], 3.6,[1.5,,7.8], 3.7,[1.6,,7.8], 0.0093, 3.3,[1.5,,7.0], 3.4,[1.5,,7.8], 3.6,[1.5,,7.4], 0.2289,
202 
 
(median),
Co[enzyme,Q10,
mmol/L, 0.8,[0.6,,1.0], 0.7,[0.5,,0.9], 0.7,[0.6,,1.0], 0.1884, 0.8,[0.6,,1.0], 0.7,[0.5,,0.9], 0.7,[0.6,,1.0], 0.2314,
CK,IU/L, 46.0,[33.0,,65.0], 44.0,[32.0,,63.0], 43.0,[32.0,,62.0], 0.094, 46.0,[33.0,,66.0], 44.0,[31.0,,61.0], 45.0,[32.0,,63.0], 0.0208,
Creatinine,
μmol/L, 114.59,±,27.63, 114.64,±,27.67, 116.58,±,28.54, 0.1847, 114.20,±,27.71, 114.92,±,27.34, 119.56,±,28.64, 0.0007,
eGFR,
ml/min/1.73m2, 56.43,±,15.28, 56.94,±,14.86, 55.86,±,15.31, 0.737, 56.71,±,15.21, 56.77,±,14.89, 53.88,±,15.60, 0.0038,
Loop/thiazide,
diuretics, 2850,(87.6%), 740,(86.5%), 489,(89.7%), 0.404, 2888,(87.4%), 799,(87.4%), 393,(90.6%), 0.1184,
ACE inhibitor 
or ARB, 3000,(92.2%), 786,(91.9%), 501,(91.9%), 0.7522, 3035,(91.8%), 845,(92.5%), 408,(94.0%), 0.109,
MRAs, 1263,(38.8%), 329,(38.5%), 218,(40.0%), 0.7147, 1286,(38.9%), 337,(36.9%), 188,(43.3%), 0.3655,
Digitalis, 1002,(30.8%), 306,(35.8%), 194,(35.6%), 0.0027, 1048,(31.7%), 313,(34.2%), 141,(32.5%), 0.3376,
Anticoagulant, 1140,(35.0%), 298,(34.9%), 201,(36.9%), 0.5088, 1145,(34.6%), 328,(35.9%), 166,(38.2%), 0.1259,
Beta[blocker, 2498,(76.8%), 637,(74.5%), 384,(70.5%), 0.0011, 2527,(76.4%), 680,(74.4%), 313,(72.1%), 0.0282,
Nitrate, 1113,(34.2%), 227,(26.5%), 163,(29.9%), 0.0006, 1110,(33.6%), 266,(29.1%), 127,(29.3%), 0.0075,
Insulin, 256,(7.9%), 66,(7.7%), 44,(8.1%), 0.9367, 259,(7.8%), 71,(7.8%), 36,(8.3%), 0.8108,
Antiarrhythmic, 403,(12.4%), 95,(11.1%), 69,(12.7%), 0.7948, 410,(12.4%), 103,(11.3%), 54,(12.4%), 0.6741,
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Cross tabulation between change in fatigue and change in dyspnoea: entire spectrum of 
LVEF 
 Dyspnoea  
Fatigue Unchanged Decrease Increase Total 
Unchanged 2803 (60.2%) 304 (6.5%) 146 (3.1%) 3253 (69.9%) 
Decrease 261 (5.6%) 559 (12.0%) 35 (0.8%) 855 (18.4%) 
Increase 242 (5.2%) 51 (1.1%) 252 (5.4%) 545 (11.7%) 
Total 3306 (71.1%) 914 (19.6%) 433 (9.3%) 4653 
 
 
 
Cross tabulation between fatigue level at baseline and 6-month visit 
 Fatigue at 6-month visit  
Fatigue 
at 
Baseline 0 1 2 3 4 Total 
0 
132 
(2.8%) 
26 
(0.6%) 
39 
(0.8%) 
16 
(0.3%) 
5 
(0.1%) 
218 
(5.5%) 
1 
29 
(0.8%) 
203 
(4.4%) 
92 
(2.0%) 
21 
(0.5%) 
5 
(0.1%) 
350 
(7.5%) 
2 
41 
(0.9%) 
168 
(3.6%) 
1,337 
(28.7%) 
268 
(5.8%) 
16 
(0.3%) 
1,830 
(39.3%) 
3 
27 
(0.6%) 
45 
(1.0%) 
479 
(10.3%) 
1528 
(32.8%) 
57 
(1.2%) 
2136 
(45.9%) 
4 
6 
(0.1%) 
11 
(0.2%) 
17 
(0.4%) 
32 
(0.7%) 
53 
(1.1%) 
119 
(2.6%) 
Total 
235 
(5.1%) 
453 
(9.7%) 
1,964 
(42.2%) 
1,865 
(40.1%) 
136 
(2.9%) 4653 
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Cross tabulation between dyspnoea level at baseline and 6-month visit: entire spectrum 
LVEF 
 Dyspnoea at 6-month visit  
Dyspnoea 
at 
Baseline 0 1 2 3 4 Total 
0 
1 
(0.02%
) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
1 
(0.02%) 
1 
18 
(0.4%) 
215 
(4.6%) 
84 
(1.8%) 
14 
(0.3%) 
3 
(0.1%) 
334 
(7.2%) 
2 
17 
(0.4%) 
196 
(4.2%) 
1,368 
(29.4%) 
265 
(5.7%) 
7 
(0.2%) 
1,853 
(39.8%) 
3 
18 
(0.4%) 
45 
(1.0%) 
557 
(12.0%) 
1690 
(36.3%) 
61 
(1.3%) 
2371 
(45.9%) 
4 
1 
(0.02%
) 
8 
(0.2%) 
9 
(0.2%) 
45 
(1.0%) 
32 
(0.7%) 
95 
(2.0%) 
Total 
55 
(1.2%) 
464 
(10.0%) 
2018 
(43.4%) 
2014 
(43.3%) 
103 
(2.2%) 4654 
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Change in symptom severity and outcomes 
Numbers of events by change in symptoms at 6 months: entire spectrum of LVEF 
 Fatigue Dyspnoea 
 Unchanged 
(n=3253) 
Decrease 
(n=855) 
Increase 
(n=545) 
P Unchanged 
(n=3306) 
Decrease 
(n=914) 
Increase 
(n=434) 
P 
Cardiovascular 
death/Heart 
failure 
hospitalisation 374/684 (32.5%) 85/159 (28.5%) 75/148 (40.9%) <0.001 386/685 (32.4%) 90/170 (28.5%) 58/136 (44.7%) <0.001 
 
Cardiovascular 
death  624 (19.2%) 141 (16.5%) 140 (25.7%) <0.001 642 (19.4%) 147 (16.1%) 116 (26.7%) <0.001 
Heart failure 
hospitalisation 684 (21.0%) 159 (18.6%) 148 (27.2%) 0.001 685 (20.7%) 170 (18.6%) 136 (31.3%) <0.001 
All-cause death  
 802 (24.7%) 192 (22.5%) 179 (32.4%) <0.001 827 (25.0%) 206 (22.5%) 140 (32.3%) 0.001 
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Unadjusted HR for change in symptom severity and outcomes: entire spectrum of LVEF 
 CV Death/HF hospitalisation 
HR (95%CI) 
P Cardiovascular death 
HR (95%CI) 
P HF hospitalisation 
HR (95%CI) 
P All-cause death  
HR (95%CI) 
P 
Change in fatigue 
Decrease 0.86 (0.75, 0.99) 0.034 0.86 (0.71, 1.03) 0.094 0.87 (0.73, 1.03) 0.105 0.90 (0.77, 1.05) 0.174 
Increase 1.40 (1.21, 1.62) <0.001 1.43 (1.20, 1.72) <0.001 1.43 (1.19, 1.71) <0.001 1.38 (1.51, 1.65) <0.001 
Change in dyspnoea 
Decrease 0.86 (0.75, 0.99) 0.032 0.83 (0.69, 0.99) 0.037 0.88 (0.74, 1.04) 0.131 0.91 (0.77, 1.06) 0.217 
Increase 1.58 (1.36, 1.84) <0.001 1.47 (1.21, 1.80) <0.001 1.73 (1.44, 2.08) <0.001 1.42 (1.21, 1.68) <0.001 
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Kaplan Meier curves for clinical outcomes according to change in fatigue severity: entire spectrum of LVEF 
  
208 
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Kaplan Meier curves for clinical outcomes according to change in dyspnoea severity: entire spectrum of LVEF 
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Adjusted HR for change in symptom severity and outcomes: entire spectrum of LVEF 
 CV Death/HF hospitalisation 
HR (95%CI) 
P Cardiovascular death 
HR (95%CI) 
P HF hospitalisation 
HR (95%CI) 
P All-cause death  
HR (95%CI) 
P 
Change in fatigue 
Decrease 0.73 (0.62, 0.87) <0.001 0.72 (0.57, 0.91) 0.006 0.71 (0.58, 0.88) 0.010 0.77 (0.63, 0.94) 0.009 
Increase 1.60 (1.32, 1.94) <0.001 1.42 (1.11, 1.83) 0.005 1.87 (1.49, 2.36) <0.001 1.43 (1.15, 1.78) 0.001 
Change in dyspnoea 
Decrease 0.71 (0.60, 0.83) <0.001 0.66 (0.52, 0.83) <0.001 0.70 (0.57,0.86) 0.001 0.75 (0.62, 0.90) 0.003 
Increase 1.85 (1.51, 2.26) <0.001 1.41 (1.08, 1.86) 0.011 2.36 (1.86, 2.99) <0.001 1.25 (0.98, 1.59) 0.074 
Adjusted for: age, sex, NYHA class, LVEF, body mass index, systolic blood pressure, heart rate, smoking, myocardial infarction, CABG or PCI, aortic 
aneurysm, hypertension, diabetes, baseline atrial fibrillation/flutter, stroke, intermittent claudication, pacemaker and cardioverter-defibrillator implantations, 
ApoA-1, ApoB, creatinine, alanine aminotransferase, creatine kinase, thyroid stimulating hormone, high-sensitivity C-reactive protein, and log NT-proBNP and 
baseline symptom severity. 
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Change in fatigue severity according to randomised treatment: entire spectrum of LVEF 
 
Change in dyspnoea severity according to randomised treatment: entire spectrum of LVEF 
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Adjusted HR for change in symptom severity and outcomes: -including randomised treatment: entire spectrum of LVEF 
 CV Death/HF hospitalisation 
HR (95%CI) 
P Cardiovascular death 
HR (95%CI) 
P HF hospitalisation 
HR (95%CI) 
P All-cause death  
HR (95%CI) 
P 
Change in fatigue 
Decrease 0.73 (0.61, 0.86) <0.001 0.72 (0.57, 0.91) 0.006 0.71 (0.57, 0.87) 0.001 0.77 (0.63, 0.94) 0.010 
Increase 1.62 (1.34, 1.97) <0.001 1.42 (1.11, 1.83) 0.005 1.90 (1.52, 2.40) <0.001 1.44 (1.16, 1.78) 0.001 
Change in dyspnoea 
Decrease 0.71 (0.60, 0.83) <0.001 0.66 (0.52, 0.83) <0.001 0.70 (0.57, 0.86) 0.001 0.75 (0.62, 0.90) 0.003 
Increase 1.86 (1.51, 2.28) <0.001 1.42 (1.08, 1.86) 0.011 2.38 (1.88, 3.01) <0.001 1.24 (0.98, 1.59) 0.073 
Adjusted for: age, sex, NYHA class, LVEF, body mass index, systolic blood pressure, heart rate, smoking, myocardial infarction, CABG or PCI, aortic 
aneurysm, hypertension, diabetes, baseline atrial fibrillation/flutter, stroke, intermittent claudication, pacemaker and cardioverter-defibrillator implantations, 
ApoA-1, ApoB, creatinine, alanine aminotransferase, creatine kinase, thyroid stimulating hormone, high-sensitivity C-reactive protein, and log NT-proBNP, 
baseline symptom severity and randomised treatment 
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